

National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Comprehensive Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025



David Brieger, MBBS, MMed(ClinEpi), PhD^{a,b,1,2}, **Louise Cullen**, MBBS, FACEM, PhD^{a,d,1,2}, **Tom Briffa**, PhD^{a,1,2}, **Sarah Zaman**, MBBS, PhD^{1,b,2}, **Ian Scott**, FRACP, MHA, Med^{b,1,2}, **Cynthia Papendick**, MBMS, FACEM^{1,2}, **Kimberley Bardsley**, MN(Cardiothoracic), GDip(ClinTeach), MN(NP)¹, **Angus Baumann**, MBBS, BSc¹, **Alexandra (Sasha) Bennett**, BPharm, PhD, FSHP^{b,m}, **Robyn A. Clark**, BN, PhD, FAAN², **J. James Edelman**, PhD, FRACS², **Sally C. Inglis**, BN, BHSc, PhD², **Lisa Kuhn**, PhD, MHlthSc, RN^{2,r}, **Adam Livori**, MClinPharm, FANZCAP, FCSANZ², **Julie Redfern**, PhD, BAppSc(Physio), BSc², **Hans Schneider**, MD, FRACP, FRCPA^{2,w}, **Jeanine Stewart**, BN, GDip(Cardiol), MN(NP)^{2,x}, **Liza Thomas**, MBBS, PhD^{2,y,z}, **Edwina Wing-Lun**, MBBS^{2,a}, **Ling Zhang**, BNurse, PhD², **Elaine Ho**, MHSc(IPH), BSc(NutrDiet)^{2b}, **Stacey Matthews**, BN, MPH^{2b}, other members of the Heart Foundation Working Group^{3,*}

^aDepartment of Cardiology, Concord Repatriation General Hospital, Sydney, NSW, Australia

^bFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia

^cEmergency and Trauma Centre, Royal Brisbane and Woman's Hospital Health Service District, Metro North Health, Herston, Qld, Australia

^dSchool of Medicine, Faculty of Health, Queensland University of Technology, Brisbane, Qld, Australia

^eSchool of Population and Global Health, The University of Western Australia, Nedlands, WA, Australia

^fDepartment of Cardiology, Westmead Hospital, Westmead, NSW, Australia

^gWestmead Applied Research Centre, The University of Sydney, Sydney, NSW, Australia

^hMetro South Digital Health and Informatics, Qld, Australia

ⁱCentre for Health Services Research, The University of Queensland, Brisbane, Qld, Australia

^jDepartment of Emergency Medicine, The Royal Adelaide Hospital, Adelaide, SA, Australia

^kThe Prince Charles Hospital, Brisbane, Qld, Australia

^lDepartment of Cardio-respiratory Medicine, Alice Springs Hospital, The Gap, NT, Australia

^mNSW Therapeutic Advisory Group, Sydney, NSW, Australia

ⁿCaring Futures Institute, Flinders University, Bedford Park, SA, Australia

^oDepartment of Cardiothoracic Surgery and Transplantation, Fiona Stanley Hospital, The University of Western Australia, Perth, WA, Australia

^pImproving Palliative, Aged and Chronic Care through Clinical Research and Translation (IMPACCT), Faculty of Health, University of Technology Sydney, Sydney, NSW, Australia

^qSchool of Nursing, Midwifery and Paramedicine, Australian Catholic University, Fitzroy, Vic, Australia

^rMonash Emergency Research Collaborative, Monash Health, Clayton, Vic, Australia

^sGrampians Health, Ballarat, Vic, Australia

^tCentre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Vic, Australia

^uInstitute for Evidence-Based Healthcare, Bond University, Gold Coast, Qld, Australia

^vDepartment of Pathology, Alfred Health, Melbourne, Vic, Australia

^wSchool of Public Health and Preventative Medicine, Monash University, Melbourne, Vic, Australia

^xSchool of Nursing and Midwifery, Griffith University, Qld, Australia

^yWestmead Clinical School, The University of Sydney, Sydney, NSW, Australia

^zSouth West Sydney School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia

^{aa}Department of Cardiology, Royal Darwin Hospital, Darwin, NT, Australia

^{ab}National Heart Foundation of Australia

Received 17 February 2025; accepted 17 February 2025

*Corresponding author at: National Heart Foundation of Australia, Level 9, 565 Bourke Street Melbourne, VIC, 3000; Email: clinicalevidence@heartfoundation.org.au;

✉ @heartfoundation

¹David Brieger, Louise Cullen and Tom Briffa contributed equally to the document and are joint first authors.

²Writing Committee.

³Other members of the Heart Foundation Working Group: Erin Bowen, Mistralle Brouillard, Amanda Buttery, Dannii Dougherty, Garry Jennings, Jasmine Just, Carol Kilkenny, Victoria Leitch, Natalie Walton. The Heart Foundation Working Group would like to specifically acknowledge Professor Derek P. Chew (MBBS, MPH, FRACP, PhD) for his contribution and involvement as the guideline's independent reviewer.

The Heart Foundation Working Group would also like to acknowledge the valuable contribution of the Consumer Advisory Panel for ensuring the content aligns with the values and preferences of people living with cardiovascular disease in Australia.

The National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand are grateful for the contributions of all persons and entities involved in the development of the guideline. See [Supplementary Material A1](#) for a full list of the guideline contributors.

Authorship: Guideline authorship has been determined based on individuals' contribution to its development. Authorship has been mutually agreed upon by all authors including members of the Heart Foundation working group.

© 2025 The Authors. Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Contents

Summary of Recommendations.....	313
Introduction	319
Purpose	319
Scope	320
Intended Audience.....	320
What's New in this Guideline?.....	320
The Guideline Update Process.....	321
Development of Recommendations and Using this Guideline	321
Conflicts of Interest.....	322
1. Preamble.....	323
1.1. Impact of ACS in Australia	323
1.2. Definitions and Terminology.....	323
1.2.1. Fourth universal definition of myocardial infarction.....	323
1.2.2. Revised definition of myocardial infarction	323
1.2.3. Definition of major adverse cardiovascular events.....	324
1.2.4. Definition of unstable angina.....	324
1.2.5. Myocardial infarction with non-obstructive coronary arteries.....	324
1.3. Shared Decision Making	325
1.4. Collaborative Approaches to Care for First Nations Peoples.....	325
2. Assessment and Diagnosis	326
2.1. Assessment of People with Suspected ACS.....	326
2.1.1. Initial assessment summary	326
2.1.2. History of the presenting complaint.....	327
2.2. Initial ECG Assessment	329
2.2.1. ECG findings of acute coronary occlusion myocardial infarction	329
2.2.2. High-risk ECG findings	331
2.2.3. Other signs of myocardial ischaemia on ECG.....	331
2.2.4. Continuous ECG monitoring	332
2.2.5. Future direction	333
2.3. Biomarkers.....	333
2.3.1. Analytic properties of cardiac troponin assays.....	333
2.3.2. Point-of-care troponin assays.....	334
2.3.3. Clinical interpretation of troponin values.....	334
2.3.4. Time from onset of coronary occlusion vs. symptom onset.....	335
2.3.5. Comparing results from different troponin assays	335
2.4. Risk Assessment and Clinical Decision Pathways for Suspected ACS.....	337
2.4.1. Clinical decision pathways.....	337
2.4.1.1. High-sensitivity troponin-based clinical decision pathways.....	338
2.4.1.2. Clinical score-based clinical decision pathways.....	339
2.4.2. Implementing a clinical decision pathway for suspected ACS.....	339
2.4.3. Future direction	341
2.5. Initial Therapeutic Management.....	341
2.6. Further Diagnostic Testing for People with Suspected ACS	342
2.6.1. Cost-effectiveness	345
2.6.2. Considerations for regional, remote and First Nations peoples	345
2.7. Role of Rapid Access Chest Pain Clinics.....	345
2.8. Re-presentation with Symptoms.....	345
2.9. Discharge Planning and Advice	345
2.9.1. Discharge communication for general practitioners	345
2.9.2. Discharge advice for people at low risk for ACS.....	345
2.9.3. Discharge advice for people at intermediate risk for ACS.....	346
2.9.4. Discharge advice for people with a prior history of coronary heart disease who have a chronic or stable coronary syndrome.....	346

2.10. Primary Care and Regional and Remote Presentations.....	346
2.10.1. Considerations for primary care presentation.....	346
2.10.2. Considerations for regional and remote presentations.....	347
3. Hospital Care and Reperfusion.....	348
3.1. Acute Management of STEMI – Reperfusion for STEMI	348
3.1.1. Eligibility for reperfusion.....	348
3.1.2. Choice of reperfusion strategy	348
3.1.3. Administration of fibrinolytic therapy	349
3.1.4. Procedural recommendations in primary percutaneous coronary intervention.....	351
3.2. Ongoing Management of Fibrinolytic-Treated People.....	352
3.3. Acute Management of NSTEMACS.....	353
3.3.1. Risk stratification for people with confirmed NSTEMACS	353
3.3.2. Routine versus selective invasive management for NSTEMACS.....	355
3.3.3. Timing of invasive management for NSTEMACS	355
3.3.4. Procedural considerations in NSTEMACS	357
3.4. Antiplatelet Therapy in the Acute Phase	358
3.5. Anticoagulant Therapy in the Acute Phase	361
3.6. Acute Management of ACS with Cardiac Arrest and/or Cardiogenic Shock.....	362
3.6.1. ACS with cardiac arrest.....	362
3.6.2. ACS with cardiogenic shock	362
3.7. Treatment for ACS with Multivessel Disease without Cardiogenic Shock	364
3.8. Coronary Artery Bypass Graft Surgery in ACS.....	365
3.9. Treatment for Spontaneous Coronary Artery Dissection	366
3.10. Myocardial Infarction with Non-Obstructive Coronary Arteries.....	366
3.11. Myocardial Infarction due to Oxygen Supply/Demand Mismatch without Acute Coronary Occlusion.....	366
3.12. Echocardiography.....	366
3.13. Duration of Cardiac Monitoring.....	367
4. Recovery and Secondary Prevention.....	368
4.1. Person-Centred Non-Pharmacological Secondary Prevention	368
4.2. Vaccination Against Influenza and Other Respiratory Pathogens.....	370
4.3. Post-ACS Pharmacotherapy.....	370
4.3.1. Antiplatelet therapy.....	370
4.3.2. Lipid-modifying therapy.....	374
4.3.3. Beta blocker therapy.....	375
4.3.4. Renin-angiotensin antagonist therapies.....	376
4.3.5. Colchicine therapy	377
Acknowledgements.....	377
Funding.....	377
Endorsements	377
Appendices.....	377
References.....	383

Acknowledgement of Country

We acknowledge the Traditional Owners and custodians of country throughout Australia and their continuing connection to land, waters and community. We pay our respects to them and their cultures, and Elders past, present and future.

First Nations peoples is the term used throughout this guideline. However, the Heart Foundation recognises that the preferred term(s) when writing for, and about, First Nations peoples can differ between communities and individuals. No disrespect is intended to First Nations peoples who may identify with an alternative term.

Disclaimer

This guideline has been developed by the National Heart Foundation of Australia ABN 98 008 419 761 (**Heart Foundation**) in collaboration with the Cardiac Society of Australia and New Zealand ABN 23 006 63505 (**CSANZ**) to support healthcare professionals in making informed clinical decisions. The content of this guideline is general advice only and provided for informational purposes only. It is not intended to serve as health, medical, or treatment advice. It is based on the best available evidence and expert consensus as at the time of publication. The recommendations are intended to support, not replace, the clinical judgment and shared decision-making process between qualified healthcare professionals and the people they care for, considering an individual's circumstances and the availability of resources.

Intended use

This guideline is expressly intended for use by appropriately qualified healthcare professionals within Australia. It is intended as a reference tool and is not designed for use by individuals without proper medical training except under the supervision of a qualified healthcare professional. Any reliance on the content by unqualified individuals is at their own risk. The Heart Foundation does not warrant that the content in this guideline is suitable for your needs or any specific purpose. Users are responsible for assessing whether the information is accurate, reliable, up-to-date, authentic, relevant, or complete, and where appropriate, should seek independent professional advice.

Liability limitation

The Heart Foundation, including its employees, officers, collaborators, and associated institutions, disclaims and excludes, to the maximum extent permitted by law, all responsibility and liability (including liability in negligence) for any direct, special, indirect, incidental, consequential, punitive, exemplary, or other loss, damage, cost, or expense arising out of, or in connection with, the use or reliance on this guideline or any information contained within it, including any inaccuracies or omissions. This guideline is not exhaustive and may not apply to all clinical situations.

Third-party references

Any reference to third-party organisations, products, or services within this guideline does not constitute an endorsement or recommendation by the Heart Foundation. The inclusion of such references is for informational purposes only, and the Heart Foundation is not responsible for the content, accuracy, or actions taken based on information from external sources.

Copyright and permissions

This material is protected by copyright, and any reproduction, distribution, or use of this guideline requires prior written permission from the Heart Foundation. For permissions or enquiries, please contact copyright@heartfoundation.org.au.

Clinical judgment and decision making

This guideline should not override the responsibility of healthcare professionals to make appropriate decisions based on the specific circumstances of each person, including consideration of applicable local regulations and the person's values and preferences. Healthcare professionals are also responsible for verifying current regulations and recommendations before applying any treatments or interventions referred to in this guideline.

Updates and revisions

Medical knowledge is continually evolving, and guidelines may be updated as new information becomes available. Users are encouraged to consult the latest version of the guideline and to consider any new evidence that may have emerged.

Jurisdictional application

This guideline has been developed in accordance with Australian regulatory and clinical standards and may not be suitable for use in other jurisdictions without appropriate adaptation.

Summary of Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
ASSESSMENT AND DIAGNOSIS		
Initial ECG assessment		
In people presenting with chest pain or other symptoms suggestive of ACS, record and assess an ECG for evidence of ACOMI within 10 minutes of first clinical contact.		Consensus
In people with suspected ACS, record and assess additional ECGs if symptoms persist, change, or recur, or there is diagnostic uncertainty. For those with ongoing ischaemic symptoms and an inconclusive standard 12-lead ECG, record and assess further ECGs with right-sided and/or posterior leads.		Consensus
In people with ongoing ischaemic symptoms or haemodynamic compromise or new ischaemic findings on ECG, continuous cardiac monitoring and defibrillator availability is recommended while assessment for ACOMI continues.	Strong	Low
Biomarkers		
In people with suspected ACS, evaluation with high-sensitivity cardiac troponin (hs-cTn) assays is recommended.	Strong	High
Elevated hs-cTn values should be defined using sex-specific >99 th percentiles.		Consensus
Apply the assay-specific troponin values relevant to the cTn assay being used.		Consensus
When evaluating changes (deltas) in troponin values, serial results from a single assay must be used.		Consensus
Risk assessment and clinical decision pathways for suspected ACS		
People with symptoms and ECG changes consistent with ACOMI require urgent reperfusion. Do not use clinical decision pathway (CDP).	Strong	Very Low
People presenting with acute chest pain or other symptoms suggestive of ACS should receive care guided by an evidence-based CDP that includes assay-specific troponin results to categorise people as high, intermediate, or low risk.		Consensus
A high-sensitivity troponin-based clinical decision pathway is recommended, using the 0/1-hour or 0/2-hour strategy, or the <i>High-sensitivity troponin in the evaluation of patients with acute coronary syndrome</i> (High-STEACS) algorithm.		Consensus
When contemporary troponin assays are used, a CDP incorporating formal clinical score-based risk stratification is recommended.		Consensus
Initial therapeutic management		
In all people with suspected or confirmed ACS, give aspirin (300 mg orally, dissolved or chewed) unless contraindicated.	Strong	High
People with suspected or confirmed ACS with oxygen saturation (SpO ₂) ≥90% do not require oxygen therapy.	Strong	Moderate
In people with suspected or confirmed ACS receiving oxygen therapy, SpO ₂ should not exceed 96%.	Strong	Moderate
In the presence of ongoing chest pain, give glyceryl trinitrate sublingual tablet or spray every 5 minutes for up to three doses if no contraindications exist.		Consensus
In people with chest pain and in the absence of contraindications, it is reasonable to administer intravenous (IV) fentanyl or morphine boluses.		Consensus

(continued).

Recommendation	Strength of recommendation	Certainty of evidence
Further diagnostic testing for people with suspected ACS		
In people at intermediate risk (as defined by a validated CDP) with elevated troponin concentrations (>99 th percentile), inpatient investigation is recommended.	Strong	Moderate
In people at intermediate risk without elevated troponin concentrations, consider outpatient investigation with non-invasive testing.		Consensus
In people at low risk who remain symptom-free, further cardiac testing for CAD is not routinely required.		Consensus
Primary care and regional and remote presentations		
For people with suspected ACS initially evaluated in the primary care setting, prompt transfer to a facility where definitive risk assessment can occur (e.g. ED) is recommended.		Consensus
Metropolitan health services should establish centralised support systems for regional and remote health services to facilitate:	Strong	Low
• prompt assistance with ECG interpretation and access to troponin results when on-site access is not available; • provision of clinical advice to healthcare professionals; • access to cardiac investigations if required.		
HOSPITAL CARE AND REPERFUSION		
Acute management of STEMI		
Eligibility for reperfusion		
In people with STEMI within 12 hours of symptom onset, perform emergency reperfusion with either primary PCI or fibrinolytic therapy.	Strong	Moderate
In people with STEMI, symptom onset over 12 hours before presentation and evidence of continuing myocardial ischaemia (persistent ischaemic symptoms, haemodynamic compromise, and/or life-threatening arrhythmias), perform emergency reperfusion with primary PCI.	Strong	Moderate
Choice of reperfusion strategy		
In people with STEMI within 12 hours of symptom onset, primary PCI is the preferred reperfusion strategy over fibrinolysis, if it can be performed within 120 minutes of first medical contact.	Strong	High
In people with STEMI within 12 hours of symptom onset, perform fibrinolysis if primary PCI cannot be delivered within 120 minutes of first medical contact.	Strong	Moderate
Administration of fibrinolytic therapy		
In people with STEMI for whom fibrinolysis is the preferred reperfusion strategy, it should be delivered within 30 minutes of first medical contact. Consider pre-hospital administration.	Strong	Moderate
In people aged ≥70 years, half the standard dose of tenecteplase is recommended as part of a pharmaco-invasive strategy.	Strong	Moderate
Procedural recommendations in primary percutaneous coronary intervention		
For people with STEMI at a PCI-capable centre, deliver primary PCI within 60 minutes of arrival.		Consensus
For people with STEMI transferred from a non-PCI centre, deliver primary PCI within 90 minutes of first hospital arrival.		
Use radial access over femoral access when performing primary PCI, unless contraindicated.	Strong	High
In people undergoing primary PCI, do not perform routine thrombus aspiration of the infarct-related artery (IRA).	Strong	Moderate
In people who are asymptomatic and stable for more than 48 hours following occlusion of an IRA, do not perform routine PCI to this artery.	Strong	Moderate

(continued).

Recommendation	Strength of recommendation	Certainty of evidence
Ongoing management of fibrinolytic-treated people		
People successfully treated with fibrinolytic therapy should be transferred to a PCI-capable centre as soon as possible. Angiography should be performed within 2–24 hours of arrival.	Strong	Moderate
Consider transferring people as soon as possible to a PCI-capable centre if fibrinolytic therapy is unsuccessful. If appropriate, consider subsequent PCI at the centre.	Weak	Moderate
Acute management of NSTEMACS		
Risk stratification for people with confirmed NSTEMACS		
In people with NSTEMACS, consider using the GRACE risk score to determine short- and long-term cardiovascular prognosis.	Weak	High
In people with ACS undergoing coronary angiography, consider using bleeding risk scores to determine short-term bleeding risk.	Weak	Moderate
Routine versus selective invasive management for NSTEMACS		
In people with NSTEMACS at high or very high-risk of adverse cardiovascular events, perform routine invasive coronary angiography, with coronary revascularisation (PCI or CABG) where appropriate.	Strong	High
In people with NSTEMACS not at high or very high risk of adverse cardiovascular events, testing for inducible ischaemia (e.g. stress testing) may guide the need for invasive coronary angiography.	Weak	Moderate
Timing of invasive management for NSTEMACS		
In people with NSTEMACS with very high-risk criteria, an immediate invasive strategy within 2 hours of diagnosis is recommended.		Consensus
In people with NSTEMACS with high-risk criteria, consider an early invasive strategy within 24 hours of diagnosis.	Weak	High
Procedural considerations in NSTEMACS		
In people with NSTEMACS undergoing an invasive approach, radial access is preferred to femoral access, unless contraindicated.	Strong	High
In people with NSTEMACS undergoing an invasive approach, consider intravascular imaging to guide PCI.	Weak	High
Antiplatelet therapy in the acute phase		
In people with STEMI treated with fibrinolytic therapy, give dual antiplatelet therapy with aspirin and clopidogrel.	Strong	Moderate
In people with STEMI undergoing primary PCI and people with NSTEMACS undergoing a routine invasive strategy, give dual antiplatelet therapy with aspirin and a potent P2Y ₁₂ inhibitor (ticagrelor or prasugrel).	Strong	High
In people with STEMI undergoing primary PCI and people with NSTEMACS undergoing a routine invasive strategy for whom ticagrelor or prasugrel are contraindicated, and those receiving oral anticoagulation, give clopidogrel.	Strong	High
In people with NSTEMACS for whom a selective invasive strategy is planned, give ticagrelor or clopidogrel.	Strong	High
In people with NSTEMACS, consider routine genotypic or platelet function guidance of P2Y ₁₂ therapy.	Weak	Moderate
In people with NSTEMACS, consider de-escalation from potent P2Y ₁₂ inhibitor to clopidogrel, but not during the first 30 days following an ACS event.	Weak	Moderate

(continued).

Recommendation	Strength of recommendation	Certainty of evidence
In people with ACS with concomitant non-valvular atrial fibrillation and CHA2DS2VA score >1, give aspirin and clopidogrel, together with a non-vitamin K oral anticoagulant.	Strong	High
In people with STEMI undergoing primary PCI or those with NSTEMI/ACS undergoing an invasive strategy, routine glycoprotein IIa/IIIb inhibitor (GPI) is not recommended.	Consensus	
Anticoagulant therapy in the acute phase		
People treated with fibrinolytic therapy should receive anticoagulation (unfractionated heparin or enoxaparin).	Strong	Moderate
People undergoing primary PCI should receive anticoagulation (unfractionated heparin or bivalirudin).	Strong	Moderate
People with NSTEMI/ACS should receive anticoagulation (unfractionated heparin, enoxaparin, or fondaparinux).	Strong	Low
Acute management of ACS with cardiac arrest		
In people with return of spontaneous circulation after resuscitated cardiac arrest and persistent STE on ECG, perform emergency reperfusion.	Strong	Low
In haemodynamically stable people with resuscitated cardiac arrest and no STE on ECG, do not perform routine emergency coronary angiography.	Strong	Moderate
Acute management of ACS with cardiogenic shock		
In people with ACS and cardiogenic shock, perform PCI of the IRA only.	Strong	Moderate
In people with ACS and cardiogenic shock, routine insertion of an intra-aortic balloon pump is not recommended.	Strong	High
In people with ACS and cardiogenic shock, routine venoarterial extracorporeal membrane oxygenation is not recommended.	Strong	Moderate
In select people with STEMI and cardiogenic shock, consider left ventricular assist devices.	Weak	Moderate
Treatment for ACS with multivessel disease without cardiogenic shock		
In haemodynamically stable people with STEMI and MVD, perform PCI of suitable non-IRA(s).	Strong	High
Consider performing PCI of the non-IRA at the time of primary PCI or within 19 days of the index procedure.	Weak	Moderate
In people with STEMI and MVD, routine invasive physiology assessment (e.g. fractional flow reserve [FFR]) to evaluate non-IRA severity is not recommended.	Consensus	
In people with NSTEMI/ACS and non-complex MVD, consider routine PCI of non-IRA in the same setting.	Weak	Low
In people with NSTEMI/ACS and MVD, consider invasive physiology assessment (e.g. FFR) to evaluate non-IRA severity.	Weak	Low
Coronary artery bypass graft surgery in ACS		
In people with STEMI, mechanical complications and mitral valve disease (e.g. ventricular septal rupture, mitral valve insufficiency because of papillary muscle infarction or rupture, or free wall rupture), perform CABG at the time of surgery.	Strong	Low
Treatment for spontaneous coronary artery dissection		
In people with ACOMI due to SCAD but who are otherwise stable, routine revascularisation is not recommended.	Consensus	
In people with SCAD and haemodynamic instability and/or ongoing ischaemia, consider selective revascularisation.	Weak	Very Low

(continued).

Recommendation	Strength of recommendation	Certainty of evidence
RECOVERY AND SECONDARY PREVENTION		
Person-centred non-pharmacological secondary prevention		
For all people with ACS, refer to a multi-disciplinary exercise-based cardiac rehabilitation program prior to discharge.	Strong	Moderate
For all people with ACS, provide advice on lifestyle* changes such as healthy eating, regular physical activity, not smoking, limiting alcohol intake, and caring for mental health.	Consensus	
For all people with ACS who smoke, advise to stop and refer for behavioural intervention (such as cognitive behaviour therapy or cessation counselling program), combined with pharmacotherapy where appropriate (nicotine replacement therapies, varenicline and bupropion individually or in combination).	Strong	Moderate
For all people with ACS, implement strategies to optimise adherence to preventive medicines.	Consensus	
Vaccination against influenza and other respiratory pathogens		
In people with ACS, vaccinations for influenza and other respiratory pathogens are recommended.	Consensus	
Post-ACS pharmacotherapy		
Antiplatelet therapy		
In people discharged following an ACS who are at high ischaemic and/or low bleeding risk, prescribe DAPT with aspirin and a P2Y ₁₂ inhibitor for 6–12 months.	Strong	High
In people discharged following an ACS who are at low ischaemic and/or high bleeding risk, cease DAPT at 1–3 months post-ACS and continue single antiplatelet therapy (SAPT).	Strong	High
In people discharged following an ACS who have completed a course of DAPT (i.e. 1–12 months), prescribe long-term P2Y ₁₂ inhibitor over aspirin.	Strong	Moderate
In people discharged following an ACS who remain at high ischaemic and low bleeding risk, consider long-term DAPT (>12 months).	Weak	Moderate
In people discharged following an ACS with an indication for long-term OAC therapy, continue OAC and DAPT (preferentially aspirin and clopidogrel) for 1–4 weeks, then cease aspirin.	Strong	High
In people discharged following an ACS with an indication for long-term OAC therapy, cease antiplatelet therapy at 6–12 months and continue anticoagulation alone.	Strong	Moderate
Lipid-modifying therapy		
In people with ACS, prior to hospital discharge, initiate and continue indefinitely, the highest tolerated dose of HMG-CoA reductase inhibitors (statins), unless contraindicated or completely statin intolerant.	Strong	High
In people with ACS with initial or partial intolerance to statin, consider using a different statin, dose or dosing frequency to achieve person-specific therapeutic objectives.	Weak	Low
In people with ACS, an initial target low density lipoprotein cholesterol (LDL-C) level of <1.4 mmol/L and a reduction of at least 50% from baseline is recommended, with further benefit gained from treating to the lowest achievable level.	Consensus	
In people with ACS with a suboptimal LDL-C level despite statin therapy or who are statin intolerant, consider adding ezetimibe.	Weak	Moderate

(continued).

Recommendation	Strength of recommendation	Certainty of evidence
In people with ACS with a suboptimal LDL-C level despite maximally tolerated statin therapy and ezetimibe, give PCSK9 inhibitors.	Strong	High
Beta blocker therapy		
In people with ACS and LV impairment, beta blockers are recommended.		Consensus
In people with ACS and preserved LV systolic function who have undergone coronary revascularisation and are receiving optimal medical therapy, consider withholding beta blockers.	Weak	Moderate
Renin-angiotensin antagonist therapies		
In people with ACS and heart failure symptoms, LVEF $\leq 40\%$, diabetes, hypertension and/or chronic kidney disease, initiate and continue angiotensin converting enzyme (ACE) inhibitors, or angiotensin receptor blockers if ACE inhibitors are not tolerated.	Strong	High
In people with ACS and LVEF $\leq 40\%$ and heart failure with or without diabetes, initiate and continue mineralocorticoid receptor antagonists.	Strong	High
In people with ACS, use of an angiotensin receptor–neprilysin inhibitor is not recommended.	Strong	High
Colchicine therapy		
In people discharged following an ACS, consider initiating colchicine (0.5 mg daily) and continuing long-term unless contraindicated or colchicine intolerant.	Weak	Moderate

*Use of the word lifestyle here refers to a collective group of modifiable risk factors. The authors wish to acknowledge that these risk factors are not solely dependent on individual choice, and instead reflect the cultural, social and environmental factors that influence behaviour. This term does not in any way attribute blame to individuals.

Introduction

This guideline has been developed to assist in the diagnosis and management of people presenting with symptoms suggestive of acute coronary syndromes (ACS), or with confirmed ACS. ACS are conditions involving sudden reduced blood flow to the heart. The main types are acute myocardial infarction (AMI) and unstable angina.

The guideline recommendations are based on contemporary evidence and are intended to meet the needs of clinicians caring for the majority of people, recognising that recommendations should inform, but not replace, clinical judgement.

Shared decision making is recommended and should be based on the person's values, preferences and circumstances. Clear communication with the person and their support people is critical to these discussions.

This guideline was developed in consultation with a broad range of clinical experts and people with lived experience,

representing different geographic regions, sex, genders, ethnicities, clinical settings and perspectives. Organisations, including those with people with lived experience interests and professional expertise, were involved.

Purpose

This guideline replaces the *National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016*.

The guideline includes:

- recommendations for assessing and managing people with suspected or confirmed ACS
- a summary of the available evidence supporting the recommendations
- practical advice on how to apply the recommendations
- specific practice points for assessing and managing ACS in underserved populations.




Figure 1 Classifications of conditions associated with ACS.

Abbreviations: ACOMI, acute coronary occlusion myocardial infarction; ACS, acute coronary syndromes; AMI, acute myocardial infarction; NSTEACS, non-ST-segment elevation acute coronary syndromes; NSTEMI, non-ST-segment elevation myocardial infarction; SCAD, spontaneous coronary artery dissection; STEACS, ST-segment elevation acute coronary syndromes; STEMI, ST-segment elevation myocardial infarction.

*Not all people with ST-segment elevation will have elevated cardiac troponin values, resulting in the diagnosis of unstable angina.

#The term ACOMI incorporates both STEMI and STEMI equivalents which should prompt consideration for emergency reperfusion (see section 3.1 [Acute Management of STEMI – Reperfusion for STEMI](#)).

Note: Coronary occlusion describes any local pathologic process that reduces flow in coronary vessels (including the microvasculature) sufficient to cause myocardial necrosis (acute troponin elevation).

Scope

This guideline makes recommendations for:

- assessing adults aged 18 years and older with suspected ACS
- managing confirmed ACS
- recovery after ACS and secondary prevention of future vascular events.

The definition of myocardial infarction (MI) has been refined from the *Fourth universal definition of myocardial infarction* to align more closely with the clinical syndromes that characterise occlusive and non-occlusive MI. This guideline adopts the term acute coronary occlusion myocardial infarction which includes both atherosclerotic and non-atherosclerotic causes.

The guideline predominantly focuses on managing people with MI due to atherosclerotic plaque rupture, ulceration, fissure, or erosion. Some recommendations presented in this guideline may be relevant to other types of MI (e.g. type 2 MI), particularly with respect to initial acute treatment and post-hospital care. Specific recommendations are presented in some cases for MI due to non-atherosclerotic causes (e.g. spontaneous coronary artery dissection [SCAD]) (Figure 1).

The guideline does not cover management of non-ACS presentations and non-cardiac chest pain. It does not include detailed guidance on managing related clinical conditions, such as heart failure, or comorbidities such as cancer or diabetes. Healthcare professionals should refer to existing guidance, where available.

Intended Audience

This guideline is intended for use by all healthcare professionals involved in the care of people with ACS. These include cardiologists, emergency physicians, general practitioners, nurses and nurse practitioners, First Nations health workers and practitioners, pharmacists and other allied healthcare professionals.

General practitioner is the term used throughout this guideline. However, the Heart Foundation recognises other primary healthcare professionals, who in some communities may be the first point of contact with the health system. Other primary healthcare professionals include primary care nurses and nurse practitioners, and First Nations health workers and practitioners.

What's New in this Guideline?

Key changes in this guideline

- Introduction of consensus recommendation as a new category of recommendation.
- Dedicated practice points to meet the unique needs of women, older adults, First Nations peoples, and people living in regional and remote areas.
- Revised terminology and definitions of myocardial infarction (section 1.2).

Assessment and diagnosis

- Guidance on assessing and interpreting the electrocardiogram in people with suspected acute coronary occlusion myocardial infarction or myocardial ischaemia (section 2.2).
- Guidance on using high-sensitivity cardiac troponin testing and interpreting the results to enable more rapid detection or exclusion of myocardial injury (section 2.3).
- Introduction of high-sensitivity troponin-based clinical decision pathways to stratify risk in people with suspected ACS (section 2.4).
- Recommendations to support management of people with suspected ACS presenting to primary care and regional and remote settings (section 2.10).

Hospital care and reperfusion

- Updates on recommended timing of reperfusion strategies in people with ST-segment elevation myocardial infarction (section 3.1).
- Consideration of intravascular imaging to guide percutaneous coronary intervention in people with non-ST-segment elevation ACS who have undergone an invasive approach (section 3.3.4).
- Revised recommendations on acute phase pharmacotherapies (sections 3.4 and 3.5).
- New recommendations related to haemodynamic support devices in people with ACS and cardiogenic shock (section 3.6.2).
- Treatment considerations for people with ACS and multi-vessel disease without cardiogenic shock (section 3.7) and spontaneous coronary artery dissection (section 3.9).

(continued).

Recovery and secondary prevention

- New recommendations and practice points on delivery of person-centred, non-pharmacological secondary prevention care (section 4.1).
- Guidance on recommended vaccinations for people with ACS (section 4.2).
- Updates on duration of dual antiplatelet therapy and indications for long-term oral anticoagulation (section 4.3.1).
- New recommendations on low-density lipoprotein cholesterol (LDL-C) treatment targets and post-ACS lipid-modifying therapy, including non-statin therapies (section 4.3.2).
- Considerations for withholding beta blockers in select people with ACS with preserved left ventricular systolic function (section 4.3.3).
- New recommendations on the use and non-use of renin-angiotensin antagonist therapies (section 4.3.4) and on initiating colchicine post-ACS (section 4.3.5).

The Guideline Update Process

This guideline appraises and summarises the available evidence on the clinical care of people with suspected or confirmed ACS. This evidence informs a set of recommendations to guide healthcare professionals in making diagnostic and therapeutic decisions. It replaces the *National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016* [1–3].

The guideline was developed based on the *Grading of recommendations, assessment, development, and evaluation* (GRADE) methodology [4]. It is also informed by the 2016 *National Health and Medical Research Council (NHMRC) Standards for Guidelines* [5], adapting them where necessary to meet the specific requirements of this guideline.

Five expert groups, including a consumer advisory panel, directed and governed the development of this guideline. Members from diverse backgrounds and geographic regions were recruited between the last quarter of 2021 and first quarter of 2022. Clinical experts were selected based on their experience in guideline development and area of expertise. Expertise was sourced across the disciplines of cardiology, emergency medicine, general medicine, general practice, nursing, pharmacy, epidemiology, cardiac rehabilitation and public health.

Please see [Supplementary Material A](#) for full details on the governance arrangements, processes for establishing the expert groups, literature search and evidence synthesis, recommendation development using the GRADE methodology, and the public consultation and approvals process [6].

Development of Recommendations and Using this Guideline

Between the second and third quarter of 2022, the Expert Steering Group (ESG) and Expert Subgroups developed the guideline scope and clinical questions. These were prioritised based on current literature, gaps identified in international guidelines, priorities and choices faced by healthcare professionals, and values and preferences of people with lived experience. The guideline scope was shared with reference group organisations and the consumer advisory panel for feedback. The clinical questions were expressed in patient/population, intervention, comparison, outcome, time, setting (PICOTS) format. In the fourth quarter of 2022, an independent reviewer conducted the literature review based on these PICOTS questions.

The literature review sought published studies from January 2015 to December 2022. Evidence summaries were completed in the first quarter of 2023. They were supplemented with studies identified from conference attendances, reference lists and database alerts. If relevant and pertinent, studies published after the literature search dates were also included.

Between the second and fourth quarter of 2023, the expert groups drafted the guideline content and recommendations. Guideline recommendations were developed using GRADE methodology. The GRADE approach offers a transparent and structured process for developing and presenting evidence summaries and recommendations [4]. In some instances, recommendations were adopted or adapted from existing international guidelines.

In the first quarter of 2024, an independent reviewer was commissioned to assess the comprehensiveness and balance of the scientific evidence, certainty of evidence and rationale to inform the wording and strength of the recommendations.

[Table 1](#) provides a summary of GRADE definitions.

The GRADE methodology considers the importance of the recommendation, which is not necessarily related to the quality or certainty of the evidence. Rather, the importance reflects the extent to which the recommendation will impact on the health status or quality of life of the target population. This allows for a strong recommendation to be made even if the certainty of the evidence is low.

Recommendations are categorised as ‘consensus’ where there is high certainty that the desirable effects of an intervention clearly outweigh its undesirable effects, but the body of supportive evidence is indirect and the application of the GRADE approach is inappropriate.

Consensus recommendations were informed by the expert opinion of the Expert Steering Group and Expert Subgroup members, with consideration of the evidence, values, preferences and resource use at the time of writing. Consensus was established when the majority of members supported the statement.

Table 1 GRADE definitions.

Certainty of evidence	
The certainty of evidence reflects the extent to which the confidence in the estimates of an effect is adequate to support a particular decision.	
Certainty of evidence	What it means
High	The authors are very confident that the true effect lies close to that of the estimate of the effect.
Moderate	The authors are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low	The authors' confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low	The authors have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect.
Strength of recommendation	
The strength of a recommendation reflects the extent to which the authors are confident that desirable effects of an intervention outweigh undesirable effects, or vice versa, across the range of people for whom the recommendation is intended. It is determined by considering the balance between benefits and harms, certainty of evidence, variability or uncertainty in the values and preferences of the target population, and resource use.	
Strength of recommendation	What it means
Strong	The authors are confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects. It implies that most or all individuals will be best served by the recommended course of action.
Weak	The authors concluded that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects but are not certain. It implies that not all individuals will be best served by the recommended course of action.

Abbreviation: GRADE, Grading of recommendations, assessment, development and evaluation.

Practice points are statements that are actionable and often describe the who, what, how, where and when of implementing a recommendation. Practice points can contain supporting information about a recommendation (e.g. medicine dosing). They may also include tools and tips that enhance implementation of the chosen intervention and/or its efficient use. Practice points are not actionable without related recommendations.

Practice points were developed with consideration of the geographical challenges in Australia and availability of resources in Australian healthcare settings. Where there were specific practice points, evidence and/or resources relevant to underserved populations, these were included under a separate subheading.

For each section in this guideline, recommendations are presented first for easy identification. These are followed by a summary of the supporting evidence, which provides a rationale for the recommendations. Relevant practice points are subsequently presented at the end of each section.

This guideline should be read in conjunction with the *Australian Commission for Safety and Quality in Health Care ACS Clinical Care Standard* which informs quality indicators to drive better outcomes for all people living in Australia

[7]. Some sections provide suggested areas for further research.

Further details of the guideline development process can be found in [Supplementary Material A3](#).

Conflicts of Interest

Conflicts of interest are considered within a framework of:

- the relationship (direct or indirect) of the individual to any third party with interests in the guideline topic being considered
- the nature (financial and non-financial) of the potential conflict.

Conflicts of interest among the expert groups required appropriate management to ensure recommendations were not compromised. Processes employed by the Heart Foundation aimed to ensure the integrity of the guideline while striking an appropriate balance between interests in certain topics and the expertise required to make sound and meaningful recommendations.

More information on conflicts of interest management and a summary of all disclosures can be found in [Supplementary Material A2](#).

1. Preamble

1.1. Impact of ACS in Australia

Acute coronary syndromes (ACS) are a significant public health concern in Australia, with substantial impacts on individuals, healthcare systems and society. In 2021, there were an estimated 57,300 acute coronary events among Australians aged 25 years and over, equating to approximately 157 events per day [8]. Hospitalisations related to ACS also remain high, with 92,400 admissions recorded in 2020–2021, representing over half of all coronary heart disease hospitalisations that year [8]. Tragically, coronary heart disease, which includes ACS, was the underlying cause of 17,300 deaths in 2021, accounting for 10% of all deaths in Australia [8].

The economic burden of ACS is considerable. In 2017–2018, the financial cost of ACS events to Australian governments was estimated at \$1.93 billion [9]. Disparities exist, with men experiencing rates of acute coronary events 2.3 times higher than women after adjusting for age [8]. Women, however, face unique challenges, including longer symptom duration, delays in receiving treatment and lower rates of secondary prevention medication use [10–12]. Furthermore, First Nations peoples experience coronary events at twice the rate of non-Indigenous Australians, highlighting ongoing inequities in healthcare access and outcomes [8,13,14].

The age-standardised rate of acute coronary events declined by 31% between 2011 and 2018, progress has slowed for younger populations [14]. Encouragingly, improvements in care have been observed, with significant reductions in in-hospital events and 6-month readmissions for people with ACS between 2000 and 2007 [9]. These trends underscore the need for continued investment in prevention, early detection and equitable access to high-quality care to further reduce the burden of ACS on Australians.

Specific recommendations to improve outcomes for these high-risk populations, including older people and/or those with frailty, are incorporated throughout the guideline wherever possible.

1.2. Definitions and Terminology

A clear understanding of definitions and terminology is essential for accurate use of this guideline. ACS encompass both AMI and unstable angina (UA).

ACS may also be classified as ST-segment elevation ACS (STEACS) and non-ST-segment elevation ACS (NSTEMACS). NSTEMACS encompasses both non-ST-segment elevation myocardial infarction (NSTEMI) and UA (Figure 1), with NSTEMI and UA differentiated by the presence or absence of biomarker evidence of cardiomyocyte necrosis respectively.

This guideline has adopted the term acute coronary occlusion myocardial infarction (ACOMI) which includes people presenting with electrocardiogram (ECG) changes of either ST-segment elevation (STE) or other changes indicative of significant epicardial artery acute coronary occlusion.

1.2.1. Fourth universal definition of myocardial infarction

The *Fourth universal definition of myocardial infarction* (UDMI) bases the diagnosis of AMI on evidence of cardiomyocyte necrosis as detected by an elevated cardiac biomarker. Preferably, this is a high-sensitivity cardiac troponin (hs-cTn) T or I assay, with at least one value above the 99th percentile of the upper reference limit [15,16].

The currently accepted international criteria for diagnosing AMI are the detection of an increase and/or decrease in troponin, with one value above the upper reference limit, and at least one of the following [15]:

- symptoms of acute myocardial ischaemia
- new ischaemic ECG changes
- development of pathological Q waves on ECG
- imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality consistent with an ischaemic aetiology
- intracoronary thrombus detected on coronary angiography or autopsy.

Type 1 myocardial infarction (MI) is spontaneous MI with coronary pathology and is characterised by atherosclerotic plaque rupture, ulceration, fissure, or erosion with resulting intraluminal thrombus in one or more coronary arteries leading to decreased myocardial blood flow and/or distal embolisation and subsequent myocardial necrosis [17]. The underlying coronary artery disease (CAD) may be non-obstructive or absent on angiography (myocardial infarction with non-obstructive coronary arteries [MINOCA]) [15].

Type 2 MI occurs when myocardial injury or necrosis is associated with an imbalance between myocardial oxygen supply and demand (usually driven by an increase in the latter) and may be seen in situations associated with hypotension, hypertension, tachyarrhythmia, bradyarrhythmia, anaemia, hypoxaemia, or pulmonary embolism. In contrast to type 1 MI, there is no new anatomical obstruction of the coronary vessels.

Acute or chronic myocardial injury may occur in both type 1 and type 2 MI. Myocardial injury occurs when there is evidence of elevated cardiac troponin (cTn) with at least one value greater than the 99th percentile upper reference limit, but in the absence of acute ischaemic symptoms. Myocardial injury is acute if there is a short-term rise and/or fall in troponin values, or chronic if the troponin level is stable.

Type 3 MI is described as MI resulting in death when biomarkers are not available.

Type 4 and 5 MI represent peri-procedural MI related to percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) respectively.

1.2.2. Revised definition of myocardial infarction

This guideline adopts refined definitions that align more closely with the clinical syndromes that characterise occlusive and non-occlusive MI [15,18].

In refinements to the Fourth UDMI adopted in this guideline, an identical clinical picture to type 1 MI may be caused by non-atherosclerotic mediated coronary occlusion

such as SCAD, coronary embolism, or coronary vasospasm or microvascular dysfunction (Figure 2), which are all associated with coronary pathology.

Such conditions (classified as type 2 MI in the Fourth UDMI) result in a spontaneous reduction in myocardial oxygen supply, with the clinical presentation, investigation findings and early management often indistinguishable from those associated with spontaneous atherosclerotic plaque events. Hence, they are classified as forms of occlusive MI in this guideline (Figure 2 and section 2.1.2 History of the presenting complaint) [19–21].

In further refinements to the Fourth UDMI, MI due to oxygen supply/demand mismatch without acute coronary occlusion may be further subclassified according to the presence or absence of fixed obstructive CAD.

Acute coronary occlusion causes downstream MI (i.e. ACOMI) in the absence of timely reperfusion. Importantly, ACOMI may present as ST-segment elevation myocardial infarction (STEMI) or STEMI equivalents (section 2.2.1 ECG findings of acute coronary occlusion myocardial infarction) [22]. This guideline uses the term ACOMI to highlight STEMI equivalents, which are often under recognised or missed in emergency settings.

This guideline predominantly focuses on managing people with MI due to atherosclerotic plaque rupture, ulceration, fissure, or erosion with resulting intraluminal thrombus in one or more coronary arteries leading to decreased myocardial blood flow and/or distal embolisation and subsequent myocardial necrosis.

1.2.3. Definition of major adverse cardiovascular events

In people presenting with suspected ACS, the risk of an index MI and major adverse cardiovascular events

(MACE) over the next 30 days should be assessed as low, intermediate or high. In people with confirmed ACS, MACE generally includes AMI, cardiac death, and stroke.

1.2.4. Definition of unstable angina

UA is myocardial ischaemia at rest or on minimal exertion in the absence of acute cardiomyocyte injury/necrosis. This is an important clinical diagnosis based upon symptoms, with or without ECG changes in the absence of elevated troponin concentrations.

Since the introduction of hs-cTn assays, the prevalence of UA has decreased, likely due to greater assay precision allowing detection of low-range changes in troponin concentrations [23–26].

1.2.5. Myocardial infarction with non-obstructive coronary arteries

MINOCA is when a person presents with symptoms suggestive of ACS, demonstrates troponin elevation and has non-obstructed coronary arteries at the time of coronary angiography (no coronary artery stenosis $\geq 50\%$ in any major epicardial vessel) and there is no specific alternate diagnosis for the clinical presentation (e.g. pulmonary embolism or myocarditis) [27,28].

MINOCA is a working, rather than a final, diagnosis and further investigations are essential to establish the underlying cause. Cardiac magnetic resonance imaging (MRI) is valuable to establish the presence of MI and to exclude differential diagnoses such as myocarditis. If atherosclerotic heart disease is likely, the person should be managed with appropriate secondary prevention medicines and lifestyle interventions.




Figure 2 Revised classification of MI. Adapted from de Lemos *et al.* [18]. Both types of MI may present with ECG changes of ST-segment elevation (STEMI) or non-ST-segment elevation (NSTEMI). Abbreviations: CAD, coronary artery disease; MI, myocardial infarction.

1.3. Shared Decision Making

Shared decision making involves open communication between a person and their healthcare provider to deliver appropriate, person-centred care. Shared decision making combines a person's values, goals and preferences with the best available evidence about benefits and potential risks of healthcare interventions [29].

A three-step approach to implement shared decision making in clinical practice involves introducing choice, describing options (often with decision aids), and assisting people to explore their preferences [30].

Shared decision making should be implemented across the care continuum for people with suspected or confirmed ACS, including risk assessment, choice of reperfusion strategy and discharge planning. Shared decision making enables alignment between peoples' values and proposed treatment options [31].

Shared decision making is well supported and encouraged in cardiovascular research and practice, although further study is needed on optimal implementation [32–36].

1.4. Collaborative Approaches to Care for First Nations Peoples

A holistic, collaborative approach is crucial to the delivery of culturally appropriate, best practice care for First Nations peoples with suspected or confirmed ACS. Shared decision making is central to this but also includes the way healthcare settings and services are designed and interact. A truly collaborative approach is one that ensures First Nations peoples with ACS feel culturally safe at every point of contact with the health system.

It is the responsibility of all healthcare professionals along the ACS care continuum to be culturally competent and to embed shared decision making in their clinical practice. Cultural competence refers to a set of consistent values, behaviours and actions that enable effective delivery of healthcare across cultures [37].

Aboriginal and Torres Strait Islander health practitioners, Aboriginal health workers and Aboriginal liaison officers, where available, should be involved in a First Nations person's care as early as possible. Aboriginal and Torres Strait Islander health practitioners and Aboriginal health workers (collectively referred to in this guideline as First Nations health practitioners) play a critical role in the ongoing management and follow up of First Nations peoples with confirmed or suspected ACS. These practitioners work in tertiary, secondary and primary care settings, including Aboriginal Community Controlled Health Organisations. Particularly in remote communities, Aboriginal health workers are vital to the delivery of primary health care.

Aboriginal liaison officers support the First Nations person and their family by acting as an intermediary with healthcare professionals. They help to overcome cultural and communication barriers to care and provide support in navigating the hospital system. Crucially, Aboriginal liaison officers also

help facilitate the transition to outpatient care, acting as the central liaison between the person's specialist team and general practitioner.

Specific practice points for First Nations peoples have been embedded throughout this guideline. These practice points recognise the different health outcomes for First Nations peoples that have resulted from dispossession, discrimination, disadvantage and disempowerment. Several resources are available on the Heart Foundation website to guide yarning and shared decision making between First Nations peoples and their healthcare providers.

2. Assessment and Diagnosis

2.1. Assessment of People with Suspected ACS

Assessment of ACS incorporates the following:

- ECG findings
- clinical findings from history and physical examination
- troponin testing.

These observations are combined to either diagnose or inform risk assessment which will guide the location and timing of further investigations, management, and appropriate follow-up. Rapid identification of people with ACS is crucial as many treatments are time sensitive and earlier intervention improves outcomes. However, only a minority of people presenting with acute chest pain to the emergency department (ED) will have a final diagnosis of ACS [38,39].

Among those presenting with acute chest pain to the ED in whom ACS is suspected, <5% will have STEMI, 5–10% NSTEMI, 5–10% UA, 15–20% other cardiac conditions, and 50–60% non-cardiac conditions [39–42]. While a definitive diagnosis may be made at index presentation, most diagnoses will be of a non-cardiac condition or remain unclear and may require further follow-up to complete assessment as an outpatient [16].

For this reason, risk assessment for ACS is the key initial goal, rather than achieving a rule in or rule out diagnosis relating to ACS which may not be possible in many people (section 2.4 Risk Assessment and Clinical Decision Pathways for Suspected ACS).

The hierarchy of assessment in suspected ACS is as follows:

1. Identify people with ACOMI (STEMI and STEMI equivalents).
2. Identify people with NSTEMI.
3. Identify people with UA at high risk for 30-day MACE.
4. Identify people with underlying CAD in whom ACS is not confirmed.

Assessment for people with suspected ACS within an ED setting is described in the following sections.

Specific guidance for people presenting in regional/remote and primary care settings is given in section 2.10 Primary Care and Regional and Remote Presentations.

2.1.1. Initial assessment summary

The first steps in the assessment of people presenting to a healthcare setting with symptoms suspicious for ACS include the following (see practice points for setting considerations):

- Vital sign measurements including blood pressure, heart rate, respiratory rate and peripheral oxygen saturation should be recorded.
- An ECG should be reviewed by a clinician experienced in ECG interpretation to examine for evidence of ACOMI

within 10 minutes of presentation (section 2.2 Initial ECG Assessment).

- If a diagnosis of ACS is considered likely, further investigations including troponin testing should be performed (section 2.3 Biomarkers and section 2.4 Risk Assessment and Clinical Decision Pathways for Suspected ACS).
- Promptly identify people with ACOMI suitable for urgent reperfusion.
- People without clinical symptoms of ACOMI but with ECG evidence of cardiac ischaemia, and/or people who are otherwise stratified as high risk of index MI or 30-day MACE (section 2.4.1 Clinical decision pathways), should have continuous cardiac monitoring.
- In people who are symptomatic and/or haemodynamically compromised, ECGs should be performed at (a minimum of) 15-minutes intervals until the symptoms have resolved.
 - a. Additional ECGs should be performed if symptoms recur, there are changes in character or a change in their clinical condition.
- If there is no evidence of ACOMI on ECG, a targeted history and physical examination should be performed and differential diagnoses considered, particularly time critical emergencies including ruptured aortic aneurysm, pulmonary embolism, or pneumothorax (Table 2) [43,44].
 - a. A chest X-ray may be useful in identifying some other causes, including pneumonia or pneumothorax, and to assess for cardiac size or evidence of cardiac failure. Acquiring a chest X-ray should not delay urgent reperfusion. This guideline does not apply to these other time-critical emergencies [43,44].

Table 2 Differential diagnoses of acute chest pain.

Cardiac: ACS	AMI, unstable angina.
Cardiac: Other	Stable angina, myopericarditis, tachyarrhythmia, hypertensive emergencies, severe aortic stenosis, Takotsubo cardiomyopathy, cardiac trauma.
Pulmonary	Pulmonary embolism, pneumothorax (including tension), infection (pneumonia, bronchitis), pleuritis.
Vascular	Aortic dissection, expanding aortic aneurysm, sickle cell crisis.
Gastrointestinal	Oesophagitis, reflux, spasm, rupture, peptic ulcer disease, pancreatitis, cholecystitis and biliary disease.
Other	Musculoskeletal disease (including costochondritis, trauma), anxiety disorder, infectious disease (including herpes zoster).

Abbreviations: ACS, acute coronary syndromes; AMI, acute myocardial infarction.

- If the ECG is normal, and a person's symptoms are clearly attributable to a non-cardiac cause, this guideline no longer applies. Clear communication with people explaining they do not have ACS is essential and may reduce a person's and their carers' anxiety (section 2.9 [Discharge Planning and Advice](#)).

The following sections describe the subsequent processes of assessment and diagnosis if ACS is suspected.

2.1.2. History of the presenting complaint

After assessing for high-risk features on ECG and/or abnormal vital signs, a focused history is required to evaluate for symptoms suggestive of myocardial ischaemia, time of onset, and risk factors for ACS.

As the history is pivotal to assessing potential risk of ACS, barriers to clear clinician-person communication such as cultural issues, language differences, or hearing deficits should be addressed [45]. Engaging with appropriate translator services or culturally competent health workers is strongly recommended (Practice points: First Nations peoples).

Chest pain, angina equivalents and associated symptoms

Chest pain due to myocardial ischaemia is most often described as substernal discomfort or pressure which may radiate to the neck, arms or jaw and is exacerbated by exertion and relieved with rest after 15 or 20 minutes [46]. While chest pain is the most common symptom of ACS, it is not always present. In addition, many people deny actual chest pain, and refer to discomfort, pressure or heaviness which in this guideline are included under the umbrella term of chest pain.

Descriptions of myocardial ischaemia pain vary considerably, and consideration needs to be given to sex, ethnic background and culture. The description of the pain may help in determining if the person's presentation is consistent with myocardial ischaemia or unlikely to be ACS (Figure 3).

A response or lack of response to treatment (such as glyceryl trinitrate, standard analgesia or anti-acids) should not be used as a diagnostic criterion for ACS (section 2.5 [Initial Therapeutic Management](#)) [47].

Shortness of breath, fatigue, nausea, diaphoresis or vomiting are relatively common in people with ACS, with women more likely than men to present with such symptoms (Practice points: Women). Some people, particularly older adults and those with diabetes, may not describe any chest pain or discomfort, instead only reporting associated symptoms (sometimes referred to as angina or chest pain equivalents).

The terms typical and atypical have previously been used to describe cardiac ischaemic symptoms. However, given their wide variation, cardiac, possible cardiac or non-cardiac symptoms are now recommended terms (Practice points: Women and Older adults) [16].

Factors associated with myocardial infarction types

An absence of risk factors for CAD does not exclude ACS. The risk factors for the different types of AMI are listed in Table 3.




Figure 3 Probability of cardiac ischaemia based on commonly used descriptors of chest pain.

Practice points

Women

- Recognise chest pain as the most common symptom in women with ACS, occurring at similar rates to men. Be aware that associated symptoms in women may include jaw, neck, shoulder or back pain, fatigue/tiredness, nausea or vomiting, dizziness, indigestion, shortness of breath [57–59].
- Remain vigilant to the risk of misdiagnosis in women presenting with ACS [60,61]. Women are more likely than men to be misdiagnosed with non-cardiac pain and are more likely to experience delays in receiving life-saving procedures in hospital [10]. Healthcare professionals should consider potential sex bias when interpreting symptoms [62].
- Increase awareness of sex differences in ACS symptoms and presentation patterns. Clinical education and recognition of these differences may improve diagnosis and management of ACS in women.
- Consider SCAD as a potential cause of ACS, particularly in young to middle-aged women. Refer to section 3.9 [Treatment for Spontaneous Coronary Artery Dissection](#) for management recommendations [50].

Older adults

- Recognise that older age (>75 years) is an independent risk factor for ACS and other conditions with similar to ACS. Comorbidities are also more prevalent in this age group, which may complicate diagnosis and management [63].

Table 3 Factors associated with spontaneous MI with coronary pathology and oxygen supply/demand imbalance.**Factors associated with atherosclerosis [48,49]:**

- Older age (>75 years)
- Diabetes mellitus
- Hypertension
- Hypercholesterolaemia
- Obesity
- Smoking
- Socioeconomic disadvantage
- Family history of premature ASCVD (first-degree male relative aged <55 years; first-degree female relative aged <65 years)

Selected additional risk factors for atherosclerosis (for full details refer to www.cvdcheck.org.au [49]):

- Chronic inflammatory conditions, such as psoriasis, rheumatoid arthritis, lupus, or systemic sclerosis
- Familial hypercholesterolaemia confirmed by genetic testing
- Chronic kidney disease (eGFR 15–59 mL/min/1.73 m² with or without albuminuria; not treated with dialysis or kidney transplantation)
- Severe mental illness (defined as a current or recent mental health condition requiring specialist treatment, whether received or not, in the five years prior to risk assessment)
- Ethnicity (e.g. South Asian or First Nations ancestry)
- History of premature (before age 40 years) or early (before age 45 years) menopause
- History of pregnancy-associated conditions that increase later ASCVD risk, such as hypertensive disorders of pregnancy (e.g. pre-eclampsia) and gestational diabetes
- Polygenic risk score indicating higher risk of atherosclerosis
- COVID-19 (historical or current infection)

Factors associated with SCAD [50,51]:

- Female sex
- Younger age (<50 years)
- Lack of cardiovascular risk factors
- Pregnancy or postpartum
- Fibromuscular dysplasia
- Inherited connective tissue disorders

Factors associated with coronary embolism [52]:

- Aortic or mitral valve, left atrial appendage or left ventricle thrombus, vegetation or neoplasm
- Patent foramen ovale, atrial septal defect or pulmonary arteriovenous malformation with a venous source (e.g. deep vein thrombosis)
- Atrial fibrillation without adequate anticoagulation

Factors associated with coronary vasospasm [53–55]:

- Smoking
- Older age (>75 years)
- Allergy
- Chemotherapy (5-fluorouracil)
- Some illicit drugs (cocaine, methamphetamine)

Table 3. Continued**Factors associated with coronary microvascular dysfunction [56]:**

- Female sex (especially post-menopausal)
- Atherosclerotic disease
- Chronic inflammation (e.g. systemic lupus erythematosus, rheumatoid arthritis)
- Myocardial diseases
 - Hypertrophic cardiomyopathy
 - Dilated cardiomyopathy
 - Anderson-Fabry's disease
 - Amyloidosis
 - Myocarditis
 - Aortic stenosis

Factors associated with oxygen supply/demand imbalance (+/- atherosclerosis) [15]:

- Severe anaemia
- Hypotension/shock
- Sustained tachycardia or tachyarrhythmia
- Sustained bradycardia or bradyarrhythmia
- Respiratory failure
- Sepsis
- Pulmonary embolism
- Critical illness

Note: Takotsubo cardiomyopathy is not classified as MI and is not discussed in this guideline.

Abbreviations: AIDS, acquired immunodeficiency syndrome; ASCVD, atherosclerotic cardiovascular disease; eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; MI, myocardial infarction; SCAD, spontaneous coronary artery dissection.

Be aware that chest pain may not be the primary symptom of AMI in older adults. In this population, including in those with STEMI and STEMI equivalents, angina equivalents (such as shortness of breath, fatigue, or dizziness) are commonly observed [64–67].

First Nations peoples

- Recognise that First Nations peoples with ACS are typically younger, have higher rates of cardiac risk factors, experience lower intervention rates and face poorer outcomes compared with non-Indigenous Australians. These disparities highlight the importance of tailored interventions and equitable care [13,68,69].
- Provide access to First Nations healthcare practitioners, liaison officers, and culturally appropriate interpreter services within hospitals. This facilitates accurate history-taking and improves quality of care [13,68].
- Incorporate culture-specific attitudes and values into health promotional tools and offer culturally appropriate pastoral care. These steps can help to bridge cultural gaps and enhance engagement with First Nations peoples [13,68].
- Prioritise education on cultural awareness, competency and safety for healthcare professionals. Such education has

been shown to reduce unconscious bias and improve health outcomes for First Nations peoples [13,68].

2.2. Initial ECG Assessment

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people presenting with chest pain or other symptoms suggestive of ACS, record and assess an ECG for evidence of ACOMI within 10 minutes of first clinical contact.	Consensus	
In people with suspected ACS, record and assess additional ECGs if symptoms persist, change, or recur, or there is diagnostic uncertainty. For those with ongoing ischaemic symptoms and an inconclusive standard 12-lead ECG, record and assess further ECGs with right-sided and/or posterior leads.	Consensus	
In people with ongoing ischaemic symptoms or haemodynamic compromise or new ischaemic findings on ECG, continuous cardiac monitoring and defibrillator availability is recommended while assessment for ACOMI continues.	Strong	Low

Evidence supporting the recommendations

The priority is to identify people with ACOMI as soon as possible to expedite reperfusion. Urgent reperfusion can save viable myocardium and reduce morbidity and mortality.

Recording and interpreting the ECG is the most important initial investigation and should be performed within 10 minutes of clinical contact for all people presenting with chest pain or other symptoms of ACS [70]. As ECGs in people with ACOMI can show different patterns (Figure 4), they should be examined by a clinician experienced in ECG interpretation. In remote areas, an established process that enables rapid ECG interpretation is required if an experienced clinician is unavailable on site [71].

If ACOMI is not initially identified, the ECG should be further examined for features associated with higher likelihood of evolving to ACOMI or signs of myocardial

ischaemia (section 2.2.2 High-risk ECG findings; 2.2.3 Other signs of myocardial ischaemia on ECG; and Figure 4). If available, pre-hospital ECGs or ECGs recorded during previous presentations should be compared to assess for new or dynamic changes.

If features of ongoing ischaemia are present or people are stratified as high risk, close clinical and continuous monitoring of cardiac rate and rhythm with 3–5 lead electrodes of an ECG monitor should be initiated to assist early recognition of arrhythmias or cardiac arrest (section 2.4 Risk Assessment and Clinical Decision Pathways for Suspected ACS) [72]. The indications for continued monitoring should be reviewed regularly.

For people with an initial non-ischaemic ECG, resolved symptoms and initial troponin concentration equal to or below the sex-specific 99th percentile, continuous cardiac monitoring is not required (section 2.3 Biomarkers and 2.4 Risk Assessment and Clinical Decision Pathways for Suspected ACS). However, repeated ECGs should be performed either at prescribed intervals (e.g. hourly), when repeated troponin samples are collected or as guided by changes in a person’s symptoms or clinical condition.

2.2.1. ECG findings of acute coronary occlusion myocardial infarction

STE is the key ECG criterion required to institute a reperfusion strategy for people with signs or symptoms of myocardial ischaemia (Figure 4A) [73]. STE is not specific to ACOMI and may occur in other disease states, both cardiac and non-cardiac [74]. Cardiac conditions with STE without acute coronary occlusion include pericarditis, left ventricular hypertrophy (LVH), left ventricular aneurysm, left bundle branch block (LBBB), right ventricular pacing, Takotsubo or other cardiomyopathies and Brugada patterns. Non-cardiac STE conditions include normal variant STE (early repolarisation), pulmonary embolism, hyperkalaemia, hypothermia and raised intracranial pressure.

In the clinical context of myocardial ischaemia, STE should be assumed to represent ACOMI until excluded.

Recognised ECG patterns of acute coronary occlusion myocardial infarction

Comparison of ECGs with coronary angiogram results have revealed multiple ECG patterns of ACOMI beyond traditional STE criteria [22,75,76]. Recognition of the following patterns improves ECG sensitivity for acute coronary occlusion and should prompt consideration of ACOMI warranting reperfusion (Figure 4) [77]. This may require supplemental lead ECGs to interrogate electrically subtle or silent areas of the heart such as the inferior, basal, posterior and right ventricular walls (Table 4). Notable ECG findings include:

- High lateral MI manifesting with STE in non-contiguous leads due to occlusion of the first diagonal branch of the left anterior descending coronary artery (Figure 4B) (referred to as the “South African flag sign”) [78,79].







	Criteria	Supporting information and illustration	Recommendation for clinical action
A. Regional STE with reciprocal STD	STE ≥ 1 mm at the J-point in two contiguous leads in all leads other than V2-4. V2-4 STE criteria: ≥ 1.5 mm in women ≥ 2 mm in men ≥ 40 years ≥ 2.5 mm in men < 40 years		Activate reperfusion pathway
B. High lateral MI	STE I, aVL, V2 STD III (+/- II, aVF) Subtle STE V5, V6 and reciprocal changes in aVF may be seen.		Activate reperfusion pathway
C. Posterior MI	Precordial STD ≥ 0.5 mm V1-3 Confirm with posterior leads (V7,8,9) with findings of STE: • ≥ 0.5 mm in women and men ≥ 40 years • ≥ 1 mm in men < 40 years	V7, 8, 9 supplementary lead placement 	Activate reperfusion pathway
D. Right ventricular MI	STE ≥ 0.5 mm in any right-sided chest lead (V3R-V6R), but particularly V4R. STE ≥ 1 mm in men < 30 years	Right precordial supplementary lead placement 	Activate reperfusion pathway
E. De Winter T waves	J-point depression with up-sloping ST segments and tall, prominent, symmetric T waves in precordial leads, with STE (≥ 0.5 mm) in aVR and an absence of STE in precordial leads.		Activate reperfusion pathway
F. Modified Sgarbossa criteria (LBBB or paced rhythm)	Any of the following: A) Concordant STE > 1 mm in leads with positive QRS complex B) Concordant STD ≥ 1 mm V1-3 C) STE ≥ 1 mm in one or more leads at the J-point which is proportionally discordant to the preceding S wave by $> 25\%$.		Activate reperfusion pathway

Figure 4 ECG findings consistent with acute coronary occlusion myocardial infarction (ACOMI).

Abbreviations: ECG, electrocardiogram; LBBB, left bundle branch block; MI, myocardial infarction; STD, ST-segment depression; STE, ST-segment elevation.

- ST-segment depression ≥ 0.5 mm in leads V1–V3 due to ACOMI of the posterior aspect of the heart should prompt recording of posterior leads (Figure 4C) [80–82].
- STE in lead V1 due to an isolated right ventricular MI should prompt recording of right-sided ECG leads (Figure 4D) [15,83,84].
- De Winter pattern (Figure 4E) [85].
- Transient STE, manifesting as STE in ≥ 2 contiguous leads of ≥ 0.5 mm that resolves spontaneously, or after aspirin

and glyceryl trinitrate administration, may represent transient occlusion. These people should continue to be observed with continuous cardiac monitoring and serial ECGs.

Detecting new ST-segment elevation with a baseline abnormal ECG

ECG evidence for ACOMI may be difficult to discern in people with abnormal baseline ECGs, such as LBBB, right ventricular pacing or LVH.

Table 4 ECG leads associated with cardiac regions.

Cardiac region	Leads with STE	Reciprocal STD
Anterior	V3, V4	None
Anterolateral	I, aVL V3–V6	II, III aVF
Anteroseptal	V1–V4	None
Septal	V1, V2	None
Inferior	II, III, aVF	I, aVL
Right ventricular	Right-sided chest leads V3–6	
Posterior	Posterior leads V7–9	V1–V3
Lateral	I, aVL, V5, V6	II, III, aVF
High lateral	I, aVL (V2)	III (II, aVF)

Abbreviations: ECG, electrocardiogram; STE, ST-segment elevation; STD, ST-segment depression.

The validated Modified Sgarbossa criteria improves diagnosis of STE in people with LBBB or right ventricular pacing with a specificity of 99% and a sensitivity of 80% (Figure 4F) [86–88]. The modification entails excessively discordant STE with an amplitude >25% of the depth of the preceding S wave in any lead with no scoring required.

There are currently no validated methods to discern STE of ACOMI from STE seen with LVH or hypertrophic cardiomyopathy. However, clinical suspicion for ACOMI should be high in the presence of haemodynamic compromise and/or symptoms consistent with ACS.

In people with LVH, comparison with previous ECGs should be performed. If unavailable, continuous cardiac monitoring with close clinical observation and serial ECGs are required to monitor for development of acute coronary occlusion. Expert consultation should be sought for people with persisting ischaemic symptoms with equivocal ECG findings of ACOMI.

2.2.2. High-risk ECG findings

Acute coronary occlusion is a dynamic process which may not be evident on the initial ECG. Certain ECG patterns are associated with potential progression to ACOMI. These patterns call for prompt and continuous clinical and ECG monitoring.

Wellens T waves: characteristic T wave inversions in precordial leads. In a person in whom symptoms have resolved, this pattern may represent a reperfusion syndrome associated with a critical stenosis of the left anterior descending artery, known as Wellens syndrome (Figure 5A) [89]. Avoid provocative testing (e.g. exercise stress testing) and strongly consider invasive coronary angiography. If/when ischaemic symptoms return, the ECG recorded during symptoms will pseudo-normalise with more upright T waves.

Diffuse ST-segment depression across multiple leads with STE in aVR: may represent global ischaemia of various

etiologies including a left main occlusion, triple vessel disease or oxygen supply/demand mismatch ischaemia (Figure 5B) [90]. People with persisting symptoms with no identifiable alternative causes of ischaemia or who do not respond to treatment of alternative causes (e.g. hypoxia, anaemia, hypotension) should be considered for coronary angiography [91].

Hyperacute T waves: symmetrical, broad-based T waves disproportionately large to the preceding QRS complex can be the first ECG finding of an evolving MI, although its prognostic significance has been questioned (Figure 5C) [92,93]. These people should be subject to close clinical and continuous cardiac monitoring and serial 12-lead ECGs to examine for signs of ACOMI. An important differential diagnosis is hyperkalaemia (Figure 5C).

2.2.3. Other signs of myocardial ischaemia on ECG

Other ECG findings in a person with suspected myocardial ischaemia which should prompt continuous cardiac monitoring and consideration of treatment for NSTEMI/ACS are as follows.

- **ST-segment depression:** ≥ 0.5 mm at the J-point in ≥ 2 contiguous leads which is horizontal or down sloping (Figure 5D). The deeper and more widespread the depression, the more severe the ischaemia [94,95]. ST-segment depression in contiguous leads should be first considered as reciprocal change of ACOMI and the ECG examined for corresponding STE, as ST-segment depression secondary to subendocardial ischaemia does not generally localise to a regional coronary territory (Figure 4, Figure 5 and Table 4) [96]. Although ST-segment depression occurs in other conditions (e.g. LVH, hypokalaemia, digoxin use), a systematic review found it to be highly specific (97.2%–99.3%) but poorly sensitive (16.6%–20.0%) for ischaemia [97].
- **T wave abnormalities:** including dynamic inversion or flattening (Figure 5E). New T wave inversion compared to a previous ECG or dynamic T wave changes during serial ECGs may represent ischaemia. Specificity of T wave inversion for ischaemia is higher in the context of other signs of ischaemia on the ECG [98].

Computer-assisted ECG interpretation

No international standardised system for computer interpretation of ECGs currently exists. ECG machine manufacturers use different algorithms with varying sensitivity and specificity for diagnosing cardiac conditions. Computer errors specific to ACS and ACOMI diagnosis include attribution of Q waves in LVH, LBBB, and/or dilated or hypertrophic cardiomyopathy to ACOMI. Other errors include an inability to discriminate STE of early repolarisation, pericarditis, or LBBBs from ACOMI [99]. ECG interpretation by a clinician who can incorporate the person-specific clinical context into the assessment is vital.





	Criteria	Supporting information and illustration	Recommendation for clinical action
A. Wellens criteria	Isoelectric or minimally elevated J-point <1 mm AND either biphasic T waves V2, V3 (Type A) or symmetric TWI V2, V3 (sometimes V1, V4, V5, V6) (Type B).	 Pattern appears when pain free. "Pseudonormalisation" of ECG changes with symptoms of ischaemia (e.g. chest pain).	Urgent consultation with cardiology. Continuous cardiac monitoring and serial ECGs. No functional testing. Low threshold for invasive angiography.
B. Diffuse STD in multiple leads and STE in aVR	STE aVR >1 mm Multi-lead STD I, II, aVL and V1-6 Absence of STE in other leads.		Consider early reperfusion if ECG findings persist despite management of symptoms or seek alternative cause. Correct hypotension, hypoxia, anaemia.
C. Hyperacute T waves	Large, symmetrical, broad-based T waves. Regional distribution.	Conditions associated with tall T waves  Symmetric, narrow-based, pointed Asymmetric, not narrow	Continuous cardiac monitoring and serial ECGs.
D. STD	Horizontal or down-sloping STD ≥0.5 mm at the J-point in ≥2 leads is suggestive of subendocardial ischaemia. STD which is sustained for ≥0.08 s in ≥1 lead (except aVR) is most significant.	ST segment depression  upsloping downsloping horizontal	Continuous cardiac monitoring and serial ECGs. If persists or worsens treat as per NSTEMI recommendations.
E. TWI	Significant for ischaemia if ≥1 mm deep; present in ≥2 contiguous leads or changing acutely in leads with a normally upright T wave (all except lead III, aVR and V1). Wide differential. If new or dynamic, consistent with ischaemia.		Continuous cardiac monitoring and serial ECGs.

Figure 5 High-risk ECG findings for ACS and findings suggestive of cardiac ischaemia.

Abbreviations: ECG, electrocardiogram; NSTEMI, non-ST-segment elevation acute coronary syndromes; STD, ST-segment depression; STE, ST-segment elevation; TWI, T wave inversion.

2.2.4. Continuous ECG monitoring

In people without ongoing symptoms, normal or non-ischaemic ECG changes and initial normal troponin values, continuous ECG monitoring is not required. High-risk features in people with suspected ACS who require ongoing ECG monitoring are listed in [Table 5](#).

Practice points

- Do not rely on an initial normal ECG to exclude ACS. If myocardial ischaemia is strongly suspected, record and interpret serial ECGs.

Table 5 High-risk clinical features for people with suspected ACS requiring ongoing ECG monitoring.

Haemodynamic instability or cardiogenic shock
Recurrent or ongoing chest pain refractory to medical treatment
Cardiac arrest
Recurrent dynamic ST-T wave changes or other changes consistent with myocardial ischaemia or infarction on ECG
Arrhythmias (e.g. sustained ventricular tachycardia, high degree atrioventricular block)
Mechanical complications of MI (e.g. new systolic murmur)
Acute heart failure

Abbreviations: ACS, acute coronary syndromes; ECG, electrocardiogram; MI, myocardial infarction.

- Do not delay treatment decisions/treatment in people with symptoms of ischaemia and clear evidence of ACOMI on ECG, while waiting for troponin test results.
- Do ensure consistent lead placement when performing serial ECGs to prevent artefactual errors in interpretation.

2.2.5. Future direction

Artificial intelligence (AI) and machine learning applied to ECG interpretation and linked with clinical data are currently being researched with the aim of delivering a more accurate and timely assessment of ACS and ACOMI [100].

2.3. Biomarkers

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with suspected ACS, evaluation with high-sensitivity cardiac troponin (hs-cTn) assays is recommended.	Strong	High
Elevated hs-cTn values should be defined using sex-specific >99 th percentiles.	Consensus	
Apply the assay-specific troponin values relevant to the cTn assay being used.	Consensus	
When evaluating changes (deltas) in troponin values, serial results from a single assay must be used.	Consensus	

Evidence supporting the recommendations

Cardiac troponin I (cTnI) or cardiac troponin T (cTnT) is the biomarker of choice in the diagnosis of ACS due to its organ-specific amino acid sequence, parts of which act as targets for assays using monoclonal antibodies [15,101,102].

Cardiac troponin assays have evolved from the 1990s to deliver improved sensitivity in detecting troponin. Currently, the most analytically sensitive assays preferred for clinical use are high-sensitivity assays [15,103]. A high-sensitivity assay is more precise than earlier assays and can detect very low troponin concentrations, with measures of imprecision or % coefficient of variation of $\leq 10\%$ at the sex-specific 99th percentiles.

Evaluation with hs-cTn assays enable more rapid detection or exclusion of myocardial injury and increase diagnostic accuracy for MI compared with earlier generation of cTn assays called contemporary (conventional) troponin assays. The ability to detect very low troponin values with accuracy has been used to achieve safe, early rule out of MI and rapid discharge from the ED based on assay-specific metrics lower than the 99th percentile (section 2.4 Risk Assessment and Clinical Decision Pathways for Suspected ACS) [104–106]. Hs-cTn assays also facilitate use of sex-specific 99th percentiles, recognising the differing trajectories of cTn in women and men across the life course [107–109].

Contemporary assays are still used in smaller hospitals around Australia, including point-of-care (POC) contemporary troponin assays in many regional and remote settings. Their lower sensitivity means they should be used in combination with clinical scores when risk stratifying people with suspected ACS (section 2.4 Risk Assessment and Clinical Decision Pathways for Suspected ACS). POC hs-cTn assays have been developed and will likely become increasingly available [110–113].

2.3.1. Analytic properties of cardiac troponin assays

The cut-off or threshold used to define an elevated cTn value which is diagnostic of myocardial injury is the 99th percentile of a healthy population and this value is assay-specific [15]. Within Australia, different units are used to report contemporary ($\mu\text{g/L}$) and high-sensitivity troponin assays (ng/L), reflecting the lower sensitivity of the older assays (Table 6). Other metrics of assay performance include limit of detection and limit of blank (Figure 6).

Use of hs-cTn assays has shown that women have lower circulating normal cTn concentrations, resulting in sex-specific differences in the 99th percentile values between women and men [115]. Consequently, use of single overall cut-off points to determine myocardial injury and potentially MI in women will result in underdiagnosis [116].

In transgender women and men, the use of sex hormones, rather than sex assigned at birth, may impact on myocardial mass and influence hs-cTn reference ranges [117]. To maintain safety, the reference range should be based upon the lower cut-off points (female), however more research is required [117].

Table 6 Contemporary vs high-sensitivity cTn assay features.

Characteristic	Contemporary troponin assays*	High-sensitivity troponin assays
Precision	Variable	≤10% CV at 99 th percentile
Detection	~ 20–50% of healthy reference population	≥50% of healthy reference population
Units	Micrograms per litre (µg/L)	Nanogram per litre (ng/L)
Sex-specific 99 th percentiles	No. Overall 99 th percentile values only	Yes. Female and male 99 th percentiles
Timing of serial testing for MI using 99 th percentile	0 and 6–8 hours	0 and 3 hours
Single low-risk troponin values for MI*	No	Yes
Ability to use in rapid, early assessment strategies	No	Yes
Platform	POC and laboratory-based	POC and laboratory-based

*Using a contemporary assay, if a person presents symptom-free for >6–8 hours, only one test needed. If ≤99th percentile at 6–8 hours, no second test is required. If >99th, a second test is needed.

Abbreviations: cTn, cardiac troponin; CV, coefficient of variation; MI, myocardial infarction; POC, point-of-care.

Despite observed increases in the 99th percentile of cTn in people aged over 60 years, changes to the 99th percentile based on age have not been implemented in clinical practice [115,118–120].

2.3.2. Point-of-care troponin assays

POC troponin assays may lead to more timely management of people with suspected ACS, with comparable safety to laboratory-based assays (Table 7 in section 2.4.1.1 High-sensitivity troponin-based clinical decision pathways) [110,111,113,121]. In comparison, use of contemporary POC assays requires serial measurements over 6–8 hours in people with suspected ACS [122].

Evaluations support rapid assessment using POC hs-cTn assays [110,111,113,123]. Knowledge of POC hs-cTn assays is rapidly evolving. Their use in clinical decision pathways in EDs, outpatient clinics and primary care may become more common given the clinical safety and cost efficacy of such assays [121].

2.3.3. Clinical interpretation of troponin values

cTn results must be carefully interpreted within the person-specific clinical context, including ECG findings (Figure 7) [16]. Serial measurements are required to identify if there is a stable or changing pattern associated with an elevated cTn. Stable elevations are seen with chronic myocardial injury but may also be seen in the plateau phase of troponin release in MI (e.g. in people with delayed presentation). People with changing values (both increasing and decreasing) warrant evaluation for evidence of myocardial ischaemia. To note, acute myocardial injury due to other causes (e.g. acute heart failure, pulmonary embolism) needs to be considered when clinically appropriate. Differentiation between types of MI also requires careful evaluation, as does differentiation from myocardial injury (Figure 7) [124].

The introduction of hs-cTn assays has led to a decrease in the frequency of UA, defined with cTn values ≤99th percentile. Improved detection of small changes in troponin




Figure 6 Various analytic definitions for troponin assays. Adapted with permission from Januzzi *et al.* [114]. Abbreviation: cTn, cardiac troponin.

Table 7 Troponin assay and metrics for use in 0/1- and 0/2-hour sampling strategies.

Assay	Sampling timepoints	A	B	C	D	E	F Female 99 th percentile	G Male 99 th percentile
Hs-cTnI (Architect; Abbott)	0/1h	<4	<5	<2	≥64	≥6	16	34
	0/2h	<4	<6	<2	≥64	≥15	16	34
Hs-cTnI (Access; Beckman Coulter)	0/1h	<4	<5	<4	≥50	≥15	11	20
	0/2h	<4	<5	<5	≥50	≥20	11	20
Hs-cTnI (Centaur; Siemens)	0/1h	<3	<6	<3	≥120	≥12	40	58
	0/2h	<3	<8	<7	≥120	≥20	40	58
Hs-cTnI (Atellica; Siemens)	0/1h	<4	<6	<3	≥120	≥12	39	54
	0/2h	NA	NA	NA	NA	NA	NA	NA
Hs-cTnI (Vitros; Clinical Diagnostics)	0/1h	<1	<2	<1	≥40	≥4	9	12
	0/2h	<1	<2	<3	≥40	≥5	9	12
Hs-cTnT (Elecsys; Roche)	0/1h	<5	<12	<3	≥52	≥5	9	17
	0/2h	<5	<14	<4	≥52	≥10	9	17
Hs-cTnI (Pathfast; LSI Medience)*	0/1h	<3	<4	<3	≥90	≥20	20	30
	0/2h	<3	TBD	TBD	≥90	TBD	20	30
Hs-cTnI (Triage True; Quidel)*	0/1h	<4	<5	<3	≥60	≥8	14	26
	0/2h	<4	TBD	TBD	≥60	TBD	14	26
Hs-cTnI (VTLi, Siemens)*	0/1h	<4	TBD	TBD	TBD	TBD	18	27
	0/2h	<4	<6	<5	≥60	≥15	18	27

*Point of care assay. 99th percentiles presented in column F/G are as per the International Federation of Clinical Chemistry tables rounded to the nearest whole number [40,42,105,123,148,151,153–155,169,170,176–185].

Abbreviations: hs-cTnI, high-sensitivity cardiac troponin I; hs-cTnT, high-sensitivity cardiac troponin T; NA, not available; TBD, to be determined.

levels has meant that a proportion of people previously classified as UA have been reclassified as MI [125].

2.3.4. Time from onset of coronary occlusion vs. symptom onset

In the setting of ACOMI, there may be a delay in elevation of cTn levels. However, this timeframe has become shorter with the ability of hs-cTn assays to detect lower concentrations of circulating troponin (Figure 8). Repeat troponin testing is required for people with ongoing or recurrent symptoms or where there is a high suspicion of ACS.

2.3.5. Comparing results from different troponin assays

cTn assays developed by various diagnostic companies use different antibody combinations, resulting in differences in numerical results for the same amount of circulating troponin. Significant differences exist in the categorisation of people based on different hs-cTn assays [126]. Results of one assay cannot be interpreted using the reference range of a different assay. Serial testing of cTn concentrations can only be interpreted when measured using the same assay.

Differences between troponin T and I assays

Both high-sensitivity cardiac troponin I (hs-cTnI) and high-sensitivity cardiac troponin T (hs-cTnT) provide comparable diagnostic accuracy in the early diagnosis of MI [127]. Troponin T is more likely to be elevated with poor renal

function (section 2.3.5 Comparing results from different troponin assays - Renal disease) and chronic muscular diseases (e.g. chronic myopathy, myositis). This is possibly due to re-expression of cTnT in the diseased muscle or due to cross reactivity of the cTnT assay with a fragment of skeletal muscle troponin T [128,129].

Non-MI causes of troponin elevation

Numerous ischaemic, non-coronary cardiac, and non-cardiac causes of myocardial injury can result in elevated cTn concentrations (Figure 9) [15,102,130,131]. Life-threatening conditions including aortic dissection and pulmonary embolism may result in elevated cTn values. Cardiac troponin elevation indicates myocardial injury but is not specific to the underlying pathophysiology [15].

Renal disease

Chronically elevated cTn concentrations are often reported with decreased renal function, more so with cTnT than cTnI. Published guidelines for MI diagnosis in people undergoing haemodialysis recommend serial cTn measurements, rather than management according to an elevated baseline value [132].

False positive and false negative cardiac troponin results

Analytically false positive and false negative cTn results are uncommon. False positive results for cTn may occur due to




Figure 7 Clinical interpretation of high-sensitivity cardiac troponin (hs-cTn) results. Adapted with permission from the Accelerated Chest Pain Risk Evaluation (ACRE) Project, Clinical Excellence Queensland, Queensland Health. For guidance on identifying evidence for acute myocardial ischaemia, refer to sections 2.2.2 High-risk ECG findings and 2.2.3 Other signs of myocardial ischaemia on ECG.

Abbreviations: ACS, acute coronary syndromes; CAD, coronary artery disease; MI, myocardial infarction; SCAD, spontaneous coronary artery dissection.

antibody interference from macrotroponins. Macrotroponins are high-molecular weight complexes of cTn fragments that bind to immunoglobulins (cTn autoantibodies) causing delayed troponin clearance. In addition, heterophilic antibodies can bind to cTn assay antibodies, causing positive signals in the absence of cTn. The causes of heterophilic antibodies are largely unknown, however they may be found in people with rheumatoid arthritis, and viral infections such as Epstein Barr virus and cytomegalovirus [133]. Conversely,

severe haemolysis and other substances in plasma, like biotin, may result in false negative results [134,135].

When cTn results and the clinical presentation are discordant, the hospital's laboratory should be contacted to exclude rare false positive cTn results [134].

Other biomarkers

Additional biomarkers exist but are not used to diagnose MI. There is no role for creatine kinase MB-isoenzyme (CK-MB), including in identifying reinfarction in people with AMI [136].

2.4. Risk Assessment and Clinical Decision Pathways for Suspected ACS

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
People with symptoms and ECG changes consistent with ACOMI require urgent reperfusion. Do not use clinical decision pathway (CDP).	Strong	Very Low
People presenting with acute chest pain or other symptoms suggestive of ACS should receive care guided by an evidence-based CDP that includes assay-specific troponin results to categorise people as high, intermediate, or low risk.	Consensus	
A high-sensitivity troponin-based clinical decision pathway is recommended, using the 0/1-hour or 0/2-hour strategy, or the <i>High-sensitivity troponin in the evaluation of patients with acute coronary syndrome</i> (High-STEACS) algorithm.	Consensus	
When contemporary troponin assays are used, a CDP incorporating formal clinical score-based risk stratification is recommended.	Consensus	

Evidence supporting the recommendations

For people with suspected ACS, a clinical decision pathway improves care and health service efficiency. The aim is to identify people with MI and those at high risk of MACE within 30 days. The latter may require further investigation or longer periods of observation before discharge [137]. A defined process also reduces unnecessary investigations and treatment and decreases avoidable inpatient admissions for people at low risk of 30-day MACE. Evidence suggests missed MI and/or 30-day MACE rates of <1% in people discharged from the ED following structured

risk assessment incorporating clinical information, cTn and ECG findings [39,138–140].

People with ECGs suggestive of ischaemia, including those at high risk of progressing to ACOMI, should receive inpatient evaluation (section 2.2 [Initial ECG Assessment](#)).

Various clinical decision pathways are available for people in whom ACOMI is initially excluded and in the absence of ischaemic ECG findings. Some pathways focus on optimum use of hs-cTn results alone (section 2.4.1.1 [High-sensitivity troponin-based clinical decision pathways](#)), while others use a clinical risk scoring system incorporating contemporary cTn values (section 2.4.1.2 [Clinical score-based clinical decision pathways](#)). Examples of the latter include the *Emergency department assessment of chest pain score* (EDACS) and the *History, ECG, age, risk factors and troponin* (HEART) score (section 2.4.1.2 [Clinical score-based clinical decision pathways](#) and [Supplementary Material B2](#)) [141].

2.4.1. Clinical decision pathways

Risk stratification

A three-tiered stratification is recommended, grouping people into high, intermediate, or low risk of MACE including MI ([Figure 10](#)). In addition to cTn measurement, all approaches incorporate history and physical examination findings, and ECG results (normal, non-ischaemic, or unchanged from previously).

- **High risk:** the probability of an event, most commonly MI, within 30 days is higher than 50–70% (positive predictive value >50%–70%) [142]. These people require admission and further evaluation.

Importantly, not all high-risk people are ultimately determined to have an MI. Clear communication about risk of MI is essential. Refer to section 3 [Hospital Care and Reperfusion](#) for further evaluation and management of high-risk people.

- **Intermediate risk:** for people identified as intermediate risk using the hs-cTn-based CDP (0/1 or 0/2-hour strategies), 30-day MACE rates vary between 2–22%. These people require further evaluation [42,143,144]. Intermediate-risk people will have either normal ($\leq 99^{\text{th}}$ percentile) or elevated ($> 99^{\text{th}}$ percentile) cTn values, with the latter requiring evaluation in an inpatient setting. For intermediate-risk people with serial cTn results $\leq 99^{\text{th}}$ percentile, outpatient testing is acceptable as the 30-day MACE rate in this group is <2% (section 2.6 [Further Diagnostic Testing for People with Suspected ACS](#)) [39].

People with elevated but unchanging cTn values consistent with chronic myocardial injury are out of the scope of this guideline (section 2.3 [Biomarkers](#)). However, it is important to note these people have an elevated risk of future cardiac events than those without myocardial injury [15,145].

- **Low risk:** the risk of MACE within 30 days is <1% using either a hs-cTn-based CDP or a clinical risk score-based CDP ([Table 7](#) and [Supplementary Material B2](#)). In general, hs-cTn strategies safely define a larger proportion of people as low-risk than clinical risk score pathways that




Figure 8 Early troponin kinetics in people with acute myocardial infarction. Abbreviations: cTn, cardiac troponin; URL, upper reference limit.

use contemporary cTn assays. When defined as low-risk using a hs-cTn strategy, further testing to exclude AMI is not required [16,146,147].

Risk stratification for people with suspected ACS: identifying myocardial infarction and unstable angina

For people without findings consistent with ACOMI on the initial ECG, further assessment aims to identify NSTEMI and UA through evaluation of clinical features with additional ECG and troponin testing. NSTEMI is associated with elevated cTn values.

People with ongoing or recurrent ischaemic symptoms, or new ECG findings suggestive of ischaemia during initial or repeat testing, should be considered high risk for ACS. Serial cTn testing should be pursued if clinical suspicion of ACS remains high, as late increases in cTn have been described in <1% of people with NSTEMI [148].

2.4.1.1. High-sensitivity troponin-based clinical decision pathways

Strategies incorporating hs-cTn assay results rather than contemporary troponin assays are recommended for safe, rapid decision making. Overall, hs-cTn-based risk stratification identifies ~50–65% of people presenting with suspected ACS as low risk, ~20–30% as intermediate risk and

~15–25% as high risk for MACE [149,150]. When used in a validated algorithm combined with non-ischaemic ECG changes, safety and efficacy are achieved without using clinical risk scores [16,142].

0-, 0/1-, and 0/2-hour strategies have been developed for most hs-cTn assays and the values are assay-specific (Figure 11, Table 7 and Supplementary Material B1) [42,106,142,143,148,151–158].

Single high-sensitivity cardiac troponin measurements

A single hs-cTn measurement is not suitable for people with symptom onset <2 hours. These people require serial testing [23,106,143,153,155,159–161]. In people with symptom onset ≥2 hours, combining a single hs-cTn result with non-ischaemic ECG findings can very safely identify 20–50% of people as low risk [42,46,105,106,143,147,149–152,155,161–168].

A single measurement approach has been extensively validated using both hs-cTnT and hs-cTnI assays, with high negative predictive value and sensitivity for excluding index MI and a <1% risk of MACE during short- and longer-term follow-up [40,104,105,147,149,161,168–171]. Unlike hs-cTn assays, using a single contemporary troponin measurement to assess risk has not been validated [172].

Clinical manifestation	Possible causes of elevation	Possible mechanism		
AMI	Prolonged ischaemia	Necrosis	Apoptosis and necroptosis	Severity or damage
Acute HF				
Pulmonary embolism				
Chest trauma or surgery	Mechanical cell destruction, local inflammation			
Stroke or brain trauma	Catecholamine-derived myocyte overload or ischaemia due to type 2 MI			
Cardiotoxicity	Cardiotoxic agents (drugs, CO, poisons)			
Myocarditis, endocarditis	Inflammation		Reversible troponin leakage (cell stretching, cell wounds, bleb formation)	
Sepsis				
Atrial fibrillation	Brief ischaemia Muscle overload			
Chronic HF				
Stable CAD				
Physical exercise				
Renal failure	Impaired clearance			
Skeletal muscle disorders	Expression of cTnT in regenerative skeletal muscles			

Severity of damage

Figure 9 Conditions associated with troponin elevation. Adapted from Katrukha et al. [102].

Abbreviations: AMI, acute myocardial infarction; CAD, coronary artery disease; CO, carbon monoxide; cTnT, cardiac troponin T; HF, heart failure; MI, myocardial infarction.

0/1-, and 0/2-hour strategies

For people identified as being at intermediate risk using the 0/1- or 0/2-hour strategies, index or 30-day MACE rates may vary between 2–22%, and additional evaluation is required (section 2.6 [Further Diagnostic Testing for People with Suspected ACS](#)) [42,143,144]. For people with normal serial cTn values, 30-day MACE rates are $\leq 2\%$ [39].

While mostly large observational studies have evaluated 0/1- and 0/2-hour strategies, randomised trials of the 0/1-hour strategy have reported 30-day MI and death rates of $<1\%$ [42,154,173–175]. In addition to values being assay dependent, the change thresholds (deltas) for the 0/1- and 0/2-hour algorithms are time dependent. This means it is crucial that blood specimens are collected within the specified windows (Table 7).

In most hospitals, delays in central laboratory assay turnaround times render the 0/1-hour strategy impractical. POC hs-cTn assays may overcome this limitation but are not yet widely available. A 0/2-hour strategy is therefore currently the most practical option in most settings.

High-STEACS algorithm

The United Kingdom (UK) High-STEACS algorithm is a well-validated, safe and effective approach using a variety of hs-

cTn assays [40,147,150,154,160]. Further details are described in the [Supplementary Material B1](#).

2.4.1.2. Clinical score-based clinical decision pathways Sites using contemporary cTn assays

Incorporation of a clinical score-based tool (e.g. EDACS, HEART) in assessing people with suspected ACS is essential if using a contemporary cTn assay. EDACS and the HEART score are the most widely validated strategies and have high sensitivity for index AMI and 30-day MACE (see [Supplementary Material B2](#)) [163,165,186–194]. However, when compared to hs-cTn-based CDP, smaller numbers of people will be identified as low/intermediate risk and additional testing may occur without an improvement in MACE [42,46,106,151,152,166,167,172,178,195,196]. Furthermore, because sex-specific considerations are not included in all scoring systems, their effectiveness in men and women may not be equal [197]. Further information on these clinical based scores is provided in the [Supplementary Material B2](#).

2.4.2. Implementing a clinical decision pathway for suspected ACS

Implementation of CDPs for suspected ACS, especially CDPs using hs-cTn assays rather than clinical risk scores, confers




Figure 10 Assessment process for people with suspected ACS.

Abbreviations: ACOMI, acute coronary occlusion myocardial infarction; ACS, acute coronary syndromes; AMI, acute myocardial infarction; CDP, clinical decision pathway; ECG, electrocardiogram; MACE, major adverse cardiovascular events.

significant benefits for people and health care systems, and requires the engagement of multidisciplinary teams [23,39,146,175,189,190,198–202].

In an Australian randomised controlled trial (RCT) using hs-cTnT, the 0/1-hour strategy resulted in more frequent ED discharge (45% vs 32%; $p < 0.001$) and a reduced ED length of stay ($p < 0.001$). Similar clinical outcomes occurred at 30 days ($p = 0.001$ for noninferiority) compared with a usual care approach using 0/3-hour cTn measurements with an hs-cTnT threshold of ≥ 30 ng/L [173]. A large, randomised trial showed failure to follow recommended management for low-risk people resulted in substantial increases in resource use with no differences in 30-day MACE [146].

Centres choosing to implement an alternate strategy to the recommended CDPs should validate this CDP. Validation should include assessment of 30-day mortality and representation with confirmed ACS in all people with chest pain.

Practice points

Women

- Apply sex-specific 99th percentile upper reference limit when using hs-cTn assays (Figure 11) [15,40,42,116,156,203].
 - Women are frequently misdiagnosed with having non-ischaemic chest pain, and their ACS risk is often underestimated [41,45,197,204,205]. This is due in part

to traditional risk tools lacking sex-specific considerations and clinician bias.

Older adults

- Use uniform hs-cTn cut-offs for clinical assessment, recognising that concentrations increase with age in healthy people. This may result in fewer older adults being deemed at low risk for MI [15].
 - In older people (≥ 65 years) with comorbidities such as renal impairment, the specificity of hs-cTn results for MI is reduced [179,203,206,207].

First Nations peoples

- Use a single hs-cTn measurement in First Nations peoples to identify people as low risk of MI and 30-day MACE [208].
- Be cautious of implementing the HEART score and IMPACT pathways, which have been evaluated in small studies in First Nations populations (see [Supplementary Material B2](#)) [209].
- Investigate all First Nations adults (18 years and over) with suspected ACS for underlying CAD, given their high risk of future cardiac events [210,211].

People with renal impairment

- Use hs-cTn-based strategies in people with renal dysfunction, noting that fewer individuals will be classified as low risk compared to other approaches [206,207].




Figure 11 0/2-hour testing recommendations.

Note: the 0/2-hour time points are shown in this figure. If using a 0/1-hour strategy, change timeframes accordingly.

[#]Refer to Table 7 for interpretation of cTn assay-specific values and sex-specific 99th percentiles.

*All people with symptom onset <2 hours need serial testing. People with ongoing symptoms should be assessed according to high-risk criteria.

Abbreviations: ACO, acute coronary occlusion; ACS, acute coronary syndromes; cTn, cardiac troponin; ECG, electrocardiogram.

- Elevations in cTn are common in this population, leading to their exclusion from many assessment trials [212]. The safety of hs-cTn-based strategies appears to be similar in people with and without renal dysfunction.

2.4.3. Future direction

Newer strategies for individualised determination of likelihood of MI

Newer strategies to determine risk of MI have been developed based on large international datasets using machine learning techniques. These include the MI³ algorithm study (derived in 3,013 people and validated in 7,998 people), the ARTEMIS study (derived in 2,575 people and validated in 23,411 people) and the CoDE-ACS study (derived in 10,038 people and externally validated in 3,035 people) [213–215]. Such strategies use additional information (e.g. specific interval time of cTn testing, biometric measurements). Validation studies suggest large proportions of people can be defined as low risk, with improved specificity for MI in high-risk people.

2.5. Initial Therapeutic Management

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In all people with suspected or confirmed ACS, give aspirin (300 mg orally, dissolved or chewed) unless contraindicated.	Strong	High
People with suspected or confirmed ACS with oxygen saturation (SpO ₂) ≥90% do not require oxygen therapy.	Strong	Moderate
In people with suspected or confirmed ACS receiving oxygen therapy, SpO ₂ should not exceed 96%.	Strong	Moderate

(continued).

Recommendation	Strength of recommendation	Certainty of evidence
In the presence of ongoing chest pain, give glyceryl trinitrate sublingual tablet or spray every 5 minutes for up to three doses if no contraindications exist.	Consensus	
In people with chest pain and in the absence of contraindications, it is reasonable to administer intravenous (IV) fentanyl or morphine boluses.	Consensus	

Evidence supporting the recommendations

Aspirin

Large meta-analyses have confirmed that the benefits of aspirin in reducing the risk of serious vascular events (vascular death, MI and stroke) in people with known ASCVD outweigh the small increased risk of major bleeding [216,217]. Although maintenance doses of 100 mg are as effective as larger doses, a loading dose of 300 mg is recommended. This is based on pharmacokinetic data showing that a larger loading dose is required to completely inhibit the thromboxane mediated pathway of platelet activation (section 3.4 Antiplatelet Therapy in the Acute Phase) [218].

Oxygen therapy

Two large pragmatic randomised trials have shown that the routine use of supplemental oxygen in people with suspected ACS without hypoxaemia does not improve mortality at 30 days or 12 months [219,220]. In addition, a meta-analysis incorporating one of these and several earlier smaller studies has found that oxygen therapy is associated with a greater incidence of recurrent MI and coronary revascularisation at 6–12 months. This study also reported evidence of a dose response relationship between oxygen saturation and increased mortality in acutely ill people and people in intensive care, including those with MI. Thus, caution against achieving higher saturations in these groups is advised [221].

Practice points

Oxygen therapy

- Provide oxygen therapy routinely if oxygen saturation falls below 90%, as hypoxaemia at this level is assumed to contribute to coronary ischaemia. The clinical outcome benefits remain uncertain [219].
- Recognise that oxygen therapy is commonly administered when oxygen saturation is between 90–92%, although its benefit is unknown [222–224].
- Exercise caution people with chronic obstructive pulmonary disease (COPD) when administering supplemental

oxygen, aiming for a target arterial oxygen saturation (SaO₂) of approximately 88–92%.

Nitrates

- Use IV glyceryl trinitrate for more effective symptom relief in acute ischaemia compared to the sublingual form, but be aware that it does not alter prognosis [225,226].
- Do not administer glyceryl trinitrate in cases of hypotension, right ventricular infarction, or recent use of a phosphodiesterase 5 inhibitor (sildenafil, vardenafil or tadalafil). Consider alternative therapy if symptoms persist.

Opioid analgesia

- Titrate doses of opioid analgesia to resolution of chest pain, adjusting for individual needs based on age, comorbidities, and concurrent medicine use [227–229].
- Consider fentanyl for its short time to peak effect, short duration of action, and minimal impact on histamine release.
 - Note that both morphine and fentanyl are associated with increased platelet reactivity, reduced antiplatelet effect of P2Y₁₂ inhibitors and slower absorption of oral medicines such as ticagrelor during the early hours of ACS [228,230–232].

Other medicines

- Do not administer non-steroidal anti-inflammatory medicines (NSAIDs) in confirmed ACS, especially in the early phase, due to the increased risk of MACE [233,234].
- Do not initiate additional antiplatelet, anticoagulation or beta blocker therapies without a confirmed or probable diagnosis of ACS (section 3.4 Antiplatelet Therapy in the Acute Phase and 3.5 Anticoagulant Therapy in the Acute Phase).

2.6. Further Diagnostic Testing for People with Suspected ACS

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people at intermediate risk (as defined by a validated CDP) with elevated troponin concentrations (>99 th percentile), inpatient investigation is recommended.	Strong	Moderate
In people at intermediate risk without elevated troponin concentrations, consider outpatient investigation with non-invasive testing.	Consensus	
In people at low risk who remain symptom-free, further cardiac testing for CAD is not routinely required.	Consensus	

Evidence supporting the recommendations

In people at intermediate risk of ACS, invasive angiography or non-invasive cardiac testing allows further risk stratification. These tests may also help establish alternative aetiology of chest pain and future risk of ACS beyond 30 days.

Invasive or non-invasive inpatient testing is recommended for people at intermediate risk with elevated hs-cTn concentrations above the sex-specific 99th percentile (Figure 11) because of the relatively high rate of a cardiac event within 30 days (2–22%, section 2.4 Risk Assessment and Clinical Decision Pathways for Suspected ACS) [235,236].

Outpatient non-invasive testing can be considered (ideally within 30 days) for people at intermediate risk with serial

values $\leq 99^{\text{th}}$ percentile, in whom the 30-day event rate is substantially lower (<2%) [39].

Non-invasive testing is not routinely recommended in people classified as low risk. The criteria used to define low-risk people in whom further investigation is not warranted have varied [16,146,147,237,238]. In people stratified as low risk using CDPs recommended in this guideline (section 2.4 Risk Assessment and Clinical Decision Pathways for Suspected ACS) the likelihood of a cardiac event over the next 2 years is low. Further cardiac anatomic or functional investigations are unnecessary, at least in the short term [42,110,149,160,169,239].

General practitioner follow-up is recommended to ensure resolution and appropriate treatment of the presenting

Table 8 Clinical considerations for the use of non-invasive testing for people at intermediate risk. Adapted with permission from Kontos et al. [246].

Ischaemic test modality	Strengths	Limitations	Considerations for use
Exercise stress ECG	• Low cost • Wide availability • Assessment of exercise symptoms, capacity • No ionising radiation	• Decreased accuracy compared with anatomical and stress-imaging tests • Requires interpretable ECG and ability to exercise sufficiently • Higher false positive rate in females	• Rarely recommended as a stand-alone test in people with known CAD, inability to exercise, or significant arrhythmias • Contraindicated in severe symptomatic aortic stenosis or severe hypertension
Stress echocardiography	• Wide availability • High diagnostic specificity • Assessment of ventricular and valvular function • No ionising radiation	• Decreased sensitivity compared with anatomical and other stress-imaging tests • Dependent on good image quality • Requires dobutamine in people unable to exercise	• Known good image quality and ability to exercise • Consider use of an ultrasound-enhancing agent to improve endocardial visualisation • Known moderate or severe valvular disease
Stress/rest SPECT	• Wide availability • Relatively high diagnostic sensitivity • Assessment of ventricular function	• Increased artefacts resulting in non-diagnostic results and decreased diagnostic accuracy compared with stress/rest PET • Radiation exposure	• Known CAD or high coronary artery calcification burden on chest computed tomography (CT) imaging • Preferred over stress echocardiography in people who cannot exercise or who have significant exercise-induced bronchospasm
Stress/rest PET	• High diagnostic accuracy • Lower radiation exposure than SPECT • Measures myocardial blood flow and flow reserve • Assessment of ventricular function	• Limited availability • Relatively higher cost • Lack of exercise assessment	• Known CAD or high coronary artery calcification burden on chest CT imaging • Preferred over SPECT due to higher diagnostic accuracy and lower rate of nondiagnostic test results

Table 8. (continued).

Ischaemic test modality	Strengths	Limitations	Considerations for use
Stress CMR	• High diagnostic accuracy • Accurate assessment of chamber sizes, ventricular and valvular function • Diagnosis of prior infarction, scar, fibrosis • Measurement of myocardial blood flow and flow reserve is possible (but not widely available currently) • No ionising radiation	• Limited availability • Relatively higher cost • Lack of exercise assessment • Long scan acquisition times • Claustrophobia • Often not immediately available to people with pacemakers or ICDs • Contraindicated in people with significant renal dysfunction	• Known CAD and/or cardiomyopathy • Elevated troponin not thought to be secondary to ACS • Known moderate or severe valvular disease • No significant renal dysfunction
CTCA	• High diagnostic accuracy • Does not require exercise • Identifies non-obstructive CAD	• Radiation exposure • Lack of exercise assessment • Contraindicated in people with significant renal dysfunction • Blooming artefacts when significant coronary calcification present • Atrial fibrillation or other arrhythmias • May require beta blockers • Incidental non-cardiac findings	• No known CAD • Absence of severe coronary calcification • Prior normal, mildly abnormal, or inconclusive stress test results • No known iodinated contrast medium allergy or significant renal dysfunction • Low likelihood of high-quality stress testing or lack of timely access

Abbreviations: ACS, acute coronary syndromes; ECG, electrocardiogram; CAD, coronary artery disease; CMR, cardiac magnetic resonance imaging; CT, computed tomography; CTCA, CT coronary angiogram; ICD, implantable cardioverter defibrillator; PET, positron emission tomography; SPECT, single photon emission computed tomography.

symptoms. If appropriate, the person's long-term risk of a cardiovascular event should be assessed as per the *Australian guideline for assessing and managing cardiovascular disease risk* (cvdcheck.org.au).

Practice points

Non-invasive test selection – anatomical versus functional

Anatomical testing (CTCA)

- Use computed tomography coronary angiography (CTCA) as a first-line investigation for people without previously known CAD presenting with intermediate-risk ACS, if no contraindications exist (Table 8).
- Consider functional testing with close monitoring and a graduated exercise regime for people with contraindications to CTCA.
- Recognise that a normal CTCA (ruling out both obstructive and non-obstructive plaque) reliably excludes ACS and indicates an extremely low risk of ACS for at least 4–5 years [240–245]. Identifying non-obstructive plaque on CTCA can guide preventative therapies, such as lipid-lowering treatment.

- Do not rely on coronary artery calcium scoring alone in ACS evaluation unless combined with CTCA.

Functional testing

- Favour functional testing for people with known CAD, prior stents or extensive coronary calcification, where CTCA interpretation may be more challenging. Functional tests can help identify whether symptoms are caused by obstructive plaque and assess ischaemic burden and short-term prognosis.
- Select functional tests based on clinical needs, including stress echocardiography, stress cardiac MRI, stress/rest single-photon emission computed tomography (SPECT), stress/rest positron emission tomography (PET), or exercise ECG (Table 8).
- Recognise the additional diagnostic benefits of stress cardiac MRI and echocardiography, such as evaluating left ventricular function, regional wall motion abnormalities and valvular function, and excluding differential diagnoses like myocarditis and Takotsubo cardiomyopathy.

Considerations for test selection

- Consider individual cardiovascular risk factors, local expertise and the availability of health services, particularly in regional and remote areas, when selecting non-invasive cardiac investigations as these all may influence the selection [16,246–248].
- Prioritise inpatient non-invasive testing for low-risk individuals with factors limiting access to timely follow-up or the ability to re-present to ED, such as First Nations peoples with suspected ACS or those facing sociodemographic challenges [210].

2.6.1. Cost-effectiveness

Reducing unnecessary testing has benefits for both people and health services, including cost benefits. One Australian study estimated a total cost saving of \$13.5 million per annum after implementation of an accelerated diagnostic pathway that reduced hospital admission rates and ED length of stay [190].

2.6.2. Considerations for regional, remote and First Nations peoples

Regional, remote and First Nations peoples are disproportionately affected by reduced access to services, longer wait times and greater travel distances to access diagnostic services. Definitive early identification of CAD using CTCA may be of significant benefit in this group [249].

To note, assigning a warranty period following a negative CTCA should be done with some caution in First Nations peoples due to limited evidence for this population.

Implementation of an Australian telemedicine program supporting remote exercise stress testing with cardiology specialist support has been shown to reduce waiting times. The program enabled a significant proportion of people to be managed in local health facilities [250].

2.7. Role of Rapid Access Chest Pain Clinics

Rapid access chest pain clinics can assist with choice of further investigations or management in certain people discharged following an ACS [251]. Multiple UK studies have found this model to be safe, efficient and cost-effective compared with hospital admission [252].

Various chest pain clinic models have been trialled throughout Australia. These models seem to deliver similar results to the UK system, regardless of referral patterns or investigations undertaken [251]. Benefits include more efficient access to testing and diagnosis, cost savings compared with hospital admission, greater individual satisfaction and, most importantly, equal or improved safety compared with traditional hospital-based care [253–257].

Other benefits demonstrated in Australia include reduced rates of invasive investigations, lower rates of ED re-presentation, and a clear mechanism for timely follow-up of test results.

It is important to prioritise access to these clinics for selected intermediate-risk people with cTn levels <99th percentile.

2.8. Re-presentation with Symptoms

People who re-present to ED within 30 days with possible ACS symptoms and who have not already undergone non-invasive testing for CAD and/or coronary ischaemia may warrant further testing. This includes functional or anatomical tests. These people also require a detailed re-appraisal for alternate diagnoses. If re-presentation occurs after prior negative exercise ECG testing, use of investigations with greater sensitivity and specificity or an anatomical test should be considered.

2.9. Discharge Planning and Advice

Following comprehensive and structured assessment of people with suspected ACS, people who do not require admission for further assessment and/or management can be discharged. The outcome of ED assessment will determine the guidance given to the person (and their support people) prior to discharge.

Many people will not receive a definitive diagnosis for their symptoms. However, acute, life-threatening diagnoses including AMI and UA will have been deemed to be of very low probability [258]. Specific discharge advice for non-ACS presentations is not within the scope of this guideline.

2.9.1. Discharge communication for general practitioners

To support ongoing management of people after discharge, concise information in the form of a discharge summary must be promptly provided to a person's general practitioner.

2.9.2. Discharge advice for people at low risk for ACS

Discharge advice for people identified as low risk should include the following, both verbally and in written form:

- Evidence-based information on the condition(s) diagnosed and any further investigation/management required.
- Clear communication that the person has been comprehensively assessed to exclude AMI and to determine UA is unlikely.
- A clear statement that CAD has not been excluded, and that follow-up with the person's general practitioner is recommended for assessment and management according to the *Australian guideline for assessing and managing cardiovascular disease risk* (cvccheck.org.au).
- Information about what steps the person should take if they experience recurrent symptoms.
- Education on cardiovascular health and cardiovascular causes of chest pain and other key symptoms.
- Guidance on where to find reliable sources of online health information and how to contact telephone-based triage services.

The use of a decision support tool may assist in conveying risks of heart disease and of the lack of benefit, and possible harm, of further testing in low-risk people (see [Supplementary Material B2](#)) [146].

2.9.3. Discharge advice for people at intermediate risk for ACS

Discharge advice for people identified as intermediate risk should include the following, both verbally and in written form:

- Clear reassurance for the person and their support people that they have been comprehensively assessed as safe to be discharged.
- Clear information on management of existing and/or new symptoms including when to call an ambulance, re-present to the ED, or contact their general practitioner.
- Information on referral for outpatient assessment and management. This should include clear guidance on the clinician/clinic referred to, and whether an appointment has already been arranged or whether the person or support people need to do this. If the latter, then a clear timeline and contact details to arrange the appointment should be provided in the written discharge advice.
- Clear guidance on new or continuing medicines, including when and how to take them.
- Education on cardiovascular disease risk and steps that the person can take to reduce their risk.
- Guidance on where to find reliable sources of online health information and how to contact telephone-based triage services.

2.9.4. Discharge advice for people with a prior history of coronary heart disease who have a chronic or stable coronary syndrome

A small number of people presenting to the ED with a prior diagnosis of CAD may be discharged with probable chronic or stable CAD. The advice given needs to balance the following:

- 1) Reassurance that the person has been comprehensively assessed and is deemed safe for discharge at this time, notwithstanding a probable cardiac cause for their symptoms and presentation.
- 2) A clear plan for further follow-up for assessment and management.
- 3) A clear plan for managing existing or new symptoms.
- 4) Education on their cardiovascular health and reiteration of when to call an ambulance, re-present to ED or contact their general practitioner.

Discharge planning and advice supports reduced ED presentations and better outcomes. Clinicians, including registered nurses and nurse practitioners, should be supported to undertake comprehensive pre-discharge assessment and discharge planning. This is important to help manage a person's anxiety; high levels of anxiety are associated with an increased likelihood of symptom recurrence and re-presentation to hospital [259,260].

Shared decision making is strongly encouraged. More research is needed on how to best implement shared decision making to achieve the goals of people at risk of or living with cardiovascular disease [34,36,261–263].

2.10. Primary Care and Regional and Remote Presentations

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
For people with suspected ACS initially evaluated in the primary care setting, prompt transfer to a facility where definitive risk assessment can occur (e.g. ED) is recommended.		Consensus
Metropolitan health services should establish centralised support systems for regional and remote health services to facilitate: • prompt assistance with ECG interpretation and access to troponin results when on-site access is not available • provision of clinical advice to healthcare professionals • access to cardiac investigations if required.	Strong	Low

Evidence supporting the recommendations

All people with suspected ACS should have the opportunity to receive best practice care, regardless of their geographic location in Australia. Coordinated centralised systems of care are needed to achieve this. Telehealth models allow prompt and consistent access to specialist services for health services outside major tertiary centres.

An Australian state-based model has demonstrated that access to early cardiologist support for ECG interpretation, POC troponin results and cardiology-assisted decision-making is associated with reduced mortality [264]. In addition, an Australian cluster randomised trial of in-hours, routine tertiary level support versus usual care for people in hospitals without emergency physicians showed fewer missed STEMIs [71].

2.10.1. Considerations for primary care presentation

Initial assessment

As outlined previously, assessment of ACS incorporates the following:

- ECG findings
- clinical findings from history and physical examination
- troponin testing.

The ability of a healthcare professional to reliably diagnose or, just as importantly, exclude ACS is determined by their capacity to perform and interpret these components. If the

clinician suspects ACS, transfer to the nearest medical facility where definitive assessment for ACS can occur is mandatory.

Initial ECG assessment

People presenting with suspected ACS require prompt access to an ECG (within 10 minutes) and interpretation by a suitably trained clinician (section 2.2 [Initial ECG Assessment](#)). However, if ACS is suspected, ECG acquisition should not delay transfer to a facility that can perform serial troponin testing and provide reperfusion therapy, as delays are associated with harm [265–270].

If an ECG cannot be performed within 10 minutes, prompt transfer via ambulance to a location where an ECG can be performed is required. This may mean the first ECG is evaluated by trained paramedics.

If an ECG is non-ischaemic and the clinical presentation does not align with ACS as the likely diagnosis, it is reasonable to continue assessment in the primary care setting.

Troponin testing

If ACS remains a possible diagnosis after initial history, examination and ECG assessment, and cTn testing is required, the person should be transferred to the nearest facility (usually an ED) for definitive risk assessment [16,38,271].

In Australia, there are no single test strategies using POC contemporary troponin assays to exclude AMI [122]. Hence, serial testing is required, which is often not feasible in the primary care setting (section 2.3 [Biomarkers](#) and 2.4 [Risk Assessment and Clinical Decision Pathways for Suspected ACS](#)). Hs-cTn POC assays are available, but not widely distributed. Currently, there is limited evidence for single test strategies to exclude MI in primary care settings [111].

Risk assessment and clinical decision pathways

In a systematic review of older risk assessment rules for use in the primary care setting without cTn results, no difference was seen between use of a risk score or a general practitioner's clinical judgement in the ability to rule out ACS [272]. As such, risk scores such as the Marburg Heart Score, Grijseels and Bruins Slot rules are not recommended for exclusion of ACS in a primary care setting [273].

2.10.2. Considerations for regional and remote presentations

Presentations to regional and remote settings impose challenges, including limited human and technical resources and potentially prolonged transfer times [274]. Roughly one quarter of people presenting with chest pain require transfer to at least one other hospital. As a result, median times to angiography and overall length of stay are prolonged [275].

Geographic location also affects clinical outcomes. Greater mortality is observed at 18 months post-event amongst people presenting with ACS to non-PCI capable centres, most of which are in regional or remote locations [276,277].

While the initial assessment remains unchanged, key factors influencing the decision to transfer people with suspected ACS include:

- local service capabilities and support available in regional and remote settings

- availability of relevant investigations including chest X-rays, cTn testing and/or other cardiac tests (e.g. CTCA, exercise stress testing, echocardiography)
- the healthcare professional's clinical judgement.

Initial ECG assessment

If the ECG can be performed but not interpreted, it is reasonable to seek urgent remote evaluation (e.g. via telehealth) [71].

When the clinical and ECG assessment supports a diagnosis of ACOMI, consideration of urgent reperfusion therapy is required. Urgent transfer of the person to the nearest facility for fibrinolysis or primary PCI is needed (section 3 [Hospital Care and Reperfusion](#)).

Troponin testing

Many regional and remote settings are reliant on contemporary cTn assays, including POC platforms [137]. Clinicians must be aware of the type of troponin assay in use locally and ensure results are used in an evidence-based CDP (section 2.3 [Biomarkers](#) and 2.4 [Risk Assessment and Clinical Decision Pathways for Suspected ACS](#)).

Where contemporary cTn assays are in use, UA should be considered in the presence of normal cTn results if clinical suspicion for ACS is high based on ECG interpretation and/or clinical history. Further serial cTn testing over 6–8 hours should occur [38]. Management may include initial treatment for presumed ACS, a period of continuous cardiac monitoring and/or transfer to a PCI-capable centre.

Risk assessment and clinical decision pathways

Evidence supporting the use of clinical risk scores without incorporating troponin values is limited. In the absence of hs-cTn assays, incorporation of contemporary cTn results with clinical risk scores within a validated CDP is crucial (section 2.4.1.2 [Clinical score-based clinical decision pathways](#) and [Supplementary Material B2](#)). In a rural New Zealand setting, use of the EDACS accelerated diagnostic pathway with serial POC contemporary cTn measurements safely stratified risk in people with suspected ACS (see [Supplementary Material B2](#)) [278].

Further diagnostic testing

If a particular diagnostic test is required (section 2.6 [Further Diagnostic Testing for People with Suspected ACS](#)) but unavailable regionally, transfer to another facility should be considered.

Tertiary centres have an obligation to support appropriate testing in people from regional and remote areas. Decisions on further diagnostic testing can be informed by consultation with metropolitan cardiac teams or, when available, rapid access chest pain clinics. Remote access to such clinics may help improve diagnostic pathways for people in regional and remote settings.

Shared decision making

Shared decision making is particularly vital for people with suspected ACS living regionally or remotely, when considering investigation and management options (section 2.9 [Discharge Planning and Advice](#)). Decisions should consider the person's preferences for ongoing management, which may include remaining in a resource-poor setting or being transferred away from community.

3. Hospital Care and Reperfusion

3.1. Acute Management of STEMI – Reperfusion for STEMI

3.1.1. Eligibility for reperfusion Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with STEMI within 12 hours of symptom onset, perform emergency reperfusion with either primary PCI or fibrinolytic therapy.	Strong	Moderate
In people with STEMI, symptom onset over 12 hours before presentation and evidence of continuing myocardial ischaemia (persistent ischaemic symptoms, haemodynamic compromise, and/or life-threatening arrhythmias), perform emergency reperfusion with primary PCI.	Strong	Moderate

Evidence supporting the recommendations

Timely reperfusion limits the extent of MI and reduces mortality by minimising total ischaemic time [279–282]. The impact on mortality is greatest in the first hour after symptom onset and diminishes with time, virtually dissipating by 12 hours [283].

Routine emergency reperfusion in people who present more than 12 hours after symptom onset is not recommended. However, a primary PCI strategy may be considered in the presence of ongoing ischaemia, as observational studies support a survival benefit. In addition, two small, randomised trials have reported reductions in infarct size and four-year mortality [284–287].

For people with STE and multivessel disease (MVD), complete revascularisation should be the goal (section 3.7 [Treatment for ACS with Multivessel Disease without Cardiogenic Shock](#)).

Practice points

- When deciding on eligibility for reperfusion, consider cognitive function, comorbidities, and frailty which

influence a person's overall survival. The superiority of PCI over fibrinolysis appears to extend to older people. However, trials have been small, with few very elderly people (>90 years), and have not included evaluation of frailty or comorbidity.

3.1.2. Choice of reperfusion strategy Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with STEMI within 12 hours of symptom onset, primary PCI is the preferred reperfusion strategy over fibrinolysis, if it can be performed within 120 minutes of first medical contact.	Strong	High
In people with STEMI within 12 hours of symptom onset, perform fibrinolysis if primary PCI cannot be delivered within 120 minutes of first medical contact.	Strong	Moderate

Evidence supporting the recommendations

Currently, the options for reperfusion for STEMI are primary PCI or fibrinolytic therapy, with the choice dependent on several factors (Figure 12). If primary PCI is the chosen reperfusion strategy, adopt quality assurance targets to reduce delay to wire crossing.

For people presenting to primary PCI-capable centres, first medical contact to wire crossing time should not exceed 60 minutes [288]. For people presenting to non-PCI-capable centres, first medical contact to wire crossing time should not exceed 90 minutes [288]. However, in keeping with the evidence, primary PCI is still the preferred strategy if it can be performed within 120 minutes.

Fibrinolytic therapy, compared with control, reduced overall mortality at 35 days with a relative risk of 0.82 (95% confidence interval (CI) 0.77–0.87) based on data from nine trials conducted during the 1980s and 1990s involving 58,600 people [289].

A meta-analysis of 23 trials including 7,739 people with STEMI compared primary PCI to fibrinolytic therapy. Primary PCI was found to be better at reducing the combined end-point of short-term death, non-fatal reinfarction and stroke (8% vs 14%, $p < 0.0001$), benefits that persisted in the long term [280].

An observational analysis from the National Registry of Myocardial Infarction in the United States demonstrated that




Figure 12 Decision making and organisation of reperfusion strategies within first 12 hours of medical contact. Adapted from Chew et al. [38].

Abbreviations: EMS, emergency medical service; FMC, first medical contact; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.

the relative benefit of primary PCI over fibrinolysis was lost after a delay to PCI of 121 minutes [290].

Importantly, the trials comparing primary PCI and fibrinolysis did not include routine early angiography in the fibrinolytic arms. There is evidence that an early fibrinolysis strategy followed by routine early angiography may be non-inferior to PCI (section 3.2 [Ongoing Management of Fibrinolytic-Treated People](#)). Also, very early administration of fibrinolysis in the pre-hospital setting may confer superior outcomes to PCI, especially among people presenting within two hours of symptom onset [291].

Efficacy of fibrinolysis has not been shown in people presenting 12 or more hours after onset of symptoms. Given the lower efficacy and persistent bleeding risks associated with fibrinolysis in such people, reperfusion with PCI is preferred in people with continued myocardial ischaemia (section 3.1.1 [Eligibility for reperfusion](#)) [286,287,292–295].

Practice points

- Establish effective care pathways tailored to the specific healthcare services available in the region. These pathways should include ambulance, primary health, emergency, cardiology and regional or remote healthcare services to optimise reperfusion times.
- Implement specific measures to reduce time to reperfusion [17], such as:
 - pre-hospital ECG and single-call catheter laboratory activation (i.e. streamlined communication between emergency services and the receiving hospital to bypass the ED and reduce reperfusion delay)
 - pre-hospital fibrinolysis by suitably trained clinicians (e.g. paramedics, nurses, First Nations health practitioners)
 - direct transfer to PCI-capable hospitals and direct transfer to the catheterisation laboratory on hospital arrival.

3.1.3. Administration of fibrinolytic therapy Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with STEMI for whom fibrinolysis is the preferred reperfusion strategy, it should be delivered within 30 minutes of first medical contact. Consider pre-hospital administration.	Strong	Moderate
In people aged ≥ 70 years, half the standard dose of tenecteplase is recommended as part of a pharmaco-invasive strategy.	Strong	Moderate

Evidence supporting the recommendations

Timing of fibrinolytic therapy

Fibrinolysis should be considered when the anticipated delay to primary PCI is >120 minutes and there are no absolute contraindications. Fibrinolysis should be delivered as soon as possible after the diagnosis is established, ideally within 30 minutes of first medical contact and, if possible, prior to hospital arrival [17,288,296,297].

People with an absolute contraindication should be transferred for PCI (Table 9). People with a relative contraindication need to have the risks and benefits of treatment considered.

Dosing fibrinolytic therapy in older people

The STREAM study ($n=1,892$) compared a pharmaco-invasive approach consisting of pre-hospital fibrinolytic therapy and routine angiography 6–24 hours later against primary PCI in people unable to receive the latter within 60 minutes. There was no significant difference in the primary composite endpoint (death, cardiogenic shock, heart failure and recurrent MI) between the groups. Among people aged 75 years and over receiving full dose tenecteplase, higher rates of intracranial haemorrhage were seen, an effect reduced by halving the tenecteplase dose with no change in efficacy [298].

The subsequent STREAM-2 study ($n=602$) restricted enrolment to older people (>60 years, mean age 70 years) and compared half dose tenecteplase and routine angiography 6–24 hours later against primary PCI [299].

Table 9 Contraindications for fibrinolysis. Adapted with permission from O’Gara *et al.* [270].

Absolute contraindications

- Any prior intracerebral haemorrhage
- Known structural cerebral vascular lesion (e.g. arteriovenous malformation)
- Known malignant intracranial neoplasm (primary or metastatic)
- Ischaemic stroke within 3 months
 - EXCEPT acute ischaemic stroke within 4.5 hours
- Suspected aortic dissection
- Active bleeding or bleeding diathesis (excluding menses)
- Significant closed-head or facial trauma within 3 months
- Intracranial or intraspinal surgery within 2 months

Relative contraindications

- History of chronic, severe, poorly-controlled hypertension
- Significant hypertension on presentation (SBP >180 mmHg or DBP >110 mmHg)
- History of prior ischaemic stroke >3 months
- Known intracranial pathology not covered in absolute contraindications
- Dementia
- Traumatic or prolonged (>10 min) CPR
- Major surgery (<3 weeks)
- Recent internal bleeding (within 2 to 4 weeks)
- Non-compressible vascular punctures
- Pregnancy
- Active peptic ulcer
- Oral anticoagulant therapy

Abbreviations: CPR, cardiopulmonary resuscitation; DBP, diastolic blood pressure; SBP, systolic blood pressure.

There was no difference between groups in the primary efficacy endpoint. The rate of intracranial haemorrhage in the pharmaco-intensive treatment arm was 1.5% compared with 0% in the PCI arm. To note, half of these events were associated with dosing protocol deviations.

Practice points

- An easily administrable fibrinolytic agent that can be given as a bolus dose, such as tenecteplase, is advisable especially in the pre-hospital setting.
- Currently available fibrinolytics include:
 - tenecteplase (weight-adjusted [30–50 mg] IV bolus and age-adjusted [half-dose] IV bolus)
 - reteplase (10 units IV followed by 10 units IV, 30 minutes later)
 - alteplase (weight adjusted accelerated bolus and infusion regimen).

3.1.4. Procedural recommendations in primary percutaneous coronary intervention

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
For people with STEMI at a PCI-capable centre, deliver primary PCI within 60 minutes of arrival. For people with STEMI transferred from a non-PCI centre, deliver primary PCI within 90 minutes of first medical contact.	Consensus	
Use radial access over femoral access when performing primary PCI, unless contraindicated.	Strong	High
In people undergoing primary PCI, do not perform routine thrombus aspiration of the infarct-related artery (IRA).	Strong	Moderate
In people who are asymptomatic and stable for more than 48 hours following occlusion of an IRA, do not perform routine PCI to this artery.	Strong	Moderate

Evidence supporting the recommendations

Time targets for primary PCI

For people with a diagnosis of STEMI, it is important to limit system delay (time from first medical contact or arrival at a healthcare system to reperfusion), as this is a predictor of mortality [300]. Targets for delivery of primary PCI include within 60 minutes from first medical contact of a person arriving at a PCI-capable centre, or within 90 minutes from first medical contact if transferred from a non-PCI capable centre [288]. Pre-activation of the catheterisation laboratory when the diagnosis is made in the pre-hospital setting (and bypassing the ED on arrival) reduces treatment delays [301,302].

Radial versus femoral access

Multiple RCTs and an individual person-level data meta-analysis (n=21,600) have shown a benefit of radial over femoral access in people with STEMI with a reduction in total mortality (1.6% vs 2.1%, hazard ratio [HR] 0.77, 95% CI 0.63–0.95) and major bleeding (1.5% vs 2.7%, OR 0.55, 95% CI

0.45–0.67) [303–307]. A radial-first approach is therefore recommended for primary PCI, unless precluded by contraindications [142,296,303,308].

Treatment of the infarct-related artery

Routine thrombus aspiration of the IRA has been associated with a small but significantly increased risk of stroke without a survival benefit, compared with routine stenting [309–311]. Thrombus aspiration may be considered in people with high thrombus burden with careful attention to technical strategies to avoid embolisation.

When stenting is required, meta-analyses have shown that currently available drug eluting stents have better efficacy and safety than bare metal stents, with lower restenosis and stent thrombosis [288,312–317]. This includes people at high bleeding risk (HBR), people who require triple antithrombotic therapy or short duration dual antiplatelet therapy (DAPT).

Routine deferred stenting of the IRA is not recommended due to an increased risk of unplanned target vessel revascularisation without a survival benefit [318,319]. Deferred stenting can be considered in select people, for example, those with residual large thrombus burden where immediate PCI is unlikely to be successful [320,321].

Routine PCI of a completely occluded IRA in asymptomatic stable people who are >48 hours from symptom onset has been associated with an increased risk of recurrent MI, with no survival or major cardiovascular outcome benefit, compared with medical therapy [293,322].

Practice points

- Where stenting is required, drug eluting stents are preferred over bare metal stents.
- Routine deferred stenting of the IRA is not recommended. In people with STEMI and risk factors for slow or no reflow, such as high thrombus burden, consider deferred stent implantation.
- In people with STEMI where primary PCI of the IRA is not feasible (e.g. severe left main artery disease or an uncrossable coronary lesion), CABG may be an appropriate primary reperfusion strategy. CABG may be particularly appropriate if there is a large area of myocardium at risk and surgery is available in a timely manner (section 3.8 Coronary Artery Bypass Graft Surgery in ACS) [323,324].

Women

- Understand that women with STEMI have documented delays to reperfusion, lower rates of invasive angiography and radial access and poorer outcomes compared with men [10–12,325].
- Improve clinician awareness of sex-specific differences in:
 - presenting symptoms
 - ECG diagnostic criteria
 - underlying MI aetiologies, such as an increased proportion of SCAD and MINOCA, as this may improve outcomes.
- Perform primary PCI as the preferred revascularisation strategy in pregnant women with STEMI, except when

caused by SCAD. Use appropriate shielding to minimise radiation exposure to the foetus [308].

3.2. Ongoing Management of Fibrinolytic-Treated People

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
People successfully treated with fibrinolytic therapy should be transferred to a PCI-capable centre as soon as possible. Angiography should be performed within 2–24 hours of arrival.	Strong	Moderate
Consider transferring people as soon as possible to a PCI-capable centre if fibrinolytic therapy is unsuccessful. If appropriate, consider subsequent PCI at the centre.	Weak	Moderate

Evidence supporting the recommendations

A network meta-analysis of 31 RCTs compared outcomes of people randomised to fibrinolytic therapy (n=4,212), primary PCI (n=6,139), or fibrinolysis followed by routine early PCI (n=5,006). The latter was categorised as facilitated PCI when the median time interval between fibrinolysis to PCI was <2 hours (n=2,259) and as a pharmaco-invasive approach when this interval was ≥2 hours (n=2,747) [326]. Primary PCI was associated with the lowest risk of mortality (odds ratio (OR) 0.73, 95% CI 0.61–0.89) when compared with fibrinolysis alone. However, among strategies in people receiving initial fibrinolysis, the pharmaco-invasive approach was associated with a trend towards lower mortality (OR 0.79, 95% CI 0.59–1.08) and showed significantly less reinfarction (OR 0.53, 95% CI 0.37–0.75) in comparison to fibrinolysis alone. Furthermore, in comparison to a facilitated approach, a Bayesian analysis showed the probability of adverse outcomes was lower with a pharmaco-invasive approach [326].

Another meta-analysis of seven studies comparing only early routine PCI after fibrinolysis versus standard therapy (i.e. fibrinolysis alone or rescue PCI where indicated) found no significant difference in 30-day mortality (OR 0.87, 95% CI

0.59–1.30, p=0.51). However, the study did find a significant reduction in reinfarction (OR 0.55, 95% CI 0.36–0.82, p=0.003) and the composite of death and reinfarction (OR 0.65, 95% CI 0.49–0.88, p=0.004) at 30 days, without a significant increase in major bleeding (OR 0.93, 95% CI 0.67–1.34). These benefits were sustained to 12 months [327].

Once a pharmaco-invasive approach is chosen, post-hoc analyses suggest the benefit is greatest the sooner PCI is achieved from symptom onset or administration of fibrinolysis (without transitioning to a facilitated approach). A meta-analysis of six randomised trials (n=1,238), demonstrated reduced 30-day recurrent ischaemia where angiography was achieved within 2 or 4 hours in comparison to beyond 4 hours (3.7% vs 3.7% vs 7.9%, p=0.02), but no reduction in 30-day mortality or reinfarction [328].

In a meta-analysis of eight RCTs (n=1,177), rescue PCI for failed fibrinolysis compared with conservative treatment was associated with a significant reduction in reinfarction (risk ratio [RR] 0.58, 95% CI 0.35–0.97), but no reduction in mortality [329]. In people being treated with fibrinolytics who are not in a PCI-capable hospital, care pathways should be developed to enable, when appropriate, immediate or early transfer for angiography (Figure 12) [330].

Practice points

- Perform regular ECG monitoring following fibrinolytic therapy according to local protocols, continuing until the person is pain free and for at least 60–90 minutes post-fibrinolysis.
- Recognise failed reperfusion in people treated by fibrinolytic therapy if they exhibit any of the following:
 - ongoing ischaemic chest pain
 - ≤50% ST recovery on an ECG performed 60–90 minutes after fibrinolysis
 - or ongoing haemodynamic instability.

First Nations peoples

- Ensure that education about ongoing management is culturally appropriate and includes the importance of transferring to a PCI-capable centre when necessary.
- Provide cultural and language support before, during and after transfer, ensuring family and cultural considerations are addressed by appropriately trained staff.

People living in regional and remote areas

- Establish formal care pathways to facilitate timely and efficient transfer between non-PCI capable centres and PCI-capable centres, often located in metropolitan areas. These pathways should address logistical challenges and ensure seamless continuity of care.
- Consider an additional half-dose of fibrinolytics with caution if fibrinolysis fails and timely transfer for rescue PCI is not feasible. However, this practice point is based on limited evidence from a single prospective trial with limited applicability to contemporary remote Australian settings [331].

3.3. Acute Management of NSTEMACS

3.3.1. Risk stratification for people with confirmed NSTEMACS

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with NSTEMACS, consider using the GRACE risk score to determine short- and long-term cardiovascular prognosis.	Weak	High
In people with ACS undergoing coronary angiography, consider using bleeding risk scores to determine short-term bleeding risk.	Weak	Moderate

Evidence supporting the recommendations

Assessment of the short- and longer-term risk of death and recurrent ischaemic and bleeding events in people admitted with ACS can guide the need for, and timing of, invasive management. Risk assessment can also guide selection and duration of antithrombotic therapy. Clinical assessment and objective tools may both contribute to risk stratification in people with confirmed NSTEMACS.

Clinical risk assessment

A subset of people presents with factors that are associated with a high risk of short-term mortality. These include people with haemodynamic instability/cardiogenic shock, life-threatening arrhythmias, mechanical complications of MI, acute heart failure clearly related to NSTEMACS, and/or ongoing symptoms in the presence of high-risk ECG criteria such as ST-segment depression >1 mm in >6 leads additional to STE in aVR and/or V1, Wellens criteria on ECG or recurrent intermittent STE (section 2.2 Initial ECG Assessment). An early invasive management strategy is recommended for these people (section 3.3.3 Timing of invasive management for NSTEMACS).

In the absence of these very high-risk criteria, clinical risk assessment performs poorly compared with objective risk tools in determining prognosis.

Objective risk prediction for ischaemic outcomes

In people admitted with NSTEMACS, prognosis is well predicted by *Global Registry of Acute Coronary Events* (GRACE) risk score which performs better than *Thrombolysis in myocardial infarction* (TIMI) risk and subjective clinical assessment [275,332–334]. Observational analyses have

shown guideline-directed care is associated with greater survival gains in higher risk people. However, the intensity of care is often inversely proportionate to the level of objectively determined individual risk [335–337].

While it is intuitive that objective risk scores may help identify people with ACS who would benefit from risk-concordant delivery of care, two prospective cluster randomised trials have failed to demonstrate an effect of routine GRACE risk score implementation on guideline-indicated treatments and clinical outcomes in people hospitalised with ACS [338,339]. Baseline levels of hs-cTn have been shown to be strongly associated with death or MI at 30 days [340].

Risk prediction for bleeding outcomes

Major bleeding in hospital is associated with increased mortality and a range of scores have been developed to predict this outcome among people presenting with ACS (Table 10).

A comparison of scoring systems reported that *Acute coronary treatment and intervention outcomes network* (ACTION) had the highest discrimination [C statistic 0.767 (0.737–0.797), three studies], followed by *Can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines* (CRUSADE) [C statistic 0.714 (0.659–0.779), 12 studies] and *Acute catheterization and urgent intervention triage strategy* (ACUITY) [C statistic 0.711 (0.626–0.797), seven studies] [341]. The *Academic Research Consortium high bleeding risk* (ARC-HBR) score is an alternative pragmatic approach recommended by European guidelines [342].

These scores have been developed in populations with a high prevalence of coronary angiography and receipt of DAPT. While they may be considered when choosing procedural and antiplatelet strategies, their impact on outcomes has not been evaluated.

Practice points

- Recognise that GRACE risk scores were developed before the introduction of hs-cTn assays. However, most people identified as high risk by the GRACE score are similarly identified using hs-cTn testing alone.
- Prioritise bleeding risk over ischaemic risk when making decisions about the duration of DAPT in people at risk of both bleeding and ischaemic events, as suggested by observational data (section 3.4 Antiplatelet Therapy in the Acute Phase and 3.5 Anticoagulant Therapy in the Acute Phase) [343].

Women

- Use the GRACE 3.0 score for risk assessment in women with NSTEMACS, as it provides a more accurate estimation of mortality risk than the GRACE 2.0 score (which

Table 10 Parameters of bleeding risk scores. Adapted with permission from Wang *et al.* [341].

Parameter	CRUSADE	ACUITY	ACTION	GRACE	HAS-BLED
Sex	x	x	x		
Renal function	x	x	x	x	x
Haematocrit/Anaemia	x	x			
Heart rate	x		x	x	
Blood pressure	x		x	x	
Congestive heart failure	x				
Vascular disease	x				
Diabetes	x		x		
Age		x	x	x	x
Antithrombotic medicines		x	x		x
Presentation		x			
White blood cell count		x			
Weight			x		
Cardiac arrest				x	
ECG ST changes				x	
Abnormal biomarkers				x	
Killip class				x	
Stroke					x
Hypertension					x
Liver disease					x
Bleeding history					x
Labile INR					x
Alcohol use					x

Abbreviations: ACTION, Acute coronary treatment and intervention outcomes network; ACUITY, Acute catheterization and urgent intervention triage strategy; CRUSADE, Can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines; ECG, electrocardiogram; GRACE, Global Registry of Acute Coronary Events; HAS-BLED, Hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly; INR, international normalised ratio.

underestimates mortality) and helps address sex inequalities in risk stratification [344].

Older adults

- Consider that the GRACE risk score heavily weights age and does not account for characteristics common in older adults such as frailty, multimorbidity, polypharmacy and cognitive dysfunction, which can contribute to higher risk scores [345].

- Assess frailty in older adults, as it is independently associated with adverse outcomes and increased bleeding risk [346]. Use validated frailty assessment tools to guide management decisions [347–350].
- Consider a conservative management approach in older adults, even if they are deemed high risk for ischaemic events based on objective scoring, particularly when frailty and bleeding risk are significant concerns.

3.3.2. Routine versus selective invasive management for NSTEMACS

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with NSTEMACS at high or very high risk of adverse cardiovascular events, perform routine invasive coronary angiography, with coronary revascularisation (PCI or CABG) where appropriate.	Strong	High
In people with NSTEMACS not at high or very high risk of adverse cardiovascular events, testing for inducible ischaemia (e.g. stress testing) may guide the need for invasive coronary angiography.	Weak	Moderate

Evidence supporting the recommendations

People with confirmed NSTEMACS at high risk of adverse cardiovascular events or death include those with:

- confirmed diagnosis of NSTEMI according to the Fourth UDMI
- high risk according to hs-cTn algorithms (section 2.4.1.1 [High-sensitivity troponin-based clinical decision pathways](#))
- dynamic ST-segment or T wave changes
- transient STE
- GRACE risk score >140.

People with confirmed NSTEMACS at very high risk of adverse cardiovascular events or death include those with:

- haemodynamic instability or cardiogenic shock
- life-threatening arrhythmias
- mechanical complications of MI
- ongoing symptoms in the presence of ECG criteria such as ST-segment depression >1 mm in >6 leads additional to STE in aVR and/or V1, or Wellens criteria on ECG (section 2.2 [Initial ECG Assessment](#))
- recurrent intermittent STE.

A routine invasive approach (coronary angiography) with subsequent revascularisation (PCI or CABG as indicated) in people with NSTEMACS has been studied in systematic reviews, meta-analyses and RCTs, in the context of evolving adjunctive

pharmacotherapies and interventional practices [351–353]. Overall, a routine invasive approach in people with NSTEMACS has net benefits in reducing the composite endpoints of death, recurrent MI and rehospitalisation for ischaemia. However, most of this benefit is in non-fatal events and only seen in people at high and very high risk [354,355].

A 2016 meta-analysis of 12 RCTs (n=9,650) of people with NSTEMACS found that routine invasive angiography reduced the composite endpoint of MI and death (OR 0.86, 95% CI 0.77–0.96) at mean 39-month follow-up, compared with a selective invasive approach [355]. Consistent with past meta-analyses, this reduction was driven by lower risk of recurrent MIs (OR 0.78, 95% CI 0.68–0.88) with non-significant reduction in risk of mortality (OR 0.88, 95% CI 0.77–1.01) [356].

The benefit of a routine invasive approach is greater in people with high-risk features with absolute risk reductions in MI and cardiovascular death of 2%, 4% and 11% in people at low, intermediate and high risk respectively, as determined by GRACE risk score [353]. In addition, RCTs investigating routine versus invasive strategies pre-dated the use of hs-cTn.

In admitted non-high-risk people with NSTEMACS, invasive management may be guided by non-invasive anatomic or functional testing. This can reduce the need for invasive angiography and is predictive of excellent short- and mid-term prognosis (section 2.6 [Further Diagnostic Testing for People with Suspected ACS](#)) [357–360].

Practice points

- Consider the goals of therapy, individual preferences and impact of other major comorbidities when deciding on the appropriateness of a routine invasive approach for people with NSTEMACS.
- Use anatomical imaging with CTCA instead of functional testing to exclude or define CAD in people with NSTEMACS who:
 - are at high or very high risk of adverse cardiovascular events
 - do not have known CAD
 - present with an unclear NSTEMACS diagnosis (section 2.6 [Further Diagnostic Testing for People with Suspected ACS](#)) [361,362].

3.3.3. Timing of invasive management for NSTEMACS

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with NSTEMACS with very high-risk criteria, an immediate invasive strategy within 2 hours of diagnosis is recommended.	Consensus	

(continued).

Recommendation	Strength of recommendation	Certainty of evidence
In people with NSTEMACS with high-risk criteria, consider an early invasive strategy within 24 hours of diagnosis.	Weak	High

Evidence supporting the recommendations

Multiple RCTs (the largest being TIMACS and VERDICT) and meta-analyses have investigated the timing of invasive coronary angiography in people with NSTEMACS [363,364]. An early invasive strategy was usually defined as within 24 hours (e.g. median of 14 hours after randomisation in TIMACS), while a delayed invasive strategy was usually defined as within 2–3 days (median 50 hours and 62 hours in the TIMACS and VERDICT trials, respectively). Overall, these studies found that an early invasive strategy did not confer a benefit in mortality, MI and stroke, compared with a delayed invasive strategy, when performed in all people with NSTEMACS without consideration of individual risk [365]. Therefore, the timing for

invasive management of NSTEMACS must take a person's risk into account.

Unstable or very high-risk people with NSTEMACS have largely been excluded from RCTs investigating an early versus delayed invasive approach. In these people, an immediate (i.e. within two hours of hospital admission) invasive strategy is recommended due to their presumed poor prognosis in the absence of invasive management. This is based on expert opinion, rather than strong randomised data (Figure 13).

In high-risk people with NSTEMACS, the TIMACS trial found a reduction in death, MI and stroke at six months associated with early versus delayed (median time 50 hours) intervention (14% vs 21%, $p=0.005$) in the subgroup of people with a GRACE risk score >140 , with no increase in major bleeding [363]. A meta-analysis (eight RCTs, $n=5,324$ people) investigating timing of invasive strategy based on individual participant data or standardised tabulated data found lower mortality with an early invasive strategy in people with elevated cardiac biomarkers at baseline (HR 0.76, 95% CI 0.581–0.996), diabetes (HR 0.67, 95% CI 0.45–0.99), a GRACE risk score >140 (HR 0.70, 95% CI 0.52–0.95), and aged 75 years and older (HR 0.65, 95% CI 0.46–0.93) although tests for risk-treatment interactions were inconclusive [366]. However, the GRACE scores calculated in these trials used CK-MB and earlier troponin assays, with no data to guide early angiography in people with elevated GRACE scores based on hs-cTn assays.




Figure 13 Timing of invasive management for NSTEMACS.

Abbreviations: ECG, electrocardiogram; GRACE, Global Registry of Acute Coronary Events; hs-cTn, high-sensitivity cardiac troponin; MI, myocardial infarction; NSTEMACS, non-ST-segment elevation acute coronary syndromes.

3.3.4. Procedural considerations in NSTEMACS

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with NSTEMACS undergoing an invasive approach, radial access is preferred to femoral access, unless contraindicated.	Strong	High
In people with NSTEMACS undergoing an invasive approach, consider intravascular imaging to guide PCI.	Weak	High

Evidence supporting the recommendations

Radial access

Multiple RCTs and meta-analyses have shown a reduction in mortality (1.6% vs 2.1%, HR 0.77, 95% CI 0.63–0.95) and major bleeding (1.5% vs 2.7%, OR 0.55, 95% CI 0.45–0.67) with radial instead of femoral access in people with NSTEMACS [303–307]. Therefore, unless precluded due to a lack of operator experience or other related contraindications, a radial first approach is recommended over femoral access.

Intravascular imaging-guided PCI

An intravascular imaging (IVI)-guided approach to PCI over standard angiography-guided PCI has been tested in multiple RCTs and meta-analyses, with a range of different complex person- and lesion-specific characteristics. A 2024 meta-analysis (22 RCTs, n=15,964) found that IVI-guided PCI (optical coherence tomography and intravascular ultrasound (IVUS)), compared to angiography-guided PCI, reduced target lesion failure (RR 0.71, 95% CI 0.63–0.80, $p<0.001$). This was driven by reductions in risks of cardiac death (RR 0.55, 95% CI 0.41–0.75, $p=0.001$), target vessel MI (RR 0.82, 95% CI 0.68–0.98; $p=0.030$) and target lesion repeat revascularisation (RR 0.72, 95% CI 0.60–0.86, $p=0.0002$) [367]. IVI-guided PCI also reduced the risks of all MI (RR 0.83, 95% CI 0.71–0.99; $p=0.033$) and all-cause death (RR 0.75, 95% CI 0.60–0.93; $p=0.0091$). Outcomes for optical coherence tomography-guided procedures were similar to IVUS-guided procedures.

From a 2023 meta-analysis of 32 RCTs (of which 19 were ACS trials), on subgroup analysis, the benefit of IVI-guided over angiography-guided PCI was of similar or greater magnitude in people with ACS [368]. Of note, RCTs included in both meta-analyses had different inclusion criteria, and largely included more complex lesions (e.g. bifurcations, presence of calcification and/or long segment of disease), and people at higher risk (e.g. people with diabetes). Therefore, the recommendation for intracoronary imaging over angiography alone should not be applied to every PCI procedure.

Practice points

Women

- Use a radial-first approach where possible for coronary interventions in both women and men, as it is associated with reduced complications and improved outcomes.
 - Consider a routine invasive approach for women with NSTEMACS, as it has demonstrated benefits. Do not overlook the disparity in care, as observational data show women are less likely than men to receive an invasive strategy or radial access [325,355].

Older adults

- Consider an invasive strategy over an initial conservative approach in older adults with NSTEMACS if they do not have frailty, multimorbidity or cognitive dysfunction based on objective assessment. The evidence to consider is:
 - Of five trials on invasive management in older adults with NSTEMACS (mostly ≥ 75 years), four found no benefit in the primary endpoints, but one showed reduced MI and urgent repeat revascularisation with a routine invasive strategy [369–374].
 - For older individuals with MI and multivessel disease, physiology-guided complete revascularisation showed benefits, although frailty data were not provided [375,376].
 - Meta-analyses of mixed designs have shown a likely reduction in MI and recurrent revascularisation with an invasive strategy versus a conservative (medical management) approach. In addition, there is a survival benefit in observational studies and a strong trend towards survival benefit in randomised trials, at the cost of a higher risk of bleeding relative to a conservative strategy in older people with NSTEMACS [376–378].
 - A small trial of frail individuals aged over 70 years (mean age 86) with NSTEMACS found no benefit from an initial invasive approach [379].
- Individualise treatment decisions for older adults, balancing the potential for improved outcomes with the risks of complications, especially bleeding.

First Nations peoples

- Ensure information about transfers or invasive management is provided with the assistance of First Nations health practitioners or Aboriginal liaison officers
- Communicate in the person's preferred language and when required to enhance understanding and informed decision making.
- Recognise that First Nations peoples from regional areas are less likely to receive angiography than non-Indigenous counterparts [380].
- Be vigilant of barriers to equitable care, including:
 - inadequate cultural competency among healthcare providers
 - perceptions about medicine compliance
 - delayed transfers to PCI-capable hospitals
 - insufficient family and community engagement by clinicians [68].

3.4. Antiplatelet Therapy in the Acute Phase

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with STEMI treated with fibrinolytic therapy, give dual antiplatelet therapy with aspirin and clopidogrel.	Strong	Moderate
In people with STEMI undergoing primary PCI and people with NSTEMACS undergoing a routine invasive strategy, give dual antiplatelet therapy with aspirin and a potent P2Y ₁₂ inhibitor (ticagrelor or prasugrel).	Strong	High
In people with STEMI undergoing primary PCI and people with NSTEMACS undergoing a routine invasive strategy for whom ticagrelor or prasugrel are contraindicated, and those receiving oral anticoagulation, give clopidogrel.	Strong	High
In people with NSTEMACS for whom a selective invasive strategy is planned, give ticagrelor or clopidogrel.	Strong	High
In people with NSTEMACS, consider routine genotypic or platelet function guidance of P2Y ₁₂ therapy.	Weak	Moderate
In people with NSTEMACS, consider de-escalation from potent P2Y ₁₂ inhibitor to clopidogrel, but not during the first 30 days following an ACS event.	Weak	Moderate
In people with ACS with concomitant non-valvular atrial fibrillation and CHA ₂ DS ₂ VA score >1, give aspirin and clopidogrel, together with a non-vitamin K oral anticoagulant.	Strong	High

(continued).

Recommendation	Strength of recommendation	Certainty of evidence
In people with STEMI undergoing primary PCI or those with NSTEMACS undergoing an invasive strategy, routine glycoprotein IIa/IIIb inhibitor (GPI) is not recommended.		Consensus

Evidence supporting the recommendations

Aspirin

The benefit of aspirin on outcomes following STEMI independently and synergistically with fibrinolytic therapy was originally shown in the ISIS 2 study (n=17,187) [381]. A meta-analysis incorporating broader populations of people with MI (15 RCTs conducted before 1997; n=19,302) found that, compared with placebo, aspirin reduces the risk of serious vascular events (vascular death, MI and stroke; OR 0.70, 95% CI 0.64–0.77) [216]. The risk of haemorrhagic stroke is increased, while that of ischaemic stroke decreased, giving an overall reduction in all-stroke risk (OR 0.62, 95% CI 0.33–0.91).

An RCT (n=25,086 with ACS) comparing high-dose aspirin (300–325 mg daily) with low-dose aspirin (75–100 mg daily) showed no significant benefit, with no difference in cardiovascular death, MI, stroke or major bleeding between groups at 30 days [382].

Platelet P2Y₁₂ inhibitor treatment with fibrinolytic therapy

In a large study enrolling 45,852 people with STEMI, clopidogrel added to aspirin reduced death, reinfarction or stroke by 9% (95% CI 3–14) when compared to aspirin alone [383]. In a trial of 3,491 people with STEMI randomised to clopidogrel or placebo at the time of fibrinolysis, coronary patency improved and ischaemic endpoints were reduced among people receiving clopidogrel [384]. The loading dose has not been studied in older people and is therefore not recommended in people over 75 years.

One small prospective open-label randomised trial (n=335) comparing ticagrelor and clopidogrel at the time of fibrinolysis found no difference in ischaemic MACE events but more minor bleeds with ticagrelor [385].

There was no difference in ischaemic or bleeding events in an RCT of 3,799 people randomised to ticagrelor or clopidogrel beyond 24 hours from fibrinolysis [386]. Thus, people initially thrombolysed and given clopidogrel, then transferred to another centre for PCI may safely be switched to ticagrelor following PCI.

Platelet P2Y₁₂ inhibitor therapy in people with STEMI undergoing primary PCI

The preferred P2Y₁₂ inhibitors are ticagrelor or prasugrel as they have more rapid onset of action, greater potency and are superior to clopidogrel in clinical outcomes [387,388]. Prasugrel is contraindicated if the person is <60 kg, ≥75 years and/or has had a previous stroke/transient ischaemic attack. Clopidogrel should be given as the preferred P2Y₁₂ inhibitor in people with previous haemorrhagic stroke, on oral anti-coagulants (OACs) or with moderate-to-severe liver disease.

The timing of P2Y₁₂ inhibitor administration in people with STEMI undergoing primary PCI has been studied in a meta-analysis (three RCTs, 14 observational studies, n=70,465) [389]. Pretreatment (P2Y₁₂ inhibitor administration before angiography) compared to no pretreatment (P2Y₁₂ administration during or immediately after PCI) did not result in reductions in all-cause mortality or major bleeding. Subgroup analysis found that P2Y₁₂ inhibitor pretreatment in the pre-hospital setting was associated with a reduction in MI, compared to no pretreatment (RR 0.73, 95% CI 0.56–0.91, p<0.01). Therefore, in people with a working diagnosis of STEMI undergoing primary PCI, pretreatment with a P2Y₁₂ inhibitor may be considered. If pretreatment is not given, all people should receive a P2Y₁₂ inhibitor loading dose at the time of PCI (see [Supplementary Material B3](#)).

Platelet P2Y₁₂ inhibitor treatment in NSTEMI/ACS

Clopidogrel with aspirin reduced the composite of cardiovascular death, MI or stroke when compared with aspirin alone in 12,562 people with NSTEMI (RR 0.80, 95% CI 0.72–0.90) [390]. As for people with STEMI, subsequent trials have shown that potent P2Y₁₂ inhibition with ticagrelor or prasugrel is preferred over clopidogrel in people with NSTEMI/ACS undergoing a routine invasive strategy [387,388]. Two RCTs have found that pretreatment with prasugrel at the time of diagnosis (before angiography) compared with treatment at the time of PCI following angiography did not reduce ischaemic events but did increase bleeding [391]. Similar results were reported from an analysis of the SWEDEHEART registry that included ticagrelor and clopidogrel in NSTEMI/ACS [392]. Therefore, P2Y₁₂ inhibitors can be withheld until the coronary anatomy is known and if coronary angiography can be performed within the time recommendations (section 2.6 Further Diagnostic Testing for People with Suspected ACS).

Ticagrelor, but not prasugrel, was found to be superior to clopidogrel in people with NSTEMI/ACS managed without PCI. Therefore, prasugrel is not recommended in people who do not undergo PCI [388,393].

In the CURRENT-OASIS trial (n=25,086), a loading dose of 600 mg of clopidogrel followed by maintenance of 150 mg showed no difference in ischaemic endpoints and a significant increase in major bleeding (HR 1.24, 95% CI 1.05–1.46) when compared against 300 mg loading and 75 mg maintenance [382]. There was, however, a benefit in the subgroup of people who underwent PCI (HR 0.85, p=0.04). Therefore, double dose clopidogrel may be considered in these people [382].

An RCT of 4,018 people with ACS (ISAR REACT 5) randomised to either ticagrelor or prasugrel, of which 83% received PCI, demonstrated an increase in death, recurrent MI and stroke, in people randomised to ticagrelor (HR 1.36, 95% CI 1.09–1.70) with no significant differences in bleeding [394]. This study has been criticised because of its open-label design, high rate of study discontinuation during follow-up (30% in both arms) and primary reliance on phone call follow-up rather than study visits to ascertain the components of the primary outcome [395].

Guiding therapy based on genetic or platelet function testing

Approximately 30% of people do not respond to clopidogrel. This is thought to be the reason for the improved efficacy and increased bleeding of the more potent P2Y₁₂ antagonists when compared with clopidogrel. Selection of therapy based on response to clopidogrel (as indicated by either genotyping or platelet function testing) has not shown a consistent benefit. This is likely because these strategies do not provide a comprehensive assessment of platelet responsiveness, together with differences in trial design and lack of power [396–398].

A network meta-analysis of 15 RCTs including 61,898 people with ACS demonstrated that therapy guided by genotyping of clopidogrel resistance compared to potent P2Y₁₂ inhibitor therapy appeared to provide the best balance between less bleeding with clopidogrel and fewer ischaemic events with potent P2Y₁₂ inhibitors ticagrelor and prasugrel [396,399,400]. However, genotyping is not readily available in Australia, and further research is required to ascertain its role in the Australian setting. In addition, when platelet function-guided escalation is used, people need to be on clopidogrel initially to demonstrate non-responsiveness. This may place people with ACS at increased risk.

De-escalation of potent P2Y₁₂ inhibitor therapy

Three major RCTs investigated the safety and efficacy of intentional de-escalation of potent P2Y₁₂ inhibitor therapy following an ACS [401–403]. One single centre study compared the impacts of de-escalation from ticagrelor or prasugrel to clopidogrel, with no switching of therapies (n=646). The primary composite outcome was cardiovascular death, urgent revascularisation, stroke and bleeding (Bleeding Academic Research Consortium scale ≥2) [403]. There was net benefit in the de-escalated group (HR 95% CI 0.48 (0.34–0.68)), driven by lower bleeding risk and no difference in ischaemic endpoints.

A multi-centre trial randomised people to ticagrelor and aspirin or intentional de-escalation to clopidogrel and aspirin after one month (n=2,697). The primary endpoint was a composite of cardiovascular death, MI, stroke, or bleeding (Bleeding Academic Research Consortium scale ≥2) at 12 months. There was a demonstrated 4.6% absolute risk benefit (HR 95% CI 0.55 (0.40–0.76)) in people undergoing de-escalation, also driven by reductions in bleeding risk [401].

Similar results were observed in another multi-centre trial using prasugrel 10 mg daily for the first month, followed by randomisation to either reduced dose prasugrel (5 mg daily) or standard dosing (n=2,338); (HR 95% CI 0.70 (0.52–0.92)) [402].

In all three studies, de-escalation did not occur until more than one month following discharge, and therefore earlier de-escalation cannot be recommended at this time [28]. Additionally, de-escalation occurred without giving a loading dose of clopidogrel upon switching.

Two of the studies were conducted in primarily east Asian populations, in whom ethnic differences in both response to clopidogrel and outcomes following PCI have been identified when compared to Caucasian populations [401,402,404].

Combining oral antiplatelet and oral anticoagulant therapy in ACS

In people with ACS requiring anticoagulation for non-valvular atrial fibrillation, studies with direct oral anticoagulants (DOACs) have shown that after an initial period (1–4 weeks) of triple therapy (aspirin in addition to a P2Y₁₂ antagonist and an OAC), lower bleeding rates are seen with DOACs and clopidogrel compared to warfarin with continued DAPT (section 4 [Recovery and Secondary Prevention](#)) [405–407].

Discontinuing P2Y₁₂ inhibition prior to cardiac surgery for ACS

Based on pharmacokinetic data, the safe windows for cessation of P2Y₁₂ inhibitors prior to non-emergency cardiac surgery are 5 days for clopidogrel, 3 days for ticagrelor and 7 days for prasugrel [408].

Intravenous glycoprotein IIb/IIIa inhibitors

Routine use of IV GPI in people undergoing primary PCI confers no benefit and significantly increases bleeding risk [409,410]. In term of intracoronary administration, a small RCT (n=162) of intracoronary tirofiban versus heparin alone in select people with STEMI who had TIMI <3 following post-dilation showed significantly greater reperfusion (32% vs 10%, p=0.001), and reduction of in-hospital in-stent thrombosis and non-fatal MI [411]. Similarly, a meta-analysis of 10 RCTs (n=1,590) found improved outcomes with intracoronary administration of GPI compared with IV administration, in terms of TIMI, target vessel revascularisation and short-term mortality. However, conclusions could not be drawn about mid and long-term outcomes [412].

Trials using GPI in people with NSTEMI/ACS showed a reduction in ischaemic events at a cost of increased bleeding when compared to heparin alone. However, all were conducted prior to the routine use of potent P2Y₁₂ inhibitors and later generation stenting [413,414]. Contemporary studies have shown that upstream use of GPI increases bleeding and transfusion requirements without offering clinical benefit [414]. In people not undergoing an invasive strategy, GPIs were not shown to reduce death or recurrent MI compared with placebo [415].

Practice points

- **Aspirin:** In the event of aspirin sensitivity, risk assessment and consideration of desensitisation should be made using a standardised protocol to achieve adequate antithrombotic therapy [416].
- **Selection of platelet P2Y₁₂ inhibitor therapy:** Prasugrel has Therapeutic Goods Administration (TGA) approval but is not currently available in Australia. Exercise care regarding timing and dosing of P2Y₁₂ inhibitors when switching between these agents to ensure their effectiveness is maintained and the bleeding risk is minimised. For guidance on switching strategies, see [Supplementary Material B3](#).
- **Timing of platelet P2Y₁₂ inhibitor administration in STEMI:** Deferring the administration of the P2Y₁₂ inhibitor until after the coronary anatomy is known is reasonable when the diagnosis of STEMI is uncertain or if there is a clinical suspicion of need for urgent cardiothoracic surgery (e.g. left main ischaemia pattern on ECG).
- **Timing of platelet P2Y₁₂ inhibitor initiation in NSTEMI/ACS:** Decisions regarding timing of initiation of P2Y₁₂ inhibitor in relation to invasive angiography may be institution-dependent and need to be clearly defined and communicated effectively between emergency and inpatient services.
- **Combining P2Y₁₂ inhibition with anticoagulation:** In people with ACS with an indication for vitamin K antagonist (e.g. mechanical heart valve), use aspirin with clopidogrel rather than ticagrelor or prasugrel to reduce the risk of bleeding. Target international normalised ratios (INRs) should be at the lower therapeutic range (e.g. 2.5–3 for mechanical mitral valves).
- **IV GPI administration:** Bailout GPI may be considered in people at high ischaemic risk such as high thrombus burden, no-flow or slow-flow.
- **Discontinuing platelet P2Y₁₂ inhibitor prior to CABG:** In people with NSTEMI/ACS with planned CABG, do not administer P2Y₁₂ inhibitor within 3 days of surgery for ticagrelor, 5 days for clopidogrel or 7 days for prasugrel.
- **Selection of GPI therapy:** Tirofiban is the only GPI marketed in Australia, while eptifibatide and abciximab can be obtained through the TGA's Special Access Scheme.
- **Discontinuing IV GPI in thrombocytopenia:** Glycoprotein IIb/IIIa inhibition is not recommended in people with thrombocytopenia (platelet count <150,000/mL) and should be suspended immediately if platelet count falls below this level or drops by 50% or more from baseline.
- **Discontinuing IV GPI prior to CABG:** In people undergoing CABG, discontinuation of short-acting GPI (eptifibatide and tirofiban) for four hours and abciximab for 12 hours before surgery is recommended to reduce the risk of bleeding and transfusion [417–419].

3.5. Anticoagulant Therapy in the Acute Phase

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
People treated with fibrinolytic therapy should receive anticoagulation (unfractionated heparin or enoxaparin).	Strong	Moderate
People undergoing primary PCI should receive anticoagulation (unfractionated heparin or bivalirudin).	Strong	Moderate
People with NSTEMACS should receive anticoagulation (unfractionated heparin, enoxaparin, or fondaparinux).	Strong	Low

Evidence supporting the recommendations

Anticoagulant treatment with fibrinolytic therapy

The GUSTO trial (n=40,021) of people with STEMI receiving fibrinolysis with tissue plasminogen activator (tPA) and IV heparin, or streptokinase and either IV or subcutaneous heparin, or combination of both fibrinolytic agents and IV heparin showed the lowest mortality among those receiving tPA and IV heparin [420]. In the ASSENT-3 trial, of people with STEMI receiving fibrinolysis with tenecteplase, enoxaparin, 30 mg IV followed by 1 mg/kg twice daily (n=2,040) resulted in fewer ischaemic endpoints than IV heparin (n=2,038) (RR 0.74, 95% CI 0.63–0.87) [421].

Anticoagulant therapy with primary PCI

Unfractionated heparin (UFH) (in combination with DAPT) has been the standard of care for many decades in people undergoing primary PCI. RCTs comparing bivalirudin and heparin prior to 2022 reported no difference in ischaemic endpoints but less bleeding with bivalirudin [312,422,423]. However, these RCTs are difficult to interpret in today's clinical practice due to heparin historically being combined with routine (instead of bailout) GPI and low rates of radial access.

The unblinded BRIGHT-4 RCT (n=6,016) published in 2022 demonstrated a benefit of bivalirudin over UFH (0.7 units/kg) in primary PCI, with a reduction in 30-day total mortality (89 vs 118 people, p=0.04) and major bleeding (5 vs 24 people, p=0.001), with high (93%) radial access use and bailout (not routine) GPI [424]. Bivalirudin can therefore be

considered instead of UFH in people undergoing primary PCI for STEMI, factoring in differences in cost and experience with administration. Bivalirudin should be used instead of UFH in people with heparin-induced thrombocytopenia.

Anticoagulant therapy in NSTEMACS

Three small studies enrolling a total of 847 people showed that UFH was associated with a 62% reduction in trial-defined MACE (OR 0.38, 95% CI 0.15–0.97) with no increase in major bleeding at 5 days when compared to placebo [425–427]. Although these trials precede the use of early invasive management and availability of troponin assays, they form the basis for recommending anticoagulation therapy in people at high and intermediate risk of ACS.

A meta-analysis of five RCTs comparing UFH with low molecular weight heparin (LMWH) on background therapy with aspirin (n=11,838) showed LMWH to be associated with a reduction in trial-defined MACE (OR 0.81, 95% CI 0.69–0.95) with no significant increase in bleeding [428]. These studies were conducted before the availability of troponin assays, with very low rates of coronary angiography. This meta-analysis did not include the largest trial comparing UFH to LMWH (n=9,978) which enrolled people on a background of DAPT with high rates of early coronary angiography (92%) and GPI use (57%) [429]. There was no difference in the ischaemic endpoint of death and MI, but a significant increase in major bleeding in people receiving LMWH (HR 1.21, 95% CI 1.05–1.40) which was commonly femoral access-related.

Contemporary meta-analyses of UFH with bivalirudin have shown no significant benefit for ischaemic outcomes, especially with the growing preference for radial access and fewer bleeding events [430].

A pooled analysis of two trials (n=20,378) comparing fondaparinux with LMWH in people on DAPT showed a halving of major bleeding at 9 days (HR 0.52, 95% CI 0.44–0.62) with no difference in trial-defined MACE. There were high rates of angiography in these trials, but the median time to angiography was long (2.5 days in the larger OASIS-5 trial) [428,431].

Practice points

Anticoagulant treatment with fibrinolytic therapy

- Omit IV bolus of enoxaparin in people >75 years receiving fibrinolysis and enoxaparin.
- Enoxaparin is recommended over UFH unless there is severe kidney impairment (estimated glomerular filtration rate (eGFR) <30 mL/min) [432,433].

Anticoagulant therapy with primary PCI

- In people requiring PCI with a history of heparin-induced thrombocytopenia, consider bivalirudin as an alternative to UFH. Outcomes with bivalirudin are optimised when followed by a high dose post-PCI infusion (1.75 mg/kg/hr) for 2–4 hours [434].

Anticoagulant therapy in NSTEMACS

- In people treated with fondaparinux undergoing coronary angiography and/or PCI, standard dose UFH is

recommended at the time of the procedure to reduce the risk of guiding-catheter thrombosis [390,431].

- In people receiving LMWH in whom femoral access for coronary angiography is planned, it is common practice to omit the morning dose of enoxaparin to minimise access-related bleeding complications [435].
- Parenteral anticoagulants can be ceased following PCI. In people who do not undergo PCI, UFH may be ceased at 48 hours and fondaparinux or LMWH at 6 days following presentation in the absence of other indications [429,431].

Anticoagulant use in people already receiving warfarin or DOACs

There are no randomised studies evaluating strategies for early anticoagulation in people with ACS who are already taking warfarin or DOACs. Guidance for these people is derived from expert opinion [436].

- In people with continued indications for oral anticoagulants (atrial fibrillation and CHA₂DS₂VA score >1, mechanical heart valves, or recurrent venous thromboembolism), do not cease this treatment.
- In people with NSTEMI/ACS undergoing invasive management, wherever possible a brief washout period from the effects of OACs is desirable. This is to reduce the risk of potential bleeding complications among those who may require femoral access or resulting from additional anticoagulation during the procedure. This can be 24 hours for people on DOACs with normal renal function and 48 hours for those with impaired renal function. For people on warfarin, an INR of <2.0 is recommended when using the radial approach and <1.5 when using the femoral approach.

3.6. Acute Management of ACS with Cardiac Arrest and/or Cardiogenic Shock

3.6.1. ACS with cardiac arrest Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with return of spontaneous circulation after resuscitated cardiac arrest and persistent STE on ECG, perform emergency reperfusion.	Strong	Low

(continued).

Recommendation	Strength of recommendation	Certainty of evidence
In haemodynamically stable people with resuscitated cardiac arrest and no STE on ECG, do not perform routine emergency coronary angiography.	Strong	Moderate

Evidence supporting the recommendations

Cardiac arrest in the context of STEMI is a common cause of early death and usually occurs out of hospital [437]. In people with resuscitated cardiac arrest and an ECG consistent with STEMI, reperfusion with primary PCI improves survival [438–440].

In the absence of STE on ECG, a meta-analysis of seven RCTs (n=1,544) found no survival or neurological benefit of early or immediate angiography over a delayed angiography strategy in people with resuscitated cardiac arrest [441]. It is important to note that people with cardiogenic shock were excluded from these trials, hence emergency angiography in the presence of haemodynamic instability may be considered.

Practice points

- In people with STEMI and resuscitated cardiac arrest, primary PCI is the preferred reperfusion strategy. Fibrinolysis may be considered if primary PCI is unavailable. However, evidence is lacking with potential for harm in cardiac arrest that is refractory, prolonged and/or traumatic [17,288,442].
- In people with STEMI and resuscitated cardiac arrest, the decision for primary PCI should factor in treatment futility. For instance, advanced age, presence of severe metabolic acidosis and/or no return of spontaneous circulation for an extended period are associated with a low likelihood of meaningful long-term survival [443].

3.6.2. ACS with cardiogenic shock Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with ACS and cardiogenic shock, perform PCI of the IRA only.	Strong	Moderate

(continued).

Recommendation	Strength of recommendation	Certainty of evidence
In people with ACS and cardiogenic shock, routine insertion of an intra-aortic balloon pump is not recommended.	Strong	High
In people with ACS and cardiogenic shock, routine venoarterial extracorporeal membrane oxygenation is not recommended.	Strong	Moderate
In select people with STEMI and cardiogenic shock, consider left ventricular assist devices.	Weak	Moderate

Evidence supporting the recommendations

Treatment of MVD in ACS with cardiogenic shock

In people with NSTEMI, MVD and cardiogenic shock, RCTs have studied the benefit of IRA-only PCI versus routine PCI of IRA and non-IRA lesions at the time of initial angiography. The CULPRIT-SHOCK trial included approximately 40% of enrolled people with a NSTEMI (n=706). At 30 days, the composite primary endpoint of death or renal replacement therapy occurred in 45.9% of the IRA-only PCI group versus 55.4% of the multivessel PCI group (RR 0.83, 95% CI 0.71–0.96) [444]. The difference was driven by significantly lower mortality in the IRA-only PCI group.

In people with STEMI complicated by cardiogenic shock, a single RCT and observational studies have found that routine PCI of non-IRAs at the time of primary PCI was associated with increased risk of death and renal failure [444–446]. Therefore, in the presence of cardiogenic shock, PCI of non-IRAs should not be performed at the time of the index procedure, but staged PCI should be considered for complete revascularisation.

Haemodynamic support devices in MI and cardiogenic shock

In people with MI and cardiogenic shock, routine insertion of an intra-aortic balloon pump has been associated with an increased risk of bleeding with no impact on survival or infarct size [447–449].

In the ECLS-SHOCK trial (n=417 people with AMI and cardiogenic shock, planned for urgent revascularisation), early venoarterial extracorporeal membrane

oxygenation (VA-ECMO) did not reduce 30-day mortality compared with usual care (RR 0.98, 95% CI 0.80–1.19, p=0.81) [450]. Early VA-ECMO was associated with higher rates of peripheral vascular complications requiring interventions (RR 2.86, 95% CI 1.31–6.25), compared with usual care.

A meta-analysis (four RCTs, n=567) did not find a reduction of 30-day mortality with the early use of VA-ECMO (OR 0.93; 95% CI 0.66–1.29), with higher major bleeding (OR 2.44, 95% CI 1.55–3.84) and peripheral ischaemic vascular complications (OR 3.53, 95% CI 1.70–7.34), compared with standard care [451]. There were no prespecified subgroups where any benefit of VA-ECMO could be seen.

The DanGer Shock trial recruited people with STEMI and cardiogenic shock (n=360), excluding those with cardiac arrest or overt right heart failure. The study found that using percutaneous left ventricular assist devices (the microaxial-flow-pump, or Impella) reduced all-cause death compared with standard care (45.8% vs 58.5%, HR 0.74, 95% CI 0.55–0.99, p=0.04) [452]. The survival benefit came at a cost of increased bleeding and vascular complications (24% vs 6.2%, HR 4.74, 95% CI 2.36–9.55). In addition to haemodynamic evidence of shock, people enrolled had left ventricular impairment (<45%, median left ventricular ejection fraction [LVEF] 25%) and elevated arterial lactate (>2.5 mmol/L, median 4.6 mmol/L). People with right ventricular impairment and those with resuscitated out-of-hospital cardiac arrest who were comatose (Glasgow Coma Scale ≤8) were excluded.

Practice points

- Consider intra-aortic balloon pump in select cases – for example, where there are mechanical complications (ventricular septal rupture, mitral regurgitation or free ventricular wall rupture) – and/or as bridging to heart transplant or left ventricular assist devices.
- Consider mechanical support including VA-ECMO on a case-by-case basis, as rescue or bridging therapy. Such support can also be considered for treatment of intractable ventricular tachyarrhythmias, in consultation with a multidisciplinary team.
- Consider left ventricular assist devices in people with STEMI and cardiogenic shock on a case-by-case basis, given the selected population enrolled and the complication rate in the DanGer Shock trial.
- In people with ACOMI and cardiogenic shock, where PCI is unavailable, consider fibrinolysis with a plan for subsequent angiography (see recommendations in section 3.2 [Ongoing Management of Fibrinolytic-Treated People](#)) [453].

3.7. Treatment for ACS with Multivessel Disease without Cardiogenic Shock

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In haemodynamically stable people with STEMI and MVD, perform PCI of suitable non-IRA(s).	Strong	High
Consider performing PCI of the non-IRA at the time of primary PCI or within 19 days of the index procedure.	Weak	Moderate
In people with STEMI and MVD, routine invasive physiology assessment (e.g. fractional flow reserve [FFR]) to evaluate non-IRA severity is not recommended.	Consensus	
In people with NSTEMI and non-complex MVD, consider routine PCI of non-IRA in the same setting.	Weak	Low
In people with NSTEMI and MVD, consider invasive physiology assessment (e.g. FFR) to evaluate non-IRA severity.	Weak	Low

Evidence supporting the recommendations

Treatment of MVD in STEMI

In people with STEMI, MVD and without cardiogenic shock, RCTs have shown a benefit of complete revascularisation over IRA-only PCI with a reduction in cardiac death, recurrent MI and repeat revascularisation [320,454–467].

The MULTISTARS-AMI trial recruited people with STEMI and MVD to undergo immediate (at the time of index procedure, n=418) versus staged (median 28 days, range 19–45 days after index procedure, n=422) PCI of the non-IRA. Immediate revascularisation was superior to staged PCI with lower death, non-fatal MI, stroke, unplanned ischaemia-driven revascularisation and heart failure hospitalisation (RR 0.52, 95% CI 0.38–0.72, $p<0.001$) [468]. This trial suggests

that complete revascularisation during the index procedure is both safe and superior to outpatient staged PCI. It is unknown if immediate non-IRA PCI is superior to inpatient staged PCI (or PCI performed within 19 days).

It should be noted that only a third of people in these trials had triple-vessel disease. People with left main disease, chronic total occlusions or planned for surgical revascularisation were largely excluded. Therefore, in people with complex MVD, CABG may be the appropriate complete revascularisation strategy (section 3.8 *Coronary Artery Bypass Graft Surgery in ACS*).

Treatment of MVD in NSTEMI

While complete revascularisation in STEMI is beneficial, currently there has been no dedicated trial comparing complete revascularisation versus PCI of the IRA only in people with NSTEMI. NSTEMI presents unique clinical challenges for management of MVD, including difficulty identifying the IRA lesion and a heterogeneous pathophysiology.

A meta-analysis of observational studies in people with NSTEMI (15 studies, n=171,279) found people who underwent multivessel revascularisation had higher short-term risk, but lower long-term MACE (OR 0.76, 95% CI 0.61–0.93), all-cause death (OR 0.83, 95% CI 0.71–0.97) and repeat revascularisation (OR 0.62, 95% CI 0.42–0.90) [469].

Invasive physiology to evaluate the non-IRA in STEMI or NSTEMI and MVD

Several RCTs have compared a physiology-guided approach (mostly using FFR) to an angiography-alone approach in people with STEMI and MVD. Meta-analyses have not shown an overall benefit of FFR-guided complete revascularisation in STEMI with MVD. Some have shown that angiography-guided complete revascularisation is associated with a lower risk of all-cause death and new MI compared with FFR-guided PCI [467,470,471]. The COMPLETE RCT demonstrated a clear benefit of complete revascularisation in people with STEMI and MVD, even without a physiology-guided approach in most cases [456]. Therefore, in people with STEMI and MVD, the decision to undertake PCI of the non-IRA can be based on angiographic severity alone.

In people with NSTEMI and MVD, physiology assessment may be of more value. Several RCTs have specifically compared a physiology-guided approach to an angiography-guided approach in treatment of the non-IRA. The overall evidence supports physiology or FFR as being reliable for non-IRA lesion estimation in NSTEMI and that FFR-guided PCI results in more people being treated medically, compared with angiography-guided PCI [472,473]. However, the results have been conflicting regarding outcomes. The FLOWER-MI trial (n=1,171) showed no difference in clinical outcomes of FFR-guided versus angiography-guided PCI of the non-IRA [474]. The FRAME-AMI trial showed a reduction in MACE with FFR-guided versus angiography-guided non-IRA PCI. However, a limitation was that the trial was terminated early due to slow recruitment, with only 43% (n=562) of the planned sample size enrolled [475].




Figure 14 Management of multivessel disease in people with ACS.

Abbreviations: ACS, acute coronary syndromes; FFR, fractional flow reserve; IRA, infarct-related artery; NSTEMACS, non-ST-segment elevation acute coronary syndromes; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.

In older people with MI and MVD, physiology assessment may be of benefit. The FIRE trial (n=1,445) included people ≥ 75 years with MI and MVD (median age 80 years, 65% NSTEMI, 35% STEMI). Findings showed FFR or angiography-derived quantitative flow ratio guided complete revascularisation versus IRA-only PCI resulted in a significant reduction in the composite endpoint of death, MI, stroke or revascularisation at one year (HR 0.73, 95% CI 0.57–0.93, $p=0.01$). This was driven by reductions in cardiovascular death and MI (HR 0.64, 95% CI 0.47–0.88), with no difference in safety outcome and similar efficacy in STEMI and NSTEMI [375]. Refer to [Figure 14](#) for guidance on management of multivessel disease in people with ACS.

Practice points

Treatment of non-IRAs

- In people with STEMI and MVD, with unknown renal function, inpatient PCI as a staged rather than immediate procedure, may be preferable if complex MVD is present or operator fatigue precludes same setting multivessel PCI.
- In people with NSTEMI and MVD, timing for complete revascularisation should consider factors such as the presence of cardiogenic shock, lesion complexity and risk of contrast nephropathy.
- While a benefit of FFR-guided over angiography-guided complete revascularisation has not been conclusively shown, it is reasonable to use FFR in intermediate (50–69%) non-infarct-related stenoses [471].

- In people with ACS and complex MVD, a multidisciplinary heart team approach to the revascularisation strategy is recommended. Management of people with ACS and complex MVD should be guided by multidisciplinary heart team discussions incorporating person-based (e.g. age, frailty, infarct size, personal preference) and lesion-based (e.g. location, severity and complexity) factors.

3.8. Coronary Artery Bypass Graft Surgery in ACS

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with STEMI, mechanical complications and mitral valve disease (e.g. ventricular septal rupture, mitral valve insufficiency because of papillary muscle infarction or rupture, or free wall rupture), perform CABG at the time of surgery.	Strong	Low

Evidence supporting the recommendations

Peri-operative mortality after mechanical complications of STEMI remains high [476]. Few percutaneous or medical treatments are available and urgent surgery most often remains the best option. A haemodynamically unstable person may require interim mechanical circulatory support. Performing CABG at the time of surgery for a mechanical complication of STEMI is based on small retrospective series with no randomised trial data [477].

Practice points

- In people with STEMI where PCI cannot be performed, consider emergency CABG if there is ongoing ischaemia and a large area of jeopardised myocardium.
- Overall, 4–10% of people with NSTEMI/ACS will require CABG [478]. Factors that should be considered when deciding between PCI and CABG are the same as for people presenting electively. These include comorbidities, fitness for major surgery, and coronary anatomy. A multidisciplinary team should be involved in decision making.
- In people with ACS and MVD where CABG has been chosen as the complete revascularisation strategy, performing CABG at day one to seven (compared to day zero or >7 days) after diagnosis has lowest risk of mortality [479].
- In people with ongoing ischaemia or haemodynamic instability with an indication for CABG, do not delay urgent surgery due to antiplatelet exposure.

3.9. Treatment for Spontaneous Coronary Artery Dissection

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with ACOMI due to SCAD but who are otherwise stable, routine revascularisation is not recommended.	Consensus	
In people with SCAD and haemodynamic instability and/or ongoing ischaemia, consider selective revascularisation.	Weak	Very Low

Evidence supporting the recommendations

As there are no RCTs to guide therapy, recommendations in SCAD are based on observational studies or expert opinion [480]. Intervention is challenging and routine revascularisation is not recommended as it has been associated with several complications. These include iatrogenic dissection, wiring of the false lumen, propagation of the intramural haematoma, acute vessel closure and stent or graft failure [481–483]. However, in a subgroup of people with SCAD who have significant ongoing ischaemia and haemodynamic compromise, urgent revascularisation with PCI or CABG may be required [484–487].

3.10. Myocardial Infarction with Non-Obstructive Coronary Arteries

In people with MINOCA, it is important to exclude alternative diagnoses [488]. Consider cardiac MRI in all people with MINOCA where the underlying cause is not obvious. Once the underlying cause has been established, manage people with MINOCA according to relevant disease-specific guidelines [27]. In all people with evidence of coronary atherosclerotic disease and/or risk factors, consider initiating secondary prevention measures (even if the underlying cause of MINOCA cannot be determined) [28].

3.11. Myocardial Infarction due to Oxygen Supply/Demand Mismatch without Acute Coronary Occlusion

No trials have examined the benefits of a routine invasive strategy in people with MI due to oxygen supply/demand mismatch without acute coronary occlusion [489]. Whether competing risks from non-cardiac conditions obscure the benefits of invasive management – and at what level of competing risk this occurs – remains uncertain. All available evidence demonstrates that people with MI due to oxygen supply/demand mismatch without acute coronary occlusion experience higher all-cause mortality than people with MI with acute coronary occlusion. This is, in part, related to associated non-coronary competing risks [489]. In the absence of any trial evidence, angiography with a view to revascularisation may be considered if there is ongoing ischaemia or haemodynamic compromise despite adequate treatment of the underlying acute stressors (section 3.1.3 Administration of fibrinolytic therapy and Table 9).

3.12. Echocardiography

Left ventricular (LV) dysfunction is an important determinant of prognosis following ACS and its detection should guide further evidence-based therapies [490]. Echocardiography to evaluate regional and global LV function, and to identify other cardiac pathology, should be performed

during hospitalisation. If echocardiography is not possible, consider other aspects suggestive of LV dysfunction, including clinical signs/symptoms, and ECG, chest X-ray and biomarker features [490].

3.13. Duration of Cardiac Monitoring

Cardiac monitoring plays a pivotal role as an adjunct therapy in the management of ACS. Continuous cardiac monitoring has become a firmly embedded standard of practice despite the absence of evidence from RCTs [491]. Clinical assessment for the risk of life-threatening arrhythmias should be individualised based on known associated risk factors: arrhythmias, ongoing symptoms, reduced LV function (LVEF <40%), failed coronary reperfusion, haemodynamic instability, and complications of PCI (side branch occlusion, unsealed dissection, embolisation).

Practice points

- In people with ACS, initiate cardiac monitoring immediately, with ST-segment ischaemia monitoring where available. Continue uninterrupted for a minimum of 24 hours.
- People with ACS post-PCI should be monitored, with ST-segment ischaemia monitoring where available, continuously and uninterrupted for 24 hours.
- Reevaluate the need for continuous ECG monitoring every 24 hours.
- Educate staff regarding proper skin preparation, assessment of skin turgor and ECG electrode replacement every 24 hours, as this reduces inappropriate alarms [492,493].
- Further guidance regarding cardiac monitoring can be found on the Agency for Clinical Innovation website (aci.health.nsw.gov.au/cardiac) [491].

4. Recovery and Secondary Prevention

Following ACS, participation in exercise-based cardiac rehabilitation and person-centred, secondary prevention programs (collectively termed cardiovascular risk management programs) is essential to help reduce future vascular events and improve quality of life and prognosis [494]. Participation in these programs facilitates earlier return to usual activities including work.

Engagement with these programs benefits all people with ACS, including women, older adults, regional and remote residents, First Nations peoples, and people from culturally and linguistically diverse backgrounds [67,494].

Risk management programs complement the care provided by a person's general practitioner and other allied healthcare professionals in the community. These programs address the following:

- Supporting people to manage their recovery post-ACS and adopt healthy behaviours (e.g. quitting smoking and/or drug and alcohol use, being physically active, eating healthily and maintaining good mental health).
- Intensive clinical risk factor education and modification (e.g. managing blood pressure, lowering blood lipids, optimising diabetes management).
- Filling prescriptions, reaffirming adherence to guideline-indicated medicines and facilitating review for actual and potential medicine-related harm, when suspected.
- Educating people on appropriate management of new or ongoing symptoms post-discharge, including use of anti-anginal medicines and when to seek urgent medical attention.
- Taking actions to protect against influenza and other pathogens, exposure to climate extremes, severe air pollution and cardiac toxins where applicable.
- Empowering people and their carers/support people towards greater self-care and management of their underlying cardiac status and comorbidities.

A system-generated referral to a flexible, tailored risk management program should be made prior to the person's discharge from hospital.

Prior to discharge, it is also crucial to ensure the person has a scheduled post-discharge review appointment with a member of their treating team (e.g. cardiologist, specialist cardiac nurse). This is important to address any immediate issues including medicines adherence, wound management and emotional and mental wellbeing.

4.1. Person-Centred Non-Pharmacological Secondary Prevention

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
For all people with ACS, refer to a multi-disciplinary exercise-based cardiac rehabilitation program prior to discharge.	Strong	Moderate
For all people with ACS, provide advice on lifestyle* changes such as healthy eating, regular physical activity, not smoking, limiting alcohol intake, and caring for mental health.		Consensus
For all people with ACS who smoke, advise to stop and refer for behavioural intervention (such as cognitive behaviour therapy or cessation counselling program), combined with pharmacotherapy where appropriate (nicotine replacement therapies, varenicline and bupropion individually or in combination).	Strong	Moderate
For all people with ACS, implement strategies to optimise adherence to preventive medicines.		Consensus

*Use of the word lifestyle here refers to a collective group of modifiable risk factors. The authors wish to acknowledge that these risk factors are not solely dependent on individual choice, and instead reflect the cultural, social and environmental factors that influence behaviour. This term does not in any way attribute blame to individuals.

Evidence supporting the recommendations

Cardiac rehabilitation is a structured, multidisciplinary program that delivers tailored interventions to people post-ACS (and those with other cardiac conditions). Key components of

these comprehensive programs include exercise training and physical activity, cardiovascular risk factor management, nutritional advice, medicines education and mental health support. Various cardiac rehabilitation delivery models are available, including in-person or via telehealth, group or individual, and home-, hospital- or community-based.

A contemporary systematic review of 85 trials randomised 23,430 people (predominantly post-MI and post-revascularisation) to either exercise-based cardiac rehabilitation or usual care with a median follow-up of 12 months (range 6 months to 19 years). Results showed meaningful reductions in MI and all-cause hospital admissions (RR 0.82, 95% CI 0.70–0.96 and RR 0.77, 95% CI 0.67–0.89, respectively) [494]. Although risk reductions in cardiovascular mortality were reported (RR 0.74, 95% CI 0.64–0.86), the certainty of evidence was downgraded due to imprecision. There was no significant effect on all-cause mortality (RR 0.96, 95% CI 0.89–1.04) and cardiovascular hospitalisation (RR 0.85, 95% CI 0.67–1.08). There was limited evidence of improved health-related quality of life and cost-effectiveness. The overall effects were independent of cardiac rehabilitation delivery models, exercise doses, duration of follow up, or risk of bias. A flexible, cardiovascular risk management program is a reasonable alternative [495].

Smoking cessation is strongly associated with decreased risk of subsequent non-fatal and fatal MI [496,497]. Smoking is prevalent among people hospitalised with ACS. An observational study in 9,375 people with ACS with a mean follow-up of 3.9 years found an 80% higher risk of death among those who continued to smoke compared with lifelong non-smokers and people who quit smoking [498].

Suboptimal adherence to prescribed medicines following ACS is associated with an increased risk of poor outcomes including cardiac-related rehospitalisation and mortality [499]. An observational analysis of 3,441 people with ACS found that 45% were not taking prescribed lipid-lowering medicines at 12 months post-event [500]. Similarly, a large prospective audit of 2,299 people with ACS evaluated the proportion that received optimal secondary prevention care [501]. Only 65% were discharged with appropriate medicines including antiplatelets, lipid-lowering medicines, beta blockers and angiotensin converting enzyme (ACE) inhibitors. Commencing people with ACS on guideline-recommended therapies while in hospital is strongly predictive of adherence at 6 months [502]. Implementing strategies to ensure prescription of preventative medicines at discharge, in addition to providing person-centred medicines education, are critical to improving adherence.

Practice points

Cardiac rehabilitation and secondary prevention programs

- Cardiac rehabilitation and secondary prevention programs should offer evidence-based aerobic and resistance training in accordance with the current Cardiac Society of Australia and New Zealand (CSANZ) Position Statement

[503]. Where an exercise-based cardiac rehabilitation program is not available, refer to a flexible, cardiovascular risk management program.

- Evidence-based cardiac rehabilitation programs should be tailored, where possible, to meet the unique needs of groups with low attendance rates, including women and people from culturally and linguistically diverse communities [504,505].
 - For First Nations peoples, enable access to cardiac rehabilitation programs facilitated by Aboriginal and Torres Strait Islander health practitioners wherever possible.
 - For people whose first language is not English, enable access to bilingual educators wherever possible.
- For people with ACS living in regional and remote communities, cardiac rehabilitation via telehealth is an acceptable alternative to in-person programs [506]. The Cardiac Services Directory (cardiacserviceslist.heartfoundation.org.au) on the Heart Foundation website lists cardiac rehabilitation programs available throughout Australia, including those delivered via telehealth.
- Embed system-generated referral to a cardiac rehabilitation/risk management program based on a person's preference, values and the available resources [507–512].
- Consider use of digital health interventions in the delivery of cardiovascular risk management programs post-ACS such as reminders, text messaging, mobile health (mHealth) apps, telehealth consultations, wearable devices and electronic decision support tools [510,513,514].
- Exercise-induced cardiac events are negligible in comparison to the risk associated with being habitually sedentary [515].

Lifestyle management

- Provide relevant disease and lifestyle education; the latter covering healthy eating, regular physical activity, not smoking, limiting alcohol intake and caring for mental health. Refer to the Heart Foundation website for guidance and resources on these topics.
- Screen people with ACS for depression and other mental health conditions using validated tools and refer for appropriate mental health support as required. People with ACS commonly experience feelings of low mood, sadness, guilt, worry and anger [516–519].

Medicines adherence

- Provide effective medicines education during hospital admission and at time of discharge. This should include discussion of:
 - what each medicine is for, the strength and dose, and when and how to take it
 - the importance of continuing to take medicines as prescribed, and not stopping or changing the dose unless advised by their GP
 - what to do if the person misses a dose
 - potential side effects and what to do if the person believes they are experiencing a side effect.
- Implement practical strategies to promote adherence, such as daily alerts/reminders, combining medicines where

possible (fixed combination medicines) and pharmacy-provided medicine packs.

- Consider post-discharge comprehensive medicine review, particularly in those with significant medicine changes, polypharmacy and/or multimorbidity, those on high-risk medicines such as anticoagulants, and those at risk of medicine non-adherence [520].

Follow-up care

- Provide a verbal and written discharge summary that includes:
 - the diagnosis and treatment, including investigation findings
 - scheduled follow-up appointments (post-discharge review with the treating team, general practitioner, cardiac rehabilitation)
 - medicines commenced, altered or ceased while in hospital, and the importance of taking medicines as prescribed
 - healthy lifestyle changes and practical strategies to implement these
 - a chest pain/angina management plan.
- Ensure chest pain/angina management plans include guidance management of new or ongoing symptoms post-discharge, including use of anti-anginal medicines, and when and how to seek urgent medical attention (i.e. calling Triple Zero (000) for an ambulance rather than driving to hospital).
- Two-way communication between the discharging hospital and the person's general practitioner is critical to support the ongoing care of people with ACS. Similarly, encourage people with ACS to establish/maintain regular contact with their general practitioner for ongoing follow up.
- Initiate a general practitioner management plan or team care arrangement to assist in the management of comorbidities. This is particularly important for older adults with geriatric syndromes including frailty, impaired cognitive function, and polypharmacy [507–512].

4.2. Vaccination Against Influenza and Other Respiratory Pathogens

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with ACS, vaccinations for influenza and other respiratory pathogens are recommended.	Consensus	

Evidence supporting the recommendations

In people with ACS, an international contemporary trial which randomised 2,571 people with STEMI or NSTEMI to influenza vaccine or placebo found that influenza vaccine reduced the primary composite outcome of all-cause death, MI, or stent thrombosis (HR 0.72, 95% CI 0.52–0.99) at one year follow up [521]. The findings are consistent with those from a meta-analysis of randomised trials and observational studies comprising almost 240,000 people with cardiovascular disease and a median follow-up of 19.5 months. Influenza vaccination was associated with reduced risk of all-cause and cardiovascular mortality but not MI when compared with the control group [522]. The *Australian immunisation handbook* outlines recommendations for people with CAD and other chronic cardiac conditions regarding respiratory syncytial virus (RSV), influenza, pneumococcal disease and COVID-19 vaccination [523].

Practice points

- People with CAD should receive influenza and pneumococcal vaccinations as per recommended schedules [523]. The influenza vaccine can be safely administered within 72 hours of hospitalisation for AMI, including for an invasive coronary procedure [521].
- People aged ≥ 60 years with CAD receive RSV vaccination due to their increased risk of severe RSV disease [523].
- People with chronic cardiac conditions, including coronary heart disease, are at increased risk of severe COVID-19 and may benefit from additional doses of COVID-19 vaccine.

4.3. Post-ACS Pharmacotherapy

4.3.1. Antiplatelet therapy

Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people discharged following an ACS who are at high ischaemic and/or low bleeding risk, prescribe DAPT with aspirin and a P2Y ₁₂ inhibitor for 6–12 months.	Strong	High
In people discharged following an ACS who are at low ischaemic and/or high bleeding risk, cease DAPT at 1–3 months post-ACS and continue single antiplatelet therapy (SAPT).	Strong	High

(continued).

Recommendation	Strength of recommendation	Certainty of evidence
In people discharged following an ACS who have completed a course of DAPT (i.e. 1–12 months), prescribe long-term P2Y ₁₂ inhibitor over aspirin.	Strong	Moderate
In people discharged following an ACS who remain at high ischaemic and low bleeding risk, consider long-term DAPT (>12 months).	Weak	Moderate
In people discharged following an ACS with an indication for long-term OAC therapy, continue OAC and DAPT (preferentially aspirin and clopidogrel) for 1–4 weeks, then cease aspirin.	Strong	High
In people discharged following an ACS with an indication for long-term OAC therapy, cease antiplatelet therapy at 6–12 months and continue anticoagulation alone.	Strong	Moderate

Evidence supporting the recommendations

The landmark P2Y₁₂ inhibitor trials in people with ACS undergoing PCI reported primary outcomes following 9–12 months of DAPT which became the standard duration of therapy [387,388]. However, these trials were designed in the era of early generation drug eluting stents when late stent thrombosis was more common than is seen in current practice.

More recent studies regard long duration therapy as being up to 6 months, particularly among people that have been stented. This is based on the observation that the incidence of ischaemic events plateaus by this time while cumulative bleeding risk continues to rise [524].

Studies on DAPT are dominated by people undergoing PCI, with those managed by CABG or medical treatment alone confined to subgroup analyses. Therefore, the applicability of these recommendations to non-PCI groups is less clear.

Short term vs standard duration of DAPT in people with ACS
Improved ischaemic outcomes attributable to developments in stent technologies and secondary prevention strategies have prompted several studies exploring outcomes following shorter duration DAPT, driven principally by the desire to reduce bleeding risk. These trials have compared short-term

(1–3 months) DAPT against standard term (6–12 months) DAPT after which aspirin or the P2Y₁₂ inhibitor is ceased, leaving the other as SAPT.

A meta-analysis of RCTs in people with ACS undergoing PCI (n=25,907) compared 1–3 months with 6–12 months of DAPT followed by SAPT. The study found a significant reduction in bleeding events in the 1–3 month treatment group (HR 0.47, 95% CI 0.47–0.62) with no significant differences in MACE [408]. This study also reported a trend towards increased MACE with short-term DAPT in people with STEMI, left main or left anterior descending artery disease (i.e. high ischaemic risk) [408].

In short duration DAPT studies, the antiplatelet selected for continuation as SAPT has most commonly been a P2Y₁₂ inhibitor (clopidogrel or ticagrelor). A network meta-analysis of people with ACS (24,838 patient-years of follow-up) and stable counterparts (85,221 patient-years) undergoing stenting showed continuation of a P2Y₁₂ inhibitor rather than aspirin appears to provide the best trade-off to reduce risk of both major bleeding and MI [525,526].

People at high bleeding risk

Several scores are available to predict HBR in people receiving DAPT following PCI. The PRECISE-DAPT score was developed to provide a standardised tool for predicting mid-term (1-year) bleeding events during DAPT in an all-comers PCI population, and shows similar discriminative capacity for bleeding when compared with the older CRUSADE and ACUTY scores [527,528]. The ARC-HBR is an alternative pragmatic approach recommended in European guidelines [142].

A meta-analysis in people at HBR (n=9,006) found that 1–3 months DAPT significantly reduced major or clinically relevant non-major bleeding (RR 0.76, 95% CI 0.61–0.94) with no difference in MACE [529]. There was no difference in outcomes when aspirin or P2Y₁₂ was used for continuing SAPT.

Another meta-analysis in people at HBR (n=16,848, including people receiving OAC therapy), compared short-term DAPT (≤3 months) followed by aspirin or P2Y₁₂ inhibitor SAPT against standard DAPT (6–12 months) after PCI [530]. Compared with standard DAPT, major bleeding was lower with short-term DAPT (OR 0.68, 95% CI 0.51–0.89). Incidence of MI, all-cause death, cardiovascular death, stroke, or stent thrombosis was not statistically different. Similar findings have been reported in people with HBR undergoing complex PCI [343].

Long-term SAPT

A network meta-analysis of people after PCI (n=73,126; consistent findings in ACS sensitivity analysis) found that compared with DAPT (of 1–18 months duration), P2Y₁₂ inhibitor and aspirin monotherapies reduced bleeding. However, the risk of MI was similar with a P2Y₁₂ inhibitor and increased with aspirin monotherapy [531].

A meta-analysis of people with established vascular disease (n=61,623, 30% with ACS) found that P2Y₁₂ inhibitor monotherapy reduced the risk of MACE (composite of stroke, MI, or death in the majority of studies) by 11%




Figure 15 Decision tree for dual antiplatelet therapy (DAPT) duration following an ACS.

*Prasugrel is not currently available in Australia.

‡Refers to the de-escalation of DAPT to aspirin and a less potent P2Y₁₂ inhibitor (clopidogrel).

#Current Pharmaceutical Benefits Scheme criteria preclude the prescription of ticagrelor as single therapy.

Abbreviations: ACS, acute coronary syndromes; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.

compared with aspirin monotherapy (RR 0.89, 95% CI 0.84–0.95) [532]. This finding was consistent irrespective of the P2Y₁₂ inhibitor used (clopidogrel or ticagrelor, $p=0.83$). There was also no significant difference in the risk of major bleeding with P2Y₁₂ inhibitor monotherapy compared with aspirin (RR 0.94, 95% CI 0.72–1.22).

These findings align with those from a meta-analysis (seven RCTs) in 24,325 people with CAD, including 12,178 people receiving P2Y₁₂ inhibitor monotherapy (clopidogrel 7,545 [62%]; ticagrelor 4,633 [38%]) and 12,147 people assigned to receive aspirin [533].

To note, ticagrelor is not currently subsidised on the Pharmaceutical Benefits Scheme (PBS) as monotherapy. Current PBS criteria state ticagrelor must be prescribed in combination with aspirin.

Prolonged (>12 months) duration of DAPT

A study of 21,162 people with previous MI (1–3 years earlier), found that DAPT with ticagrelor and aspirin was associated with a reduction in the composite outcome of cardiovascular death, MI or stroke compared with aspirin alone (HR 0.85, 95% CI 0.75–0.96), which was balanced by an increase in major bleeding (HR 2.69, 95% CI 1.96–3.7) [534].

A meta-analysis ($n=25,985$, 42.4% ACS) comparing prolonged DAPT (>12 months) with standard DAPT (6–12 months) following PCI found that prolonged DAPT reduced the risk of MI and stent thrombosis, but increased the risk of bleeding, compared with standard DAPT. There was no

difference in the risk of all-cause death or cardiovascular death [535]. People with a prior MI, with ACS at presentation, without diabetes, or younger than 75 years may derive the most ischaemic benefit from extended DAPT.

A pooled post-hoc analysis of eight RCTs ($n=14,963$) of people treated with PCI, stratified by PCI complexity and bleeding risk, found that long-term DAPT reduced ischaemic events in non-HBR people in both complex (absolute risk

Table 11 Determinants of recurrent ischaemic risk following an ACS [343,408].

Low ischaemic risk	High ischaemic risk	Persisting high ischaemic risk
• Aged <75 years • Not left main/left anterior descending artery disease • Non-complex PCI	• STEMI • Left main/left anterior descending artery disease • Complex PCI* • Recurrent events on DAPT	• Complex PCI* • Recurrent events on DAPT

*Complex PCI: >2 stents/lesions/vessels treated, bifurcation stenting, >60 mm of stent, chronic total occlusion.

Abbreviations: ACS, acute coronary syndromes; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.

Table 12 The Academic Research Consortium (ARC) high bleeding risk criteria. Adapted with permission from Urban et al. [342].

High bleeding risk ARC score (one major and two minor criteria)	
Major criteria	Minor criteria
• Anticipated long term OAC use • Severe CKD (eGFR <30 mL/min) • Hb <11 g/dL • Spontaneous bleeding requiring hospitalisation or transfusion in the past six months or at any time if recurrent • Baseline platelet count <100x10⁹/L • Chronic bleeding diathesis • Liver cirrhosis with portal hypertension • Active malignancy within 12 months • Previous spontaneous ICH (at any time) • Traumatic ICH within 12 months • Brain arteriovenous malformation • Moderate or severe ischaemic stroke within 12 months • Recent major surgery or major trauma within 30 days before PCI	• Age >75 years • Moderate CKD (eGFR 30–59 mL/min) • Hb 11–12.9 g/dL for men and 11–11.9 g/dL for women • Spontaneous bleeding requiring hospitalisation or transfusion within 12 months not meeting major criteria • Long term NSAID or steroid use • Prior ischaemic stroke not meeting major criterion

Abbreviations: ARC, Academic Research Consortium; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; ICH, intracranial haemorrhage; NSAID, nonsteroidal anti-inflammatory drug; OAC, oral anticoagulant; PCI, percutaneous coronary intervention.

difference: −3.86%; 95% CI −7.71–0.06) and noncomplex PCI (absolute risk difference: −1.14%; 95% CI −2.26– −0.02). There was no benefit of prolonged DAPT seen in people with HBR. Results in people with ACS at presentation were consistent with the whole cohort [343]. Refer to [Figure 15](#) and [Table 11](#) and [Table 12](#) for guidance on DAPT duration following an ACS.

People with atrial fibrillation requiring long-term anticoagulation

A meta-analysis of the four DOAC-based RCTs comparing dual antithrombotic therapy with triple antithrombotic therapy in people with atrial fibrillation undergoing PCI (n=10,234, >50% ACS) found significantly less bleeding with dual therapy (clopidogrel + DOAC) (RR 0.63, 95% CI 0.50–0.79). While there was no difference in the composite of ischaemic events for dual therapy, there was a significant increase in stent thrombosis (RR 1.60, 95% CI 1.02–2.52) [536]. In

each of these studies, aspirin was administered periprocedurally and was ceased from one day to one week following PCI in the dual antithrombotic arms.

A subsequent network meta-analysis of five RCTs (n=11,542) comparing different double and triple antithrombotic regimens found that non-vitamin K OAC plus P2Y₁₂ inhibitor without aspirin had the best safety profile, when compared with treatments that included aspirin (as a component of triple therapy) or vitamin K antagonists [537].

Additional secondary and pooled analyses of these studies have found that stent thrombosis was highest in the first 30 days after randomisation, with higher rates in the non-aspirin group [538]. This suggested the potential for increased thrombotic complications among people receiving dual therapy (i.e. no aspirin) within the first month [536,539]. It may therefore be reasonable to continue aspirin for up to one month following PCI in people who are not at HBR, although this recommendation is based on consensus opinion and has not been specifically addressed in any of the randomised trials [436].

A trial evaluating longer term antithrombotic therapy in people requiring anticoagulation found that ceasing SAPT at 6 months and continuing with a DOAC for more than one year following stenting had no effect on ischaemic or bleeding events in people with HBR [540]. Another trial of DOAC-containing regimens showed that concomitant treatment with aspirin compared with DOAC monotherapy for more than one year following stenting was associated with increased mortality with event rates of 4% and 6% per patient-year, respectively (HR 0.72, 95% CI 0.55–0.95) [541]. Antiplatelet therapy should be ceased and the DOAC continued at 12 months in people following an ACS with an indication for long-term OAC.

Refer to [Figure 16](#) for guidance on recommended antiplatelet treatment strategies for people with ACS requiring long-term DOAC for atrial fibrillation.

Practice points

Short term vs standard duration of DAPT in people with ACS

- In older people (e.g. ≥70 years) with ACS, particularly if HBR, consider clopidogrel as the P2Y₁₂ receptor inhibitor [28].

People at high bleeding risk

- A mobile phone-based application has been developed to assist with decision-making for people at HBR (see www.cerc-europe.org/arc-hbr-high-bleeding-risk-evaluator/). This is based on an algorithm that predicts risk of major ischaemic and bleeding events [542].
- In people receiving DAPT with high risk of gastrointestinal bleeding, a proton pump inhibitor is recommended.

People requiring long-term anticoagulation

- In people with ACS undergoing PCI with other conditions that require long-term anticoagulation (e.g. mechanical heart valve), lack of evidence prevents recommendations being made.

- The recommendations in this section can be applied to people with ACS and MI undergoing medical management [407].
- In people who have undergone PCI and are at HBR, de-escalating therapy to anticoagulation alone after 6 months may be reasonable [436].
- In people receiving triple therapy, a proton pump inhibitor is recommended.

4.3.2. Lipid-modifying therapy Recommendations

Recommendation	Strength of recommendation	Certainty of evidence
In people with ACS, prior to hospital discharge, initiate and continue indefinitely, the highest tolerated dose of HMG-CoA reductase inhibitors (statins), unless contraindicated or completely statin intolerant.	Strong	High
In people with ACS with initial or partial intolerance to statin, consider using a different statin, dose or dosing frequency to achieve person-specific therapeutic objectives.	Weak	Low
In people with ACS, an initial target low density lipoprotein cholesterol (LDL-C) level of <1.4 mmol/L and a reduction of at least 50% from baseline is recommended, with further benefit gained from treating to the lowest achievable level.	Consensus	
In people with ACS with a suboptimal LDL-C level despite statin therapy or who are statin intolerant, consider adding ezetimibe.	Weak	Moderate
In people with ACS with a suboptimal LDL-C level despite maximally tolerated statin therapy and ezetimibe, give PCSK9 inhibitors.	Strong	High

Evidence supporting the recommendations

In a meta-analysis of statin therapy versus controls in a subset of people with pre-existing vascular disease (n=64,443; 45% ACS) the composite endpoint of MI, stroke, coronary revascularisation or vascular death was reduced by 20% for

every 1.0 mmol/L reduction in LDL-C [543]. Similar benefits were found in a meta-analysis of high versus lower dose statin therapy [544]. These randomised trials of statin therapy before or after PCI in people with ACS (n=6,743) found high-dose versus no- or low-dose statins reduced the combined outcomes of death, recurrent MI and stroke by 28% (OR 0.82, 95% CI 0.70–0.95) beyond 30 days. This aligned with the lower risk of MI and MACE at 30 days. The latter benefit occurred within the first 6 months after ACS [543].

A meta-analysis of placebo-controlled RCTs (n=123,940, 16.4% ACS) found almost half (48%) reported at least one episode of muscle pain or weakness during a median of 4.3 years corresponding to a 3% relative increase in those taking statins compared with placebo (RR 1.03, 95% CI 1.01–1.06) [543]. Up to 70% of people reporting statin intolerance may tolerate reduced dose regimens or substitution of a hydrophilic statin [545].

The IMPROVE-IT randomised trial in people with ACS (n=18,144) found a modest reduction in study-specific MACE in the statin-ezetimibe group versus statin monotherapy (HR 0.936, 95% CI 0.89–0.99) [546].

Monoclonal antibodies to PCSK9, known as PCSK9 inhibitors, are very effective at significantly lowering LDL-C in people already receiving intensive lipid-lowering therapy. Examples of PCSK9 inhibitors include alirocumab, evolocumab and inclisiran. In a randomised trial of 18,924 people with a recent ACS on maximally tolerated statins and an LDL-C of at least 1.8 mmol/L, the PCSK9 inhibitor alirocumab reduced the composite cardiovascular endpoint over a median follow up of 2.8 years (HR 0.85 95% CI 0.78–0.93) compared with placebo. There was also a lower risk of all-cause mortality favouring active treatment over placebo [547].

Practice points

- Initiate or continue high-potency statin therapy (e.g. atorvastatin or rosuvastatin) as early as possible during the ACS admission, irrespective of baseline LDL-C level [544].
- For people on lipid-lowering therapy prior to index ACS admission, consider intensifying existing lipid-lowering therapy.
- Re-assess total cholesterol and LDL-C levels approximately four to six weeks after initiating or intensifying treatment. Adjust statin therapy or add non-statin therapy according to whether levels are at target values. Note that additional non-statin therapies are frequently required to achieve target LDL-C levels and to prevent recurrent coronary events.
- In people with ACS (men <55 years and women <60 years), the Dutch Lipid Clinic Network score can guide the need for diagnostic genetic testing. If genetic predisposition is confirmed, consider cascade testing, genetic counselling, and initiating statins in family members [548].
- In people with ACS with triglyceride levels of 1.5–5.6 mmol/L and LDL-C 1.0–2.6 mmol/L despite statin therapy, consider adding icosapent ethyl [549]. Note that the current PBS eligibility criteria for icosapent ethyl is a triglyceride level of 1.7 mmol/L.




Figure 16 Recommended antiplatelet treatment strategies for people with ACS requiring long-term DOAC for atrial fibrillation.

[#]DAPT: aspirin plus clopidogrel preferred.

^{*}SAPT: clopidogrel preferred.

Note: People receiving triple therapy should be given a proton pump inhibitor.

Abbreviations: ACS, acute coronary syndromes; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; SAPT, single antiplatelet therapy.

Women

- In women at risk of a major vascular event, commence statin therapy [550].
- Note that women are less likely than men to be prescribed statin therapy post-ACS [551].

Older adults

- In older adults with evidence of occlusive vascular disease (such as prior MI), consider statin therapy to reduce the risk of major vascular events [552].

4.3.3. Beta blocker therapy Recommendations

Recommendation	Strength of recommendation	Certainty of Evidence
In people with ACS and LV impairment, beta blockers are recommended.	Consensus	

(continued).

Recommendation	Strength of recommendation	Certainty of Evidence
In people with ACS and preserved LV systolic function who have undergone coronary revascularisation and are receiving optimal medical therapy, consider withholding beta blockers.	Weak	Moderate

Evidence supporting the recommendations

In a meta-analysis of RCTs (n=102,003 people post-MI), beta blockers lowered all-cause mortality in the pre-perfusion era (incidence rate ratio [IRR] 0.86, 95% CI 0.79–0.94), but not in the reperfusion era (IRR 0.98, 95% CI 0.92–1.05), ($P_{\text{interaction}}=0.02$) [553]. However, significant reductions in recurrent MI occurred in both the pre-perfusion

and reperfusion eras, respectively (IRR 0.78, 95% CI 0.78–0.98 and IRR 0.72, 95% CI 0.62–0.83). The reduced effect on mortality in the reperfusion era likely reflects a reduction in the frequency and severity of LV dysfunction, as the benefits of beta blockers in people with LV dysfunction are well established [554,555].

Findings from the REDUCE-AMI study are consistent with the hypothesis that beta blockers are of limited value in the absence of LV dysfunction. This randomised registry-based trial enrolling 5,020 people with AMI and preserved ejection fraction, undergoing early angiography, showed that long-term use of beta blockers did not reduce the composite endpoint of all-cause death and MI at 3.5 years of follow-up [556].

Practice points

- In people with MI and risk factors for cardiogenic shock, exercise caution when initiating beta blockers as these people may be at increased risk of early mortality [557].
- IV beta blockade in STEMI prior to PCI has not been shown to reduce death or MI at one year [558,559].
- In people with confirmed LV dysfunction, consider using a beta blocker of proven benefit in heart failure with reduced ejection fraction (specifically bisoprolol, carvedilol, metoprolol [controlled or extended release], or nebivolol). See the *Guidelines for the prevention, detection, and management of heart failure in Australia* for further details including other recommended therapies [490].
- In people with preserved ejection fraction, no benefit in continuing beta blockers beyond 12 months has been seen, but more research on this is being undertaken [560–563].
- In asymptomatic people discharged following an episode of UA (i.e. without MI) and with normal LVEF, there is paucity of evidence for protection against MACE from beta blocker therapy in the absence of other indications.

4.3.4. Renin-angiotensin antagonist therapies Recommendations

Recommendation	Strength of recommendation	Certainty of Evidence
In people with ACS and heart failure symptoms, LVEF $\leq 40\%$, diabetes, hypertension and/or chronic kidney disease, initiate and continue ACE inhibitors, or angiotensin receptor blockers if ACE inhibitors are not tolerated.	Strong	High

(continued).

Recommendation	Strength of recommendation	Certainty of Evidence
In people with ACS and LVEF $\leq 40\%$ and heart failure with or without diabetes, initiate and continue mineralocorticoid receptor antagonists.	Strong	High
In people with ACS, use of an angiotensin receptor–neprilysin inhibitor is not recommended.	Strong	High

Evidence supporting the recommendations

A meta-analysis of randomised trials in AMI ($n=98,496$), indicated use of ACE inhibitors results in a 7% decrease in mortality at 30 days, with the greatest benefit in people with heart failure or anterior MI [564].

The evidence for long-term benefit comes from a meta-analysis of randomised trials of people with stable vascular disease ($n=29,805$; $>50\%$ with prior MI) where long-term use of ACE inhibitors significantly reduced cardiovascular mortality, non-fatal MI and stroke in the context of long-term secondary prevention (OR 0.82, 95% CI 0.76–0.88) [565]. However, a more recent meta-analysis of ACE inhibitor or angiotensin receptor blocker treatment in people with coronary disease ($n=61,961$) found that this benefit was not seen in people receiving active anti-hypertensive therapy, or those with low anticipated event rates [566]. The recommendations, then, are for the long-term use of these medicines in people with anticipated high event rates, particularly those with conditions shown to benefit from ACE inhibition such as diabetes, hypertension, or chronic kidney disease.

Angiotensin receptor blockers have been shown to have a comparable effect to ACE inhibitors in people post-MI with reduced LVEF [567].

In an RCT of people with recent MI and LV dysfunction and symptoms of either heart failure or a diagnosis of diabetes ($n=6,632$), the mineralocorticoid receptor antagonist, eplerenone, in combination with standard therapy within 3–14 days of an AMI reduced mortality and cardiovascular hospitalisations (RR 0.87, 95% CI 0.79–0.95) [568].

In a randomised trial ($n=5,661$, post-MI with LVEF $\leq 40\%$ or transient pulmonary congestion), people received either an angiotensin receptor–neprilysin inhibitor or ACE inhibitor before hospital discharge. There was no difference in cardiovascular death or incident heart failure at 22 months [569]. Therefore, angiotensin receptor–neprilysin inhibitors are not recommended in this context.

Practice points

- In people with ACS and LVEF $\geq 40\%$ or without clinical heart failure, consider use of ACE inhibitors (or angiotensin receptor blockers if ACE inhibitors not tolerated) to improve survival [566].
- For people with ACS and concurrent hypertension, ACE inhibitors and angiotensin receptor blockers are indicated as first-line agents for hypertension management. Current blood pressure management and targets are provided in the Heart Foundation's *Guideline for the diagnosis and management of hypertension in adults* [570].
- In people with ACS and heart failure, ongoing management should align with the *Guidelines for the prevention, detection, and management of heart failure in Australia*, with consideration of referral to specialised heart failure services to optimise care and improve outcomes [490].

4.3.5. Colchicine therapy Recommendation

Recommendation	Strength of recommendation	Certainty of evidence
In people with ACS, consider initiating colchicine (0.5 mg daily) and continuing long-term unless contraindicated or colchicine intolerant.	Weak	Moderate

Evidence supporting the recommendation

Residual inflammation in the coronary vasculature after ACS may contribute to subsequent reinfarction. Anti-inflammatory medicines such as colchicine have the potential to directly address such an inflammatory environment, thereby minimising the risk of recurrent MACE.

A systematic review and meta-analysis (n=7,207) of people with ACS, with <1 month to 22.6 months follow-up, found that colchicine resulted in a lower risk of coronary revascularisation (RR 0.46, 95% CI 0.29–0.73) and stroke (RR 0.39, 95% CI 0.18–0.81) [571]. There was no significant difference in all-cause mortality (RR 1.25, 95% CI 0.70–2.24), cardiovascular mortality, or recurrent MI. Colchicine increased the risk of gastrointestinal adverse reactions (RR 1.89, 95% CI 1.25–2.84).

A randomised trial of people with MI (n=7,062) found no benefit of colchicine on the composite cardiovascular endpoint of death from cardiovascular causes, recurrent MI, stroke, or unplanned ischemia-driven coronary revascularisation at a median follow up of 3 years (HR 0.99, 95% CI 0.85–1.16, P=0.93). Further meta-analyses integrating this trial with prior studies are needed to confirm the limited role of colchicine in the management of people post-ACS.

Acknowledgements

The guideline authors would like to gratefully thank the following people for their valuable contribution:

- Members of the Consumer Advisory Panel for ensuring the content aligns with the values and preferences of people living with cardiovascular disease in Australia.
 - Darren Hicks (Chair)
 - David Follent
 - Sarah Hatzivlastou
 - Sharon Kort
 - Michael McGowan
 - Jarrod McMaugh
 - Léa Zeestraten
- Professor Derek P. Chew (MBBS, MPH, FRACP, PhD) for his contribution and involvement as the guideline's independent reviewer.
- Jacinta Hegarty, Acting First Nations Heart Health Lead, National Heart Foundation of Australia, for her contribution to section 1.4 *Collaborative Approaches to Care for First Nations Peoples*.

Funding

The guideline was jointly funded by the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (CSANZ). Funding was also received from trusts managed by Perpetual for the guideline development in 2020 and 2021.

Endorsements

Organisations that have endorsed this guideline can be found on the National Heart Foundation of Australia website at: <https://www.heartfoundation.org.au/for-professionals/acs-guideline>.

Declaration of Competing Interests

For a full list of disclosures/conflicts of interest, refer to *Supplementary Material A2*.

Appendices

Supplementary Materials associated with this article can be found at <https://doi.org/10.1016/j.hlc.2025.02.102>

Appendices

Appendix A. Abbreviations and Acronyms

ACE	angiotensin converting enzyme
ACOMI	acute coronary occlusion myocardial infarction
ACS	acute coronary syndromes
ACTION	Acute coronary treatment and intervention outcomes network
ACUITY	Acute catheterization and urgent intervention triage strategy
AMI	acute myocardial infarction
ARC-HBR	Academic Research Consortium high bleeding risk
CABG	coronary artery bypass grafting
CAD	coronary artery disease
CDP	clinical decision pathway
CI	confidence interval
CK-MB	creatinine kinase MB-isoenzyme
COPD	chronic obstructive pulmonary disease
CRUSADE	Can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines
CSANZ	Cardiac Society of Australia and New Zealand
CTCA	computed tomography coronary angiography
cTn	cardiac troponin
cTnI	cardiac troponin I
cTnT	cardiac troponin T
DAPT	dual antiplatelet therapy
DOAC	direct oral anticoagulants
ECG	electrocardiogram
ED	emergency department
EDACS	Emergency department assessment of chest pain score
eGFR	estimated glomerular filtration rate
ESG	Expert steering group
FFR	fractional flow reserve
GPI	glycoprotein IIb/IIIa inhibitor
GRACE	Global Registry of Acute Coronary Events
GRADE	Grading of recommendations, assessment, development and evaluation
HBR	high bleeding risk
HEART	History, electrocardiogram, age, risk factors, troponin
High-STEACS	High sensitivity troponin in the evaluation of patients with acute coronary syndrome
HR	hazard ratio
hs-cTn	high-sensitivity cardiac troponin
INR	international normalised ratio
IRA	infarct-related artery
IRR	incidence rate ratio
IV	intravenous
IVI	intravascular imaging
IVUS	intravascular ultrasound
kg	kilogram
LBBB	left bundle branch block
LDL-C	low density lipoprotein cholesterol
LMWH	low molecular weight heparin
LV	left ventricular
LVEF	left ventricular ejection fraction
LVH	left ventricular hypertrophy
MACE	major adverse cardiovascular events
mg	milligram

Appendix A. Continued

MI	myocardial infarction
MINOCA	myocardial infarction with non-obstructive coronary arteries
mL/min	millilitres per minute
mm	millimetre
mmol/L	millimoles per litre
MRI	magnetic resonance imaging
MVD	multivessel disease
ng/L	nanograms per litre
NHMRC	National Health and Medical Research Council
NSAIDS	non-steroidal anti-inflammatory medicines
NSTEACS	non-ST-segment elevation acute coronary syndromes
NSTEMI	non-ST-segment elevation myocardial infarction
OAC	oral anticoagulant
OR	odds ratio
P	probability
PBS	Pharmaceutical Benefits Scheme
PCI	percutaneous coronary intervention
PET	positron emission tomography
PICOTS	patient/population, intervention, comparison, outcome, time, setting
POC	point-of-care
RCT	randomised controlled trial
RR	risk ratio
RSV	respiratory syncytial virus
SaO ₂	arterial oxygen saturation
SAPT	single antiplatelet therapy
SCAD	spontaneous coronary artery dissection
SPECT	stress/rest single-photon emission computed tomography
SpO ₂	oxygen saturation
STE	ST-segment elevation
STEACS	ST-segment elevation acute coronary syndromes
STEMI	ST-segment elevation myocardial infarction
TIMI	Thrombolysis in myocardial infarction
tPA	tissue plasminogen activator
UA	unstable angina
UDMI	Universal definition of myocardial infarction
UFH	unfractionated heparin
UK	United Kingdom
VA-ECMO	venoarterial extracorporeal membrane oxygenation
µg	microgram
µg/L	microgram per litre

Appendix B Terminology and Definitions

Term	Definition
Chest pain – cardiac	Chest pain due to an underlying cardiac aetiology. Includes classic chest discomfort based on quality, location, radiation, and provoking and relieving factors that make it more likely to be of cardiac ischaemic origin.
Chest pain – non-cardiac	Chest pain symptoms likely due to a non-cardiac cause.
Chest pain – possible cardiac	Chest pain symptoms that suggest a cardiac origin.
Coronary artery disease (CAD)	CAD refers to the narrowing and/or blockage of the coronary arteries due to accumulation of plaque (atherosclerosis).
Coronary heart disease	Coronary heart disease refers to heart muscle damage that is caused by CAD, where there is reduced blood flow through the coronary arteries. Coronary heart disease is the major underlying cause of acute coronary syndromes.
Coronary microvascular dysfunction	Epicardial or microvascular endothelial or non-endothelial dysfunction that limits myocardial perfusion, most often detected as reduced coronary flow reserve.
Heart failure	Heart failure is a complex clinical syndrome resulting from any structural or functional impairment of ventricular filling or ejection of blood. The main manifestations of heart failure are dyspnoea and fatigue (which may limit exercise tolerance) and fluid retention. These may lead to pulmonary or splanchnic congestion and/or peripheral oedema. There is no single diagnostic test for heart failure; it is largely a clinical diagnosis based on a careful history and physical examination including 12-lead ECG, chest X-ray, transthoracic echocardiography and laboratory blood testing. When the diagnosis is unclear following initial clinical assessment and an echocardiogram cannot be arranged in a timely fashion, measurement of plasma natriuretic peptide levels is recommended.
Myocardial infarction (MI)	MI is the irreversible necrosis of heart muscle. A common cause of infarction is deprivation in myocardial oxygen supply due to interruption of blood flow in at least one coronary artery caused by plaque rupture, erosion, fissure, or coronary dissection. MI can also result from inflammatory, metabolic, or toxic insults to the myocardium. Early and accurate detection of MI is important for initiating and maintaining appropriate therapy. In clinical trials, lack of a uniform MI definition can result in low concurrence between the initial clinical and later adjudicated assessments of MI, which will affect accuracy of primary end points and trial outcomes. Thus, uniform definitions are needed to ensure accurate reporting of MI events across clinical trials and registries.
MI – Type 1 as per Fourth UDMI	Type 1 MI is characterised by atherosclerotic plaque rupture, ulceration, fissure, or erosion with resulting intraluminal thrombus in one or more coronary arteries leading to decreased myocardial blood flow and/or distal embolisation and subsequent myocardial necrosis. The person may have underlying CAD but non-obstructive coronary atherosclerosis or there may be no angiographic evidence of CAD.
MI – Type 2 as per Fourth UDMI	Type 2 MI is myocardial necrosis associated with an imbalance between myocardial oxygen supply and demand, and may be associated with hypotension, hypertension, tachy/bradyarrhythmias, anaemia, hypoxaemia, coronary artery spasm, spontaneous coronary artery dissection (SCAD), coronary embolism, and coronary microvascular dysfunction.
MI – Type 3 as per Fourth UDMI	Type 3 MI is MI resulting in death when biomarkers are not available.
MI – Type 4 and 5 as per Fourth UDMI	Types 4 and 5 MI relate to percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) respectively

Appendix B. (continued).

Term	Definition
Myocardial infarction with non-obstructive coronary arteries (MINOCA)	The diagnosis of MINOCA is made in people with acute myocardial infarction (AMI) that fulfills all following criteria: 1. AMI (modified from the <i>Fourth universal definition of myocardial infarction</i> criteria [15]): Detection of a rise or fall of cardiac troponin (cTn) with at least one value above the 99th percentile upper reference limit and corroborative clinical evidence of infarction based on at least one of the following: • symptoms of myocardial ischaemia • new ischaemic electrocardiographic changes • development of pathological Q waves • imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic cause • identification of a coronary thrombus by angiography or autopsy. 2. Non-obstructive coronary arteries on angiography, defined as the absence of obstructive disease on angiography (i.e. no coronary artery stenosis $\geq 50\%$) in any major epicardial vessel. (Note that additional review of the angiogram may be required to ensure the absence of obstructive disease). This includes people with normal coronary arteries (no angiographic stenosis), mild luminal irregularities (angiographic stenosis $<30\%$ stenoses), moderate coronary atherosclerotic lesions (stenoses $>30\%$ but $<50\%$). 3. No specific alternate diagnosis for the clinical presentation. Alternate diagnoses include but are not limited to non-ischaemic causes such as sepsis, pulmonary embolism, and myocarditis [27].
Myocardial injury	Myocardial injury, acute versus chronic (or acute-on-chronic), is defined by the presence of an elevated cardiac troponin (cTn) concentration above the 99th percentile of the upper reference limit. Myocardial injury is a frequently encountered clinical syndrome and is associated with an adverse prognosis. Myocardial injury is considered acute if there is a rise or fall of cTn concentrations over time, and chronic when cTn concentrations are persistently elevated. Clinicians must distinguish between one of the MI subtypes and non-ischaemic myocardial injury. Acute myocardial injury is related to the diagnosis of MI, particularly when accompanied by supportive evidence in the form of symptoms, electrocardiographic abnormalities, or imaging evidence of new regional wall motion abnormalities or new loss of viable myocardium. Non-ischaemic myocardial injury may arise secondary to cardiac or non-cardiac conditions.
Myocarditis	Myocarditis is an inflammatory disease of the myocardium caused by viral infections or a post-viral immune-mediated response. Clinical manifestations of myocarditis are varied and include chest pain that is often sharp and reflective of epicardial inflammation involving the pericardium. Myocardial dysfunction often causes fatigue and exercise intolerance. Predominance of heart failure distinguishes myocarditis from pericarditis; cTn is usually elevated.
Non-ST-segment elevation acute coronary syndromes (NSTEMACS)	NSTEMACS encompasses non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. NSTEMIs are characterised by the presence of both criteria: 1. Detection of a rise or fall of cardiac biomarker values (preferably cTn) with at least one value above the 99th percentile upper reference limit. Electrocardiographic changes or ischaemic symptoms may or may not be present. 2. Absence of electrocardiographic changes that are diagnostic of a ST-segment elevation myocardial infarction (STEMI) (see STEMI).
Occlusion myocardial infarction (OMI)	Refer to definition of unstable angina. Occlusion MI is acute coronary occlusion or near occlusion with insufficient collateral circulation, such that downstream myocardium will undergo imminent infarction without timely reperfusion. Occlusion MI may not always result in ECG findings of STEMI.

Appendix B. (continued).

Term	Definition
Older adults	Adults older than 75 years old.
Pericarditis	Pericarditis is inflammation of the pericardial layers characterised by chest pain, electrocardiographic changes, and often pericardial effusion. It is often caused by an infectious or non-infectious process but can also be idiopathic. Pericarditis usually presents with sharp pleuritic chest pain, which may be improved by sitting up or leaning forward, although in many instances such findings are not present. A pericardial friction rub may be audible. Widespread STE with PR depression is the electrocardiographic hallmark, although changes are non-specific and may be transient.
Pulmonary embolism	Intravascular migration of a venous thrombus to the pulmonary arterial circulation. It is diagnosed by a positive pulmonary angiogram, an unequivocally positive helical CT scan, a high-probability ventilation-perfusion scan, or autopsy.
Regional and remote	Based on the Australian Bureau of Statistics Australian Statistical Geography Standard (ASGS) Edition 3 Remoteness Structure that categorises areas based on relative access to services. Categories are 'major cities', 'inner regional', 'outer regional', 'remote' and 'very remote'.
Spontaneous coronary artery dissection (SCAD)	Epicardial coronary artery dissection that is not associated with atherosclerosis or trauma and is not iatrogenic. Predominant mechanism of myocardial injury occurring due to SCAD is coronary artery obstruction caused by an intramural hematoma or intimal disruption rather than atherosclerotic plaque rupture or intraluminal thrombus.
ST-segment elevation myocardial infarction (STEMI)	STEMI is characterised by the presence of both criteria: 1. Electrocardiographic evidence of STEMI: new or presumed new ST-segment elevation at the J-point in two contiguous leads with the cut-off point: ≥ 1 mm in all leads other than leads V2–V3 where the following cut off points apply: ≥ 2 mm in men ≥ 40 years; ≥ 2 –5 mm in men < 40 years; or ≥ 1 –5 mm in women regardless of age. When the magnitudes of J-point elevation in leads V2 and V3 are registered from a prior ECG, new J-point elevation ≥ 1 mm (as compared with the earlier ECG) should be considered an ischaemic response. 2. Detection of a rise or fall of cardiac cTn with at least one value above the 99 th percentile upper reference limit.
Unstable angina (UA)	Myocardial ischaemia at rest or on minimal exertion in the absence of acute cardiomyocyte injury/necrosis. UA is characterised by angina pectoris that occurs without stress or activity, or with decreasing stress or activity compared with stable angina and has been present for < 2 weeks. ECG changes of ACOMI and elevated troponin values are not seen in UA.

References

- [1] Aroney CN, Aylward P, Chew DP, Huang N, Kelly AM, White H, et al. 2007 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes 2006. *Med J Aust.* 2008;188:302–3.
- [2] Chew DP, Aroney CN, Aylward PE, Kelly AM, White HD, Tideman PA, et al. 2011 Addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes (ACS) 2006. *Heart Lung Circ.* 2011;20:487–502.
- [3] Acute Coronary Syndrome Guidelines Working Group. Guidelines for the management of acute coronary syndromes 2006. *Med J Aust.* 2006;184:S1–32.
- [4] Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE Handbook: Introduction to GRADE Handbook. Available at: gdt.grade.org/app/handbook/handbook.html; 2013.
- [5] National Health and Medical Research Council. 2016 NHMRC Standards for Guidelines. Available at www.nhmrc.gov.au/guidelinesforguidelines/standards.
- [6] Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ.* 2008;336:924–6.
- [7] Australian Commission on Safety and Quality in Health Care. Acute Coronary Syndromes Clinical Care Standard. Available at: www.safetyandquality.gov.au/sites/default/files/2019-12/acute_coronary_syndromes_ccs_-_december_2019.pdf; 2019.
- [8] Australian Institute of Health and Welfare. Heart, Stroke and vascular disease: Australian facts. Available at www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts. [accessed 16.8.24].
- [9] The National Heart Foundation of Australia. Acute coronary syndromes (ACS) clinical guidelines. Available at: www.heartfoundation.org.au/for-professionals/fp-acs-guidelines. [accessed 9.1.25].
- [10] Stehli J, Martin C, Brennan A, Dinh DT, Lefkowitz J, Zaman S. Sex differences persist in time to presentation, revascularization, and mortality in myocardial infarction treated with percutaneous coronary intervention. *J Am Heart Assoc.* 2019;8:e012161.
- [11] Khan E, Brieger D, Amerena J, Atherton JJ, Chew DP, Farshid A, et al. Differences in management and outcomes for men and women with ST-elevation myocardial infarction. *Med J Aust.* 2018;209:118–23.
- [12] Stehli J, Dinh D, Dagan M, Duffy SJ, Brennan A, Smith K, et al. Sex differences in prehospital delays in patients with ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention. *J Am Heart Assoc.* 2021;10:e019938.
- [13] Australian Institute of Health and Welfare. Estimating the incidence of stroke and acute coronary syndrome using the National Integrated Health Services Information Analysis Asset. Available at: www.aihw.gov.au/reports/heart-stroke-vascular-diseases/incidence-of-stroke-acute-coronary-syndrome/contents/technical-report. [accessed 20.12.24].
- [14] Australian Institute of Health and Welfare. Better Cardiac Care measures for Aboriginal and Torres Strait Islander people. Available at www.aihw.gov.au/reports/indigenous-australians/better-cardiac-care-measures-for-indigenous-people/summary. [accessed 14.8.24].
- [15] Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). *Circulation.* 2018;138(20):e618–51.
- [16] Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2021;70(22):e187–285.
- [17] Wong GC, Welsford M, Ainsworth C, Abuzeid W, Fordyce CB, Greene J, et al. 2019 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Guidelines on the acute management of ST-elevation myocardial infarction: focused update on regionalization and reperfusion. *Can J Cardiol.* 2019;35(2):107–32.
- [18] de Lemos JA, Newby LK, Mills NL. A proposal for modest revision of the definition of type 1 and type 2 myocardial infarction. *Circulation.* 2019;140(22):1773–5.
- [19] Chapman AR, Shah ASV, Lee KK, Anand A, Francis O, Adamson P, et al. Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury. *Circulation.* 2018;137(12):1236–45.
- [20] Nestelberger T, Boeddinghaus J, Badertscher P, Twerenbold R, Wildi K, Breitenbücher D, et al. Effect of definition on incidence and prognosis of type 2 myocardial infarction. *J Am Coll Cardiol.* 2017;70(13):1558–68.
- [21] Neumann JT, Sørensen NA, Rübsamen N, Ojeda F, Renné T, Qaderi V, et al. Discrimination of patients with type 2 myocardial infarction. *Eur Heart J.* 2017;38(47):3514–20.
- [22] Tzimas G, Antiochos P, Monney P, Eeckhout E, Meier D, Fournier S, et al. Atypical electrocardiographic presentations in need of primary percutaneous coronary intervention. *Am J Cardiol.* 2019;124(8):1305–14.
- [23] Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Chapman AR, et al. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. *Lancet.* 2018;392(10151):919–28.
- [24] Reichlin T, Twerenbold R, Maushart C, Reiter M, Moehring B, Schaub N, et al. Risk stratification in patients with unstable angina using absolute serial changes of 3 high-sensitive troponin assays. *Am Heart J.* 2013;165(3):371–8.
- [25] Reichlin T, Twerenbold R, Reiter M, Steuer S, Bassetti S, Balmelli C, et al. Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. *Am J Med.* 2012;125(12):1205–13.
- [26] Nedkoff L, Goldacre R, Greenland M, Goldacre MJ, Lopez D, Hall N, et al. Comparative trends in coronary heart disease subgroup hospitalisation rates in England and Australia. *Heart.* 2019;105(17):1343.
- [27] Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM, et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association. *Circulation.* 2019;139(18):e891–908.
- [28] Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J.* 2023;44(38):3720–826.
- [29] Australian Commission on Safety and Quality in Health Care. Partnering with Consumers Standard. Available at www.safetyandquality.gov.au/standards/nsqhs-standards/partnering-consumers-standard. [accessed 14.8.24].
- [30] Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. *J Gen Intern Med.* 2012;27(10):1361–7.
- [31] Lin GA, Fagerlin A. Shared decision making: state of the science. *Circ Cardiovasc Qual Outcomes.* 2014;7(2):328–34.
- [32] Dennison-Himmelfarb CR, Koirala B, Coke LA. Shared decision making: partnering with patients to improve cardiovascular care and outcomes. *J Cardiovasc Nurs.* 2018;33(4):301–3.
- [33] Klein LW, Anderson HV, Cigarroa J. Shared decision-making in cardiovascular practice. *Cardiol Rev.* 2023;31(1):52–6.
- [34] Mitropoulou P, Grüner-Hegge N, Reinhold J, Papadopoulou C. Shared decision making in cardiology: a systematic review and meta-analysis. *Heart.* 2022;109(1):34–9.
- [35] Turkson-Ocran RN, Ogunwole SM, Hines AL, Peterson PN. Shared decision making in cardiovascular patient care to address cardiovascular disease disparities. *J Am Heart Assoc.* 2021;10(20):e018183.
- [36] Lauck S, Lewis K. Shared decision-making in cardiac care: can we close the gap between good intentions and improved outcomes? *Heart.* 2022;109(1):4–5.
- [37] Australian Institute of Health and Welfare. Cultural competency in the delivery of health services for Indigenous people. Available at www.aihw.gov.au/reports/indigenous-australians/cultural-competency-in-the-delivery-of-health-serv/summary. [accessed 11.11.24].
- [38] Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. *Med J Aust.* 2016;205(3):128–33.
- [39] Cullen L, Greenslade J, Merollini K, Graves N, Hammett CJK, Hawkins T, et al. Cost and outcomes of assessing patients with chest pain in an Australian emergency department. *Med J Aust.* 2015;202(8):427–32.
- [40] Chapman AR, Lee KK, McAllister DA, Cullen L, Greenslade JH, Parsonage W, et al. Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes in patients with suspected acute coronary syndrome. *JAMA.* 2017;318(19):1913–24.
- [41] Sørensen NA, Neumann JT, Ojeda F, Schäfer S, Magnussen C, Keller T, et al. Relations of sex to diagnosis and outcomes in acute coronary syndrome. *J Am Heart Assoc.* 2018;7(6):e007297.
- [42] Twerenbold R, Neumann JT, Sørensen NA, Ojeda F, Karakas M, Boeddinghaus J, et al. Prospective validation of the 0/1-h algorithm for early diagnosis of myocardial infarction. *J Am Coll Cardiol.* 2018;72(6):620–32.

- [43] Fanaroff AC, Rymer JA, Goldstein SA, Simel DL, Newby LK. Does this patient with chest pain have acute coronary syndrome? The rational clinical examination systematic review. *JAMA*. 2015;314(18):1955–65.
- [44] Hsia RY, Hale Z, Tabas JA. A national study of the prevalence of life-threatening diagnoses in patients with chest pain. *JAMA Intern Med*. 2016;176(7):1029–32.
- [45] van der Meer MG, Backus BE, van der Graaf Y, Cramer MJ, Appelman Y, Doevendans PA, et al. The diagnostic value of clinical symptoms in women and men presenting with chest pain at the emergency department, a prospective cohort study. *PLoS One*. 2015;10(1):e0116431.
- [46] Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2016;37(3):267–315.
- [47] Rubini Gimenez M, Reiter M, Twerenbold R, Reichlin T, Wildi K, Haaf P, et al. Sex-specific chest pain characteristics in the early diagnosis of acute myocardial infarction. *JAMA Intern Med*. 2014;174(2):241–9.
- [48] National Institute for Health and Care Excellence. Guideline scope: acute coronary syndromes (unstable angina, NSTEMI, STEMI): management and secondary prevention (update). 2020
- [49] Department of Health and Aged Care. Australian Guideline for assessing and managing cardiovascular disease risk 2023. Available at www.cvdcheck.org.au/. [accessed 20.12.24].
- [50] Adlam D, Alfonso F, Maas A, Vrints C, Writing C. European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. *Eur Heart J*. 2018;39(36):3353–68.
- [51] Dang QM, Psaltis PJ, Burgess S, Chandrasekhar J, Mukherjee S, Kritharides L, et al. The Australian-New Zealand Spontaneous Coronary Artery Dissection Cohort study: predictors of major adverse cardiovascular events and recurrence. *Eur Heart J*. 2025; in press.
- [52] Raphael CE, Heit JA, Reeder GS, Bois MC, Maleszewski JJ, Tilbury RT, et al. Coronary embolus: an underappreciated cause of acute coronary syndromes. *JACC: Cardiovasc Imaging*. 2018;11:172–80.
- [53] Shimokawa H, Suda A, Takahashi J, Berry C, Camici PG, Crea F, et al. Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. *Eur Heart J*. 2021;42:4592–600.
- [54] Talarico GP, Crosta ML, Giannico MB, Summaria F, Calò L, Patrizi R. Cocaine and coronary artery diseases: a systematic review of the literature. *J Cardiovasc Med*. 2017;18:291–4.
- [55] Kevil CG, Goeders NE, Woolard MD, Bhuiyan MS, Dominic P, Kolluru GK, et al. Methamphetamine use and cardiovascular disease. *Arterioscler Thromb Vasc Biol*. 2019;39:1739–46.
- [56] Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. *Eur Heart J*. 2014;35:1101–11.
- [57] Lichtman JH, Leifheit EC, Safdar B, Bao H, Krumholz HM, Lorenze NP, et al. Sex differences in the presentation and perception of symptoms among young patients With myocardial infarction. *Circulation*. 2018;137:781–90.
- [58] Khan NA, Daskalopoulou SS, Karp I, Eisenberg MJ, Pelletier R, Tsadok MA, et al. Sex differences in prodromal symptoms in acute coronary syndrome in patients aged 55 years or younger. *Heart*. 2017;103:863.
- [59] Ferry AV, Anand A, Strachan FE, Mooney L, Stewart SD, Marshall L, et al. Presenting symptoms in men and women diagnosed with myocardial infarction using sex-specific criteria. *J Am Heart Assoc*. 2019;8:e012307.
- [60] Pelletier R, Khan NA, Cox J, Daskalopoulou SS, Eisenberg MJ, Bacon SL, et al. Sex versus gender-related characteristics: which predicts outcome after acute coronary syndrome in the young? *J Am Coll Cardiol*. 2016;67:127–35.
- [61] Hemal K, Pagidipati NJ, Coles A, Dolor RJ, Mark DB, Pellikka PA, et al. Sex differences in demographics, risk factors, presentation, and noninvasive testing in stable outpatients with suspected coronary artery disease: insights from the PROMISE Trial. *JACC: Cardiovasc Imaging*. 2016;9:337–46.
- [62] Chiamonte GR, Friend R. Medical students' and residents' gender bias in the diagnosis, treatment, and interpretation of coronary heart disease symptoms. *Healthy Psychol*. 2006;25:255–66.
- [63] Jokhadar M, Wenger NK. Review of the treatment of acute coronary syndrome in elderly patients. *Clin Interv Aging*. 2009;4:435–44.
- [64] Gupta R, Munoz R. Evaluation and management of chest pain in the elderly. *Emerg Med Clin North Am*. 2016;34:523–42.
- [65] Lowenstern A, Alexander KP, Hill CL, Alhanti B, Pellikka PA, Nanna MG, et al. Age-related differences in the noninvasive evaluation for possible coronary artery disease: insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Trial. *JAMA Cardiol*. 2020;5:193–201.
- [66] Nanna MG, Hajduk AM, Krumholz HM, Murphy TE, Dreyer RP, Alexander KP, et al. Sex-based differences in presentation, treatment, and complications among older adults hospitalized for acute myocardial infarction: the SILVER-AMI Study, 12. *Circ Cardiovasc Qual Outcomes*. 2019, e005691.
- [67] Damuji AA, Forman DE, Wang TY, Chikwe J, Kunadian V, Rich MW, et al. Management of acute coronary syndrome in the older adult population: a scientific statement from the American Heart Association. *Circulation*. 2023;147:e32–62.
- [68] Ilton MK, Walsh WF, Brown ADH, Tideman PA, Zeitz CJ, Wilson J. A framework for overcoming disparities in management of acute coronary syndromes in the Australian Aboriginal and Torres Strait Islander population. A consensus statement from the National Heart Foundation of Australia. *Med J Aust*. 2014;200:639–43.
- [69] Stephensen L, Greenslade J, Starmer K, Starmer G, Stone R, Bonnin R, et al. Clinical characteristics of Aboriginal and Torres Strait Islander emergency department patients with suspected acute coronary syndrome. *Emerg Med Australas*. 2023;35:442–9.
- [70] Diercks DB, Peacock WF, Hiestand BC, Chen AY, Pollack CV Jr, Kirk JD, et al. Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). *Am J Cardiol*. 2006;97:437–42.
- [71] Dee F, Savage L, Leitch JW, Collins N, Loten C, Fletcher P, et al. Management of acute coronary syndromes in patients in rural Australia: The MORACS randomized clinical trial. *JAMA Cardiol*. 2022;7:690–8.
- [72] Scirica BM, Morrow DA, Budaj A, Dalby AJ, Mohanavelu S, Qin J, et al. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. *J Am Coll Cardiol*. 2009;53:1411–21.
- [73] Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *Circulation*. 1996;94:2341–50.
- [74] Barbagelata A, Ware DL. Denying reperfusion or falsely declaring emergency: the dilemma posed by ST-segment elevation. *J Electrocardiol*. 2006;39:S73–4.
- [75] Pendell Meyers H, Bracey A, Lee D, Lichtenheld A, Li WJ, Singer DD, et al. Accuracy of OMI ECG findings versus STEMI criteria for diagnosis of acute coronary occlusion myocardial infarction. *Int J Cardiol Heart Vasc*. 2021;33:100767.
- [76] Miranda DF, Lobo AS, Walsh B, Sandoval Y, Smith SW. New insights into the use of the 12-lead electrocardiogram for diagnosing acute myocardial infarction in the emergency department. *Can J Cardiol*. 2018;34:132–45.
- [77] Warren J, Mehran R, Yu J, Xu K, Bertrand ME, Cox DA, et al. Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarction. *Am J Cardiol*. 2015;115:428–33.
- [78] Durant E, Singh A. Acute first diagonal artery occlusion: a characteristic pattern of ST elevation in noncontiguous leads. *Am J Med*. 2015;33:1326.
- [79] Littmann L. South African flag sign: a teaching tool for easier ECG recognition of high lateral infarct. *Am J Med*. 2016;34:107–9.
- [80] Schmitt C, Lehmann G, Schmieder S, Karch M, Neumann FJ, Schömig A. Diagnosis of acute myocardial infarction in angiographically documented occluded infarct vessel Chest, 120; 2001. p. 1540–6.
- [81] Vives-Borrás M, Moustafa A-H, Álvarez-García J, Ferrero-Gregori A, Balcells J, García-Picart J, et al. Clinical and prognostic value of the electrocardiogram in patients with acute occlusion of the left circumflex coronary artery. *Am J Cardiol*. 2017;120:1487–94.
- [82] de Winter RJ, Verouden NJ, Wellens HJ, Wilde AA. A new ECG sign of proximal LAD occlusion. *N Engl J Med*. 2008;359:2071–3.

- [83] Inohara T, Kohsaka S, Fukuda K, Menon V. The challenges in the management of right ventricular infarction. *Eur Heart J Acute Cardiovasc Care*. 2013;2:226–34.
- [84] Haji SA, Movahed A. Right ventricular infarction–diagnosis and treatment. *Clin Cardiol*. 2000;23:473–82.
- [85] de Winter RW, Adams R, Verouden NJ, de Winter RJ. Precordial junctional ST-segment depression with tall symmetric T-waves signifying proximal LAD occlusion, case reports of STEMI equivalence. *J Electrocardiol*. 2016;49:76–80.
- [86] Smith SW, Dodd KW, Henry TD, Dvorak DM, Pearce LA. Diagnosis of ST-elevation myocardial infarction in the presence of left bundle branch block with the ST-elevation to S-wave ratio in a modified Sgarbossa rule. *Ann Emerg Med*. 2012;60:766–76.
- [87] Cai Q, Mehta N, Sgarbossa EB, Pinski SL, Wagner GS, Califf RM, et al. The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: from falsely declaring emergency to denying reperfusion in a high-risk population. Are the Sgarbossa Criteria ready for prime time? *Am Heart J*. 2013;166:409–13.
- [88] Sgarbossa EB, Pinski SL, Barbagelata A, Underwood DA, Gates KB, Topol EJ, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. *N Engl J Med*. 1996;334:481–7.
- [89] de Zwaan C, Bär FW, Wellens HJ. Characteristic electrocardiographic pattern indicating a critical stenosis high in left anterior descending coronary artery in patients admitted because of impending myocardial infarction. *Am Heart J*. 1982;103:730–6.
- [90] Knotts RJ, Wilson JM, Kim E, Huang HD, Birnbaum Y. Diffuse ST depression with ST elevation in aVR: Is this pattern specific for global ischemia due to left main coronary artery disease? *J Electrocardiol*. 2013;46:240–8.
- [91] Wong CK, Gao W, Stewart RA, Benatar J, French JK, Aylward PE, et al. aVR ST elevation: an important but neglected sign in ST elevation acute myocardial infarction. *Eur Heart J*. 2010;31:1845–53.
- [92] Koechlin L, Strebel I, Zimmermann T, Nestelberger T, Walter J, Lopez-Ayala P, et al. Hyperacute T wave in the early diagnosis of acute myocardial infarction. *Ann Emerg Med*. 2023;82:194–202.
- [93] Smith SW, Meyers HP. Hyperacute T-waves can be a useful sign of occlusion myocardial infarction if appropriately defined. *Ann Emerg Med*. 2023;82:203–6.
- [94] Kaul P, Fu Y, Chang WC, Harrington RA, Wagner GS, Goodman SG, et al. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. *J Am Coll Cardiol*. 2001;38:64–71.
- [95] Savonitto S, Cohen MG, Politi A, Hudson MP, Kong DF, Huang Y, et al. Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes. *Eur Heart J*. 2005;26:2106–13.
- [96] Giffit K, Ghadban R, Assefa N, Luebbering Z, Allaham H, Enezate T. The accuracy of distribution of non-ST elevation electrocardiographic changes in localising the culprit vessel in non-ST elevation myocardial infarction. *Arch Med Sci Atheroscler Dis*. 2020;5:e226–9.
- [97] Morris N, Reynard C, Body R. The low accuracy of the non-ST-elevation myocardial infarction electrocardiograph criteria of the fourth universal definition of myocardial infarction. *Hong Kong J Emerg Med*. 2020;27:229–35.
- [98] Somers MP, Brady WJ, Perron AD, Mattu A. The prominent T wave: electrocardiographic differential diagnosis. *Am J Med*. 2002;20:243–51.
- [99] Schläpfer J, Wellens HJ. Computer-interpreted electrocardiograms: benefits and limitations. *J Am Coll Cardiol*. 2017;70:1183–92.
- [100] Wang Z, Stavrakis S, Yao B. Hierarchical deep learning with Generative Adversarial Network for automatic cardiac diagnosis from ECG signals. *Comput Biol Med*. 2023;155:106641.
- [101] Vylegzhanina AV, Kogan AE, Katrukha IA, Koshkina EV, Bereznikova AV, Filatov VL, et al. Full-size and partially truncated cardiac troponin complexes in the blood of patients with acute myocardial infarction. *Clin Chem*. 2019;65:882–92.
- [102] Katrukha IA, Katrukha AG. Myocardial injury and the release of troponins I and T in the blood of patients. *Clin Chem*. 2021;67:124–30.
- [103] Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. *J Am Coll Cardiol*. 2012;60:1581–98.
- [104] Zhelev Z, Hyde C, Youngman E, Rogers M, Fleming S, Slade T, et al. Diagnostic accuracy of single baseline measurement of Elecsys Troponin T high-sensitive assay for diagnosis of acute myocardial infarction in emergency department: systematic review and meta-analysis. *BMJ*. 2015;350:h15.
- [105] Pickering JW, Than MP, Cullen L, Aldous S, Ter Avest E, Body R, et al. Rapid rule-out of acute myocardial infarction with a single high-sensitivity cardiac troponin T measurement below the limit of detection: a collaborative meta-analysis. *Ann Intern Med*. 2017;166:715–24.
- [106] Neumann JT, Twerenbold R, Ojeda F, Sörensen NA, Chapman AR, Shah ASV, et al. Application of high-sensitivity troponin in suspected myocardial infarction. *N Engl J Med*. 2019;380:2529–40.
- [107] Sandoval Y, Smith SW, Schulz KM, Murakami MM, Love SA, Nicholson J, et al. Diagnosis of type 1 and type 2 myocardial infarction using a high-sensitivity cardiac troponin I assay with sex-specific 99th percentiles based on the third universal definition of myocardial infarction classification system. *Clin Chem*. 2015;61:657–63.
- [108] Aw T-C, Phua S-K, Tan S-P. Measurement of cardiac troponin I in serum with a new high-sensitivity assay in a large multi-ethnic Asian cohort and the impact of gender. *Clin Chim Acta*. 2013;422:26–8.
- [109] Shah AS, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. *BMJ*. 2015;350:g7873.
- [110] Boeddinghaus J, Nestelberger T, Koechlin L, Wussler D, Lopez-Ayala P, Walter JE, et al. Early diagnosis of myocardial infarction with point-of-care high-sensitivity cardiac troponin I. *J Am Coll Cardiol*. 2020;75:1111–24.
- [111] Apple FS, Smith SW, Greenslade JH, Sandoval Y, Parsonage W, Ranasinghe I, et al. Single high-sensitivity point-of-care whole-blood cardiac troponin I measurement to rule out acute myocardial infarction at low risk. *Circulation*. 2022;146:1918–29.
- [112] Pickering JW, Young JM, George PM, Watson AS, Aldous SJ, Troughton RW, et al. Validity of a novel point-of-care troponin assay for single-test rule-out of acute myocardial infarction. *JAMA Cardiol*. 2018;3:1108–12.
- [113] Sörensen NA, Neumann JT, Ojeda F, Giannitsis E, Spanuth E, Blankenberg S, et al. Diagnostic evaluation of a high-sensitivity troponin I point-of-care assay. *Clin Chem*. 2019;65:1592–601.
- [114] Januzzi JL, Mahler SA, Christenson RH, Rymer J, Newby LK, Body R, et al. Recommendations for institutions transitioning to high-sensitivity troponin testing. *J Am Coll Cardiol*. 2019;73:1059–77.
- [115] Aakre KM, Saenger AK, Body R, Collinson P, Hammarsten O, Jaffe AS, et al. Analytical considerations in deriving 99th percentile upper reference limits for high-sensitivity cardiac troponin assays: Educational recommendations from the IFCC Committee on Clinical Application of Cardiac Bio-Markers. *Clin Chem*. 2022;68:1022–30.
- [116] Lee KK, Ferry AV, Anand A, Strachan FE, Chapman AR, Kimenai DM, et al. Sex-specific thresholds of high-sensitivity troponin in patients with suspected acute coronary syndrome. *J Am Coll Cardiol*. 2019;74:2032–43.
- [117] Greene DN, Schmidt RL, Christenson RH, Rongitsch J, Imborek KL, Rebuck H, et al. Distribution of high-sensitivity cardiac troponin and N-terminal pro-brain natriuretic peptide in healthy transgender people. *JAMA Cardiol*. 2022;7:1170–4.
- [118] Welsh P, Preiss D, Hayward C, Shah ASV, McAllister D, Briggs A, et al. Cardiac troponin T and troponin I in the general population. *Circulation*. 2019;139:2754–64.
- [119] Hickman PE, Abhayaratna WP, Potter JM, Koerbin G. Age-related differences in hs-cTnI concentration in healthy adults. *Clin Biochem*. 2019;69:26–9.
- [120] Welsh P, Preiss D, Shah ASV, McAllister D, Briggs A, Boachie C, et al. Comparison between high-sensitivity cardiac troponin T and cardiac troponin I in a large general population cohort. *Clin Chem*. 2018;64:1607–16.
- [121] Collinson P, Aakre KM, Saenger A, Body R, Hammarsten O, Jaffe AS, et al. Cardiac troponin measurement at the point of care: educational recommendations on analytical and clinical aspects by the IFCC Committee on Clinical Applications of Cardiac Bio-Markers (IFCC C-CB). *Clin Chem Lab Med*. 2023;61:989–98.
- [122] Collinson PO, Saenger AK, Apple FS. High sensitivity, contemporary and point-of-care cardiac troponin assays: educational aids developed by the IFCC Committee on Clinical Application of Cardiac Bio-Markers. *Clin Chem Lab Med*. 2019;57:623–32.
- [123] Cullen L, Greenslade J, Parsonage W, Stephensen L, Smith SW, Sandoval Y, et al. Point-of-care high-sensitivity cardiac troponin in

- suspected acute myocardial infarction assessed at baseline and 2 h. *Eur Heart J*. 2024;45:2508–15.
- [124] Rafiudeen R, Barlis P, White HD, Wv Gaal. Type 2 MI and myocardial injury in the era of high-sensitivity troponin. *Eur Cardiol*. 2022;17:e03.
 - [125] Sandoval Y, Apple FS, Smith SW. High-sensitivity cardiac troponin assays and unstable angina. *Eur Heart J Acute Cardiovasc Care*. 2018;7:120–8.
 - [126] Karády J, Mayrhofer T, Ferencik M, Nagurney JT, Udelson JE, Kammerlander AA, et al. Discordance of high-sensitivity troponin assays in patients with suspected acute coronary syndromes. *J Am Coll Cardiol*. 2021;77:1487–99.
 - [127] Rubini Gimenez M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Schaefer M, et al. Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. *Eur Heart J*. 2014;35:2303–11.
 - [128] Wens SC, Schaaf GJ, Michels M, Kruijshaar ME, van Gestel TJ, In 't Groen S, et al. Elevated plasma cardiac troponin T levels caused by skeletal muscle damage in Pompe disease. *Circ Cardiovasc Genet*. 2016;9:6–13.
 - [129] Schmid J, Liesinger L, Birner-Gruenberger R, Stojakovic T, Scharnagl H, Dieplinger B, et al. Elevated cardiac troponin T in patients with skeletal myopathies. *J Am Coll Cardiol*. 2018;71:1540–9.
 - [130] Stavroulakis GA, George KP. Exercise-induced release of troponin. *Clin Cardiol*. 2020;43:872–81.
 - [131] Aakre KM, Omland T. Physical activity, exercise and cardiac troponins: clinical implications. *Prog Cardiovasc Dis*. 2019;62:108–15.
 - [132] O'Lone E, Apple FS, Burton JO, Caskey FJ, Craig JC, deFilippi CR, et al. Defining myocardial infarction in trials of people receiving hemodialysis: consensus report from the SONG-HD MI Expert Working group. *Kidney Int*. 2023;103:1028–37.
 - [133] Ammann P, Pfisterer M, Fehr T, Rickli H. Raised cardiac troponins. *BMJ*. 2004;328:1028–9.
 - [134] Mair J, Lindahl B, Müller C, Giannitsis E, Huber K, Möckel M, et al. What to do when you question cardiac troponin values. *Eur Heart J Acute Cardiovasc Care*. 2018;7:577–86.
 - [135] Böhner J, von Pape KW, Hannes W, Stegmann T. False-negative immunoassay results for cardiac troponin I probably due to circulating troponin I autoantibodies. *Clin Chem*. 1996;42:2046.
 - [136] Jaffe AS, Lindahl B, Giannitsis E, Mueller C, Cullen L, Hammarsten O, et al. ESC study group on cardiac biomarkers of the Association for Acute CardioVascular Care: A fond farewell at the retirement of CKMB. *Eur Heart J*. 2021;42:2260–4.
 - [137] Brownlee E, Greenslade JH, Kelly AM, Meek RA, Parsonage WA, Cullen L. Snapshot of suspected acute coronary syndrome assessment processes in the emergency department: a national cross-sectional survey. *Emerg Med Australas*. 2023;35:261–8.
 - [138] Kwok CS, Bennett S, Azam Z, Welsh V, Potluri R, Loke YK, et al. Misdiagnosis of acute myocardial infarction: a systematic review of the literature. *Critical Pathw Cardiol*. 2021;20:155–62.
 - [139] Weinstock MB, Weingart S, Orth F, VanFossen D, Kaide C, Anderson J, et al. Risk for clinically relevant adverse cardiac events in patients with chest pain at hospital admission. *JAMA Intern Med*. 2015;175:1207–12.
 - [140] Mahmoud O, Mahmalji H, Elias H, Campoverde EH, Youniss M, Stanton M, et al. A comparative 30-day outcome analysis of inpatient evaluation vs outpatient testing in patients presenting with chest pain in the high-sensitivity troponin era. A propensity score matched case-control retrospective study. *Clin Cardiol*. 2020;43:1248–54.
 - [141] Than M, Flaws D, Sanders S, Doust J, Glasziou P, Kline J, et al. Development and validation of the Emergency Department Assessment of Chest pain Score and 2 h accelerated diagnostic protocol. *Emerg Med Australas*. 2014;26:34–44.
 - [142] Collet JP, Thiele H, Barbato E, Barthélemy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2021;42:1289–367.
 - [143] Mueller C, Giannitsis E, Christ M, Ordóñez-Llanos J, deFilippi C, McCord J, et al. Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac troponin T. *Ann Emerg Med*. 2016;68:76–87.
 - [144] Peacock WF, Christenson R, Diercks DB, Fromm C, Headden GF, Hogan CJ, et al. Myocardial infarction can be safely excluded by high-sensitivity troponin I resting 3 hours after emergency department presentation. *Acad Emerg Med*. 2020;27:671–80.
 - [145] Taggart C, Wereski R, Mills NL, Chapman AR. Diagnosis, investigation and management of patients with acute and chronic myocardial injury. *J Clin Med*. 2021;10:2331.
 - [146] Cohen B, Cohen S, Tor R, Shochat T, Fuchs S, Kornowski R, et al. Suspected non-ST-elevation acute coronary syndrome meeting rapid rule-out criteria: resource utilization, diagnostic yield, and clinical outcomes of hospital admission. *Eur Heart J Qual Care Clin Outcomes*. 2023;9:207–15.
 - [147] Anand A, Lee KK, Chapman AR, Ferry AV, Adamson PD, Strachan FE, et al. High-sensitivity cardiac troponin on presentation to rule out myocardial infarction: a stepped-wedge cluster randomized controlled trial. *Circulation*. 2021;143:2214–24.
 - [148] Neumann JT, Sörensen NA, Schwemer T, Ojeda F, Bourry R, Sciacca V, et al. Diagnosis of myocardial infarction using a high-sensitivity troponin I 1-hour algorithm. *JAMA Cardiol*. 2016;1:397–404.
 - [149] Boeddinghaus J, Nestelberger T, Twerenbold R, Wildi K, Badertscher P, Cupa J, et al. Direct comparison of 4 very early rule-out strategies for acute myocardial infarction using high-sensitivity cardiac troponin I. *Circulation*. 2017;135:1597–611.
 - [150] Chapman AR, Anand A, Boeddinghaus J, Ferry AV, Sandeman D, Adamson PD, et al. Comparison of the efficacy and safety of early rule-out pathways for acute myocardial infarction. *Circulation*. 2017;135:1586–96.
 - [151] Cullen L, Mueller C, Parsonage WA, Wildi K, Greenslade JH, Twerenbold R, et al. Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. *J Am Coll Cardiol*. 2013;62:1242–9.
 - [152] Rubini Gimenez M, Twerenbold R, Jaeger C, Schindler C, Puelacher C, Wildi K, et al. One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I. *Am J Med*. 2015;128:861–70.
 - [153] Boeddinghaus J, Twerenbold R, Nestelberger T, Badertscher P, Wildi K, Puelacher C, et al. Clinical validation of a novel high-sensitivity cardiac troponin I assay for early diagnosis of acute myocardial infarction. *Clin Chem*. 2018;64:1347–60.
 - [154] Chapman AR, Fujisawa T, Lee KK, Andrews JP, Anand A, Sandeman D, et al. Novel high-sensitivity cardiac troponin I assay in patients with suspected acute coronary syndrome. *Heart*. 2019;105:616–22.
 - [155] Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, Zellweger C, et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. *Arch Intern Med*. 2012;172:1211–8.
 - [156] Bularga A, Lee KK, Stewart S, Ferry AV, Chapman AR, Marshall L, et al. High-sensitivity troponin and the application of risk stratification thresholds in patients with suspected acute coronary syndrome. *Circulation*. 2019;140:1557–68.
 - [157] Lee C-C, Huang S-S, Yeo YH, Hou Y-T, Park JY, Inoue K, et al. High-sensitivity-cardiac troponin for accelerated diagnosis of acute myocardial infarction: a systematic review and meta-analysis. *Am J Med*. 2020;38:1402–7.
 - [158] Westwood ME, Armstrong N, Worthy G, Fayter D, Ramaekers BLT, Grimm S, et al. Optimizing the use of high-sensitivity troponin assays for the early rule-out of myocardial infarction in patients presenting with chest pain: a systematic review. *Clin Chem*. 2021;67:237–44.
 - [159] Boeddinghaus J, Nestelberger T, Badertscher P, Twerenbold R, Fitze B, Wussler D, et al. Predicting acute myocardial infarction with a single blood draw. *Clin Chem*. 2019;65:437–50.
 - [160] Chapman AR, Sandeman D, Ferry AV, Stewart S, Strachan FE, Wereski R, et al. Risk stratification using high-sensitivity cardiac troponin T in patients with suspected acute coronary syndrome. *J Am Coll Cardiol*. 2020;75:985–7.
 - [161] Body R, Carley S, McDowell G, Jaffe AS, France M, Cruickshank K, et al. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. *J Am Coll Cardiol*. 2011;58:1332–9.
 - [162] Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. *Circulation*. 2007;115:e352–5.
 - [163] Bandstein N, Ljung R, Johansson M, Holzmänn MJ. Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction. *J Am Coll Cardiol*. 2014;63:2569–78.
 - [164] Body R, Burrows G, Carley S, Cullen L, Than M, Jaffe AS, et al. High-sensitivity cardiac troponin T concentrations below the limit of detection

- to exclude acute myocardial infarction: a prospective evaluation. *Clin Chem.* 2015;61:983–9.
- [165] Peacock WF, Baumann BM, Bruton D, Davis TE, Handy B, Jones CW, et al. Efficacy of high-sensitivity troponin T in identifying very-low-risk patients with possible acute coronary syndrome. *JAMA Cardiol.* 2018;3:104–11.
- [166] Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. *Eur Heart J.* 2012;33:2252–7.
- [167] Reichlin T, Twerenbold R, Wildi K, Gimenez MR, Bergsma N, Haaf P, et al. Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay. *CMAJ.* 2015;187:E243.
- [168] Body R, Mueller C, Giannitsis E, Christ M, Ordóñez-Llanos J, de Filippi CR, et al. The use of very low concentrations of high-sensitivity troponin T to rule out acute myocardial infarction using a single blood test. *Acad Emerg Med.* 2016;23:1004–13.
- [169] Greenslade J, Cho E, Van Hise C, Hawkins T, Parsonage W, Ungerer J, et al. Evaluating rapid rule-out of acute myocardial infarction using a high-sensitivity cardiac troponin I assay at presentation. *Clin Chem.* 2018;64:820–9.
- [170] Shah AS, Anand A, Sandoval Y, Lee KK, Smith SW, Adamson PD, et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. *Lancet.* 2015;386:2481–8.
- [171] Than MP, Aldous SJ, Troughton RW, Pemberton CJ, Richards AM, Frampton CMA, et al. Detectable high-sensitivity cardiac troponin within the population reference interval conveys high 5-year cardiovascular risk: an observational study. *Clin Chem.* 2018;64:1044–53.
- [172] Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. *N Engl J Med.* 2009;361:868–77.
- [173] Chew DP, Lambrakis K, Blyth A, Seshadri A, Edmonds MJR, Briffa T, et al. A randomized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible Acute Coronary Syndrome in the Emergency Department With High-Sensitivity Troponin T Study (RAPID-TnT). *Circulation.* 2019;140:1543–56.
- [174] Nowak RM, Christenson RH, Jacobsen G, McCord J, Apple FS, Singer AJ, et al. Performance of novel high-sensitivity cardiac troponin I assays for 0/1-hour and 0/2- to 3-hour evaluations for acute myocardial infarction: results from the HIGH-US Study. *Ann Emerg Med.* 2020;76:1–13.
- [175] Stoyanov KM, Hund H, Biener M, Gandowitz J, Riedle C, Löhr J, et al. RAPID-CPU: a prospective study on implementation of the ESC 0/1-hour algorithm and safety of discharge after rule-out of myocardial infarction. *Eur Heart J Acute Cardiovasc Care.* 2020;9:39–51.
- [176] IFCC Committee on Clinical Applications of Cardiac Bio-Markers (C-CB). High-sensitivity cardiac troponin I and T assay analytical characteristics designated by manufacturer. Available at: ifccfiles.com/2024/03/High-Sensitivity-Cardiac-Troponin-I-and-T-Assay-Analytical-Characteristics-Designated-By-Manufacturer-v062024.pdf; 2022.
- [177] Boeddinghaus J, Nestelberger T, Twerenbold R, Koechlin L, Meier M, Troester V, et al. High-sensitivity cardiac troponin I assay for early diagnosis of acute myocardial infarction. *Clin Chem.* 2019;65:893–904.
- [178] Wildi K, Cullen L, Twerenbold R, Greenslade JH, Parsonage W, Boeddinghaus J, et al. Direct comparison of 2 rule-out strategies for acute myocardial infarction: 2-h accelerated diagnostic protocol vs 2-h algorithm. *Clin Chem.* 2017;63:1227–36.
- [179] Boeddinghaus J, Nestelberger T, Twerenbold R, Neumann JT, Lindahl B, Giannitsis E, et al. Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis of myocardial infarction. *Eur Heart J.* 2018;39:3780–94.
- [180] Reichlin T, Irfan A, Twerenbold R, Reiter M, Hochholzer W, Burkhalter H, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. *Circulation.* 2011;124:136–45.
- [181] Neumann JT, Sörensen NA, Rübsamen N, Ojeda F, Schock A, Seddighzadeh P, et al. Evaluation of a new ultra-sensitivity troponin I assay in patients with suspected myocardial infarction. *Int J Cardiol.* 2019;283:35–40.
- [182] Boeddinghaus J, Reichlin T, Cullen L, Greenslade JH, Parsonage WA, Hammett C, et al. Two-hour algorithm for triage toward rule-out and rule-in of acute myocardial infarction by use of high-sensitivity cardiac troponin I. *Clin Chem.* 2016;62:494–504.
- [183] Nestelberger T, Boeddinghaus J, Greenslade J, Parsonage WA, Than M, Wussler D, et al. Two-hour algorithm for rapid triage of suspected acute myocardial infarction using a high-sensitivity cardiac troponin I assay. *Clin Chem.* 2019;65:1437–47.
- [184] Wildi K, Boeddinghaus J, Nestelberger T, Lopez-Ayala P, Yufera Sanchez A, Okamura B, et al. 0/2 h-algorithm for rapid triage of suspected myocardial infarction using a novel high-sensitivity cardiac troponin I assay. *Clin Chem.* 2021;68:303–12.
- [185] Wildi K, Lopez-Ayala P, Koechlin L, Boeddinghaus J, Nestelberger T, Wussler D, et al. Validation of the novel European Society of Cardiology 0/2-hour algorithm using Hs-cTnT in the early diagnosis of myocardial infarction. *Am J Cardiol.* 2021;154:128–30.
- [186] Chan Pin Yin D, Azzahafi J, James S. Risk assessment using risk scores in patients with acute coronary syndrome. *J Clin Med.* 2020;9:3039.
- [187] Than M, Cullen L, Aldous S, Parsonage WA, Reid CM, Greenslade J, et al. 2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. *J Am Coll Cardiol.* 2012;59:2091–8.
- [188] Mahler SA, Riley RF, Hiestand BC, Russell GB, Hoekstra JW, Lefebvre CW, et al. The HEART pathway randomized trial. 8. *Circ Cardiovasc Qual Outcomes.* 2015; p. 195–203.
- [189] Cullen L, Greenslade JH, Hawkins T, Hammett C, O’Kane S, Ryan K, et al. Improved Assessment of Chest pain Trial (IMPACT): assessing patients with possible acute coronary syndromes. *Med J Aust.* 2017;207:195–200.
- [190] Parsonage WA, Milburn T, Ashover S, Skoien W, Greenslade JH, McCormack L, et al. Implementing change: evaluating the Accelerated Chest pain Risk Evaluation (ACRE) project. *Med J Aust.* 2017;207:201–5.
- [191] Mark DG, Huang J, Chettipally U, Kene MV, Anderson ML, Hess EP, et al. Performance of coronary risk scores among patients with chest pain in the emergency department. *J Am Coll Cardiol.* 2018;71:606–16.
- [192] Stopyra JP, Miller CD, Hiestand BC, Lefebvre CW, Nicks BA, Cline DM, et al. Chest pain risk stratification: a comparison of the 2-Hour Accelerated Diagnostic Protocol (ADAPT) and the HEART Pathway. *Critical Pathw Cardiol.* 2016;15:46–9.
- [193] Stopyra JP, Miller CD, Hiestand BC, Lefebvre CW, Nicks BA, Cline DM, et al. Validation of the no objective testing rule and comparison to the HEART pathway. *Acad Emerg Med.* 2017;24:1165–8.
- [194] Stopyra JP, Riley RF, Hiestand BC, Russell GB, Hoekstra JW, Lefebvre CW, et al. The HEART pathway randomized controlled trial one-year outcomes. *Acad Emerg Med.* 2019;26:41–50.
- [195] Chapman AR, Hesse K, Andrews J, Ken Lee K, Anand A, Shah ASV, et al. High-sensitivity cardiac troponin I and clinical risk scores in patients with suspected acute coronary syndrome. *Circulation.* 2018;138:1654–65.
- [196] Khan E, Lambrakis K, Blyth A, Seshadri A, Edmonds MJR, Briffa T, et al. Classification performance of clinical risk scoring in suspected acute coronary syndrome beyond a rule-out troponin profile. *Eur Heart J Acute Cardiovasc Care.* 2021;10:1038–47.
- [197] Bank IEM, de Hoog VC, de Kleijn DPV, Pasterkamp G, Doevendans PA, den Ruijter HM, et al. Sex-based differences in the performance of the HEART Score in patients presenting to the emergency department with acute chest pain. *J Am Heart Assoc.* 2017;6:e005373.
- [198] Greenslade JH, Parsonage W, Foran L, McCormack L, Ashover S, Milburn T, et al. Widespread introduction of a high-sensitivity troponin assay: assessing the impact on patients and health services. *J Clin Med.* 2020;9(6):1883.
- [199] Ambavane A, Lindahl B, Giannitsis E, Roiz J, Mendivil J, Frankenstein L, et al. Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department. *PLoS One.* 2017;12:e0187662.
- [200] Ljung L, Lindahl B, Eggers KM, Frick M, Linder R, Löfmark HB, et al. A rule-out strategy based on high-sensitivity troponin and HEART Score reduces hospital admissions. *Ann Emerg Med.* 2019;73:491–9.
- [201] Twerenbold R, Jaeger C, Rubini Gimenez M, Wildi K, Reichlin T, Nestelberger T, et al. Impact of high-sensitivity cardiac troponin on use of coronary angiography, cardiac stress testing, and time to discharge in suspected acute myocardial infarction. *Eur Heart J.* 2016;37:3324–32.
- [202] Westwood M, Ramaekers B, Grimm S, Worthy G, Fayter D, Armstrong N, et al. High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation. *Health Technol Assess.* 2021;25:1–276.
- [203] Mueller-Hennesen M, Lindahl B, Giannitsis E, Biener M, Vafaie M, deFilippi CR, et al. Diagnostic and prognostic implications using

- age- and gender-specific cut-offs for high-sensitivity cardiac troponin T-Sub-analysis from the TRAPID-AMI study. *Int J Cardiol.* 2016;209:26–33.
- [204] Canto JG, Rogers WJ, Goldberg RJ, Peterson ED, Wenger NK, Vaccarino V, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. *JAMA.* 2012;307:813–22.
- [205] Hillinger P, Twerenbold R, Wildi K, Rubini Gimenez M, Jaeger C, Boeddinghaus J, et al. Gender-specific uncertainties in the diagnosis of acute coronary syndrome. *Clin Res Cardiol.* 2017;106:28–37.
- [206] Twerenbold R, Badertscher P, Boeddinghaus J, Nestelberger T, Wildi K, Puelacher C, et al. 0/1-Hour triage algorithm for myocardial infarction in patients with renal dysfunction. *Circulation.* 2018;137:436–51.
- [207] Miller-Hodges E, Anand A, Shah ASV, Chapman AR, Gallacher P, Lee KK, et al. High-sensitivity cardiac troponin and the risk stratification of patients with renal impairment presenting with suspected acute coronary syndrome. *Circulation.* 2018;137:425–35.
- [208] Greenslade JH, Berndt S, Stephensen L, Starmer K, Starmer G, Parsonage W, et al. Value of single troponin values in the emergency department for excluding acute myocardial infarction in Aboriginal and Torres Strait Islander people. *Med J Aust.* 2022;217:48–9.
- [209] Bodapati SN, Gunnarsson R, McBride WJ, Stone R, Sutcliffe S. Chest pain risk assessment in Indigenous and non-Indigenous Australians using HEART Score. *Emerg Med Australas.* 2016;28:138–44.
- [210] Agostino JW, Wong D, Paige E, Wade V, Connell C, Davey ME, et al. Cardiovascular disease risk assessment for Aboriginal and Torres Strait Islander adults aged under 35 years: a consensus statement. *Med J Aust.* 2020;212:422–7.
- [211] Cullen L, Stephensen L, Greenslade J, Starmer K, Starmer G, Stone R, et al. Emergency department assessment of suspected acute coronary syndrome using the IMPACT Pathway in Aboriginal and Torres Strait Islander People. *Heart Lung Circ.* 2022;31:1029–36.
- [212] deFilippi C, Seliger SL, Kelley W, Duh SH, Hise M, Christenson RH, et al. Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. *Clin Chem.* 2012;58:1342–51.
- [213] Doudesis D, Lee KK, Bularga A, Ferry AV, Tuck C, Anand A, et al. Machine learning to optimise use of cardiac troponin in the diagnosis of acute myocardial infarction. *Eur Heart J.* 2022;43:1201–10.
- [214] Than MP, Pickering JW, Sandoval Y, Shah ASV, Tsanas A, Apple FS, et al. Machine learning to predict the likelihood of acute myocardial infarction. *Circulation.* 2019;140:899–909.
- [215] Neumann JT, Twerenbold R, Ojeda F, Aldous SJ, Allen BR, Apple FS, et al. Personalized diagnosis in suspected myocardial infarction. *Clin Res Cardiol.* 2023;9:1288–301.
- [216] Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ.* 2002;324:71–86.
- [217] Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ.* 1994;308:81–106.
- [218] Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. *Blood.* 1987;69:180–6.
- [219] Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N, et al. Oxygen therapy in suspected acute myocardial infarction. *N Engl J Med.* 2017;377:1240–9.
- [220] Stewart RAH, Jones P, Dicker B, Jiang Y, Smith T, Swain A, et al. High flow oxygen and risk of mortality in patients with a suspected acute coronary syndrome: pragmatic, cluster randomised, crossover trial. *BMJ.* 2021;372:n355.
- [221] Chu DK, Kim LH, Young PJ, Zamiri N, Almenawer SA, Jaeschke R, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. *Lancet.* 2018;391:1693–705.
- [222] Cabello JB, Burls A, Emparanza JJ, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction. *Cochrane Database Syst Rev.* 2016;12:CD007160.
- [223] Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, et al. Air versus oxygen in ST-segment-elevation myocardial infarction. *Circulation.* 2015;131:2143–50.
- [224] Hofmann R, James SK, Svensson L, Witt N, Frick M, Lindahl B, et al. DETermination of the role of OXYgen in suspected acute myocardial infarction trial. *Am Heart J.* 2014;167:322–8.
- [225] ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. *Lancet.* 1995;345:669–85.
- [226] Italian Group for the Study of Survival in Myocardial Infarction. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. *Lancet.* 1994;343:1115–22.
- [227] Duarte GS, Nunes-Ferreira A, Rodrigues FB, Pinto FJ, Ferreira JJ, Costa J, et al. Morphine in acute coronary syndrome: systematic review and meta-analysis. *BMJ Open.* 2019;9:e025232.
- [228] Iglesias JF, Valgimigli M, Carbone F, Lauriers N, Masci PG, Degrauw S. Effects of fentanyl versus morphine on ticagrelor-induced platelet inhibition in patients with ST-segment elevation myocardial infarction. *Circulation.* 2020;142:2479–81.
- [229] Ghadban R, Enezate T, Payne J, Allaham H, Halawa A, Fong HK, et al. The safety of morphine use in acute coronary syndrome: a meta-analysis. *Heart Asia.* 2019;11:e011142.
- [230] Parodi G, Bellandi B, Xanthopoulos I, Capranzano P, Capodanno D, Valenti R, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. *Circ Cardiovasc Interv.* e001593.
- [231] Lapostolle F, van't Hof AW, Hamm CW, Stibbe O, Ecollan P, Collet J-P, et al. Morphine and ticagrelor interaction in primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: ATLANTIC-morphine. *Am J Cardiovasc Drugs.* 2019;19:173–83.
- [232] Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. *Eur Heart J.* 2016;37:245–52.
- [233] Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction. *Circulation.* 2006;113:2906–13.
- [234] Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. *BMJ.* 2006;332:1302–8.
- [235] Melki D, Lugnegård J, Alfredsson J, Lind S, Eggers KM, Lindahl B, et al. Implications of introducing high-sensitivity cardiac troponin t into clinical practice: Data from the SWEDEHEART registry. *J Am Coll Cardiol.* 2015;65:1655–64.
- [236] Celik S, Giannitsis E, Wollert KC, Schwöbel K, Lossnitzer D, Hilbel T, et al. Cardiac troponin T concentrations above the 99th percentile value as measured by a new high-sensitivity assay predict long-term prognosis in patients with acute coronary syndromes undergoing routine early invasive strategy. *Clin Res Cardiol.* 2011;100:1077–85.
- [237] Hermann LK, Weingart SD, Duvall WL, Henzlva MJ. The limited utility of routine cardiac stress testing in emergency department chest pain patients younger than 40 years. *Ann Emerg Med.* 2009;54:12–6.
- [238] Greenslade JH, Parsonage W, Ho A, Scott A, Dalton E, Hammett C, et al. Utility of routine exercise stress testing among intermediate risk chest pain patients attending an emergency department. *Heart Lung Circ.* 2015;24:879–84.
- [239] Sandoval Y, Apple FS, Mahler SA, Body R, Collinson PO, Jaffe AS. High-sensitivity cardiac troponin and the 2021 AHA/ACC/AHA/ESC/CHES/SAEM/SCCT/SCMR Guidelines for the evaluation and diagnosis of acute chest pain. *Circulation.* 2022;146:569–81.
- [240] Mowatt G, Cook JA, Hillis GS, Walker S, Fraser C, Jia X, et al. 64-Slice computed tomography angiography in the diagnosis and assessment of coronary artery disease: systematic review and meta-analysis. *Heart.* 2008;94:1386–93.
- [241] von Ballmoos MW, Haring B, Juillerat P, Alkadhi H. Meta-analysis: diagnostic performance of low-radiation-dose coronary computed tomography angiography. *Ann Intern Med.* 2011;154:413–20.
- [242] Hultén EA, Carbonaro S, Petrillo SP, Mitchell JD, Villines TC. Prognostic value of cardiac computed tomography angiography: a systematic review and meta-analysis. *J Am Coll Cardiol.* 2011;57:1237–47.
- [243] Andreini D, Pontone G, Mushtaq S, Bartorelli AL, Bertella E, Antonioli L, et al. A long-term prognostic value of coronary CT angiography in suspected coronary artery disease. *JACC: Cardiovasc Imaging.* 2012;5:690–701.

- [244] Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J, Halamert E, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. *J Am Coll Cardiol*. 2008;52:1724–32.
- [245] Samad Z, Hakeem A, Mahmood SS, Pieper K, Patel MR, Simel DL, et al. A meta-analysis and systematic review of computed tomography angiography as a diagnostic triage tool for patients with chest pain presenting to the emergency department. *J Nucl Cardiol*. 2012;19:364–76.
- [246] Kontos MC, de Lemos JA, Deitelzweig SB, Diercks DB, Gore MO, Hess EP, et al. 2022 ACC expert consensus decision pathway on the evaluation and disposition of acute chest pain in the emergency department: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2022;80:1925–60.
- [247] Zito A, Galli M, Biondi-Zoccai G, Abbate A, Douglas PS, Princi G, et al. Diagnostic strategies for the assessment of suspected stable coronary artery disease: a systematic review and meta-analysis. *Ann Intern Med*. 2023;176:817–26.
- [248] Genders TS, Petersen SE, Pugliese F, Dastidar AG, Fleischmann KE, Nieman K, et al. The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis. *Ann Emerg Med*. 2015;162:474–84.
- [249] Alexander M, Lan NSR, Dallo MJ, Briffa TG, Sanfilippo FM, Hooper A, et al. Clinical outcomes and health care costs of transferring rural Western Australians for invasive coronary angiography, and a cost-effective alternative care model: a retrospective cross-sectional study. *Med J Aust*. 2023;219:155–61.
- [250] Scott AC, McDonald A, Roberts T, Martin C, Manns T, Webster M, et al. Cardiovascular telemedicine program in rural Australia. *N Engl J Med*. 2020;383:883–4.
- [251] Cho KK, French JK, Figtree GA, Chow CK, Kozor R. Rapid access chest pain clinics in Australia and New Zealand. *Med J Aust*. 2023;219:168–72.
- [252] Tenkorang JN, Fox KF, Collier TJ, Wood DA. A rapid access cardiology service for chest pain, heart failure and arrhythmias accurately diagnoses cardiac disease and identifies patients at high risk: a prospective cohort study. *Heart*. 2006;92:1084–90.
- [253] Kozor R, Mooney J, Lowe H, Kritharides L, Altman M, Klimis H, et al. Rapid access chest pain clinics: an Australian cost-benefit study. *Heart Lung Circ*. 2022;31:177–82.
- [254] Black JA, Cheng K, Flood JA, Hamilton G, Parker S, Enayati A, et al. Evaluating the benefits of a rapid access chest pain clinic in Australia. *Med J Aust*. 2019;210:321–5.
- [255] Yu C, Brazete S, Gullick J, Garcia MT, Brieger D, Kritharides L, et al. Long-term outcomes following rapid access chest pain clinic assessment: first Australian data. *Heart Lung Circ*. 2021;30:1309–13.
- [256] Klimis H, Khan ME, Thiagalingam A, Bartlett M, Altman M, Wynne D, et al. Rapid access cardiology (RAC) services within a large tertiary referral centre—first year in review. *Heart Lung Circ*. 2018;27:1381–7.
- [257] Klimis H, Thiagalingam A, Altman M, Atkins E, Figtree G, Lowe H, et al. Rapid-access cardiology services: can these reduce the burden of acute chest pain on Australian and New Zealand health services? *Intern Med J*. 2017;47:986–91.
- [258] Wen LS, Espinola JA, Kosowsky JM, Camargo CA Jr. Do emergency department patients receive a pathological diagnosis? A nationally-representative sample. *West J Emerg Med*. 2015;16:50–4.
- [259] Sawatzky JA, Christie S, Singal RK. Exploring outcomes of a nurse practitioner-managed cardiac surgery follow-up intervention: a randomized trial. *J Adv Nurs*. 2013;69:2076–87.
- [260] Musey Jr PI, Patel R, Fry C, Jimenez G, Koene R, Kline JA. Anxiety associated with increased risk for emergency department recidivism in patients with low-risk chest pain. *Am J Cardiol*. 2018;122:1133–41.
- [261] Dennison Himmelfarb CR, Koirala B, Coke LA. Shared decision making: partnering with patients to improve cardiovascular care and outcomes. *Journal of Cardiovascular Nursing*. 2018;33:301–3.
- [262] Klein LW, Anderson HV, Cigarroa J. Shared decision-making in cardiovascular practice. *Cardiology in Review*. 2023;31:52–6.
- [263] Turkson-Ocran RN, Ogunwole SM, Hines AL, Peterson PN. Shared decision making in cardiovascular patient care to address cardiovascular disease disparities. *Journal of the American Heart Association*. 2021;10:e018183.
- [264] Tideman PA, Tirimacco R, Senior DP, Setchell JJ, Huynh LT, Tavella R, et al. Impact of a regionalised clinical cardiac support network on mortality among rural patients with myocardial infarction. *Med J Aust*. 2014;200:157–60.
- [265] Puymirat E, Simon T, Steg PG, Schiele F, Guéret P, Blanchard D, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. *JAMA*. 2012;308:998–1006.
- [266] Jollis JG, Granger CB, Henry TD, Antman EM, Berger PB, Moyer PH, et al. Systems of care for ST-segment-elevation myocardial infarction: a report from the American Heart Association's Mission: Lifeline, 5. *Circ Cardiovasc Qual Outcomes*. 2012; p. 423–8.
- [267] Postma S, Bergmeijer T, ten Berg J, van 't Hof A. Pre-hospital diagnosis, triage and treatment in patients with ST elevation myocardial infarction. *Heart*. 2012;98:1674–8.
- [268] Patel M, Dunford JV, Aguilar S, Castillo E, Patel E, Fisher R, et al. Pre-hospital electrocardiography by emergency medical personnel: effects on scene and transport times for chest pain and ST-segment elevation myocardial infarction patients. *J Am Coll Cardiol*. 2012;60:806–11.
- [269] Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014;64:e139–228.
- [270] O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction. *Circulation*. 2013;127(4):e362–425.
- [271] Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41:407–77.
- [272] Demandt JPA, Zelis JM, Koks A, Smits GHJM, Harst Pvd, Tonino PAL, et al. Prehospital risk assessment in patients suspected of non-ST-segment elevation acute coronary syndrome: a systematic review and meta-analysis. *BMJ Open*. 2022;12:e057305.
- [273] Harskamp RE, Laeven SC, Himmelreich JC, Lucassen WAM, Weert HCPMv. Chest pain in general practice: a systematic review of prediction rules. *BMJ Open*. 2019;9:e027081.
- [274] Thompson SC, Nedkoff L, Katzenellenbogen J, Hussain MA, Sanfilippo F. Challenges in managing acute cardiovascular diseases and follow up care in rural areas: a narrative review. *Int J Environ Res Public Health*. 2019;16:1–17.
- [275] Chew DP, French J, Briffa TG, Hammett CJ, Ellis CJ, Ranasinghe I, et al. Acute coronary syndrome care across Australia and New Zealand: the SNAPSHOT ACS study. *Med J Aust*. 2013;199:185–91.
- [276] Brieger DB, Chew DP, Redfern J, Ellis C, Briffa TG, Howell TE, et al. Survival after an acute coronary syndrome: 18-month outcomes from the Australian and New Zealand SNAPSHOT ACS study. *Med J Aust*. 2015;203:368.
- [277] Alston L, Allender S, Peterson K, Jacobs J, Nichols M. Rural inequalities in the Australian burden of ischaemic heart disease: a systematic review. *Heart Lung Circ*. 2017;26:122–33.
- [278] Norman T, Young J, Jones JS, Egan G, Pickering J, Toit SD, et al. Implementation and evaluation of a rural general practice assessment pathway for possible cardiac chest pain using point-of-care troponin testing: a pilot study. *BMJ Open*. 2022;12:e044801.
- [279] Zijlstra F, Hoorntje JCA, de Boer M-J, Reijnders S, Miedema K, Ottervanger JP, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. *N Engl J Med*. 1999;341:1413–9.
- [280] Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet*. 2003;361:13–20.
- [281] Widimský P, Budešínský T, Voráč D, Groch L, Želízko M, Aschermann M, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: Final results of the randomized national multicentre trial—PRAGUE-2. *Eur Heart J*. 2003;24:94–104.
- [282] Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thyssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med*. 2003;349:733–42.
- [283] Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. *Eur Heart J*. 2006;27:779–88.
- [284] Gierlotka M, Gasior M, Wilczek K, Hawranek M, Szkodzinski J, Paczek P, et al. Reperfusion by primary percutaneous coronary

- intervention in patients with ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of symptoms (from a prospective national observational study [PL-ACS]). *Am J Cardiol.* 2011;107:501–8.
- [285] Busk M, Kalltoft A, Nielsen SS, Böttcher M, Rehling M, Thuesen L, et al. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for <12 h vs. 12–72 h. *Eur Heart J.* 2009;30:1322–30.
- [286] Schömig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. *JAMA.* 2005;293:2865–72.
- [287] Ndrepepa G, Kastrati A, Mehilli J, Antoniucci D, Schömig A. Mechanical reperfusion and long-term mortality in patients with acute myocardial infarction presenting 12 to 48 hours from onset of symptoms. *JAMA.* 2009;301:487–8.
- [288] Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Rev Esp Cardiol (Engl Ed).* 2017;70:1082.
- [289] Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. *Lancet.* 1994;343:311–22.
- [290] Pinto DS, Frederick PD, Chakrabarti AK, Kirtane AJ, Ullman E, Dejam A, et al. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. *Circulation.* 2011;124:2512–21.
- [291] Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. *Circulation.* 2003;108:2851–6.
- [292] Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. *Lancet.* 1996;348:771–5.
- [293] Hochman JS, Reynolds HR, Dzavik V, Buller CE, Ruzyllo W, Sadowski ZP, et al. Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. *Circulation.* 2011;124:2320–8.
- [294] Menon V, Pearte CA, Buller CE, Steg PG, Forman SA, White HD, et al. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. *Eur Heart J.* 2009;30:183–91.
- [295] Ioannidis JPA, Katritsis DG. Percutaneous coronary intervention for late reperfusion after myocardial infarction in stable patients. *Am Heart J.* 2007;154:1065–71.
- [296] Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. *N Engl J Med.* 2013;368:1379–87.
- [297] Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. *JAMA.* 2000;283:2686–92.
- [298] Armstrong PW, Zheng Y, Westerhout CM, Rosell-Ortiz F, Sinnaeve P, Lambert Y, et al. Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STRategic Reperfusion Early After Myocardial infarction trial. *Am Heart J.* 2015;169:890–8.
- [299] Werf FvD, Ristić AD, Averkov OV, Arias-Mendoza A, Lambert Y, Saraiva JFK, et al. STREAM-2: Half-dose tenecteplase or primary percutaneous coronary intervention in older patients with ST-segment-elevation myocardial infarction: A randomized, open-label trial. *Circulation.* 2023;148:753–64.
- [300] Terkelsen CJ, Sørensen JT, Maeng M, Jensen LO, Tilsted HH, Trautner S, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. *JAMA.* 2010;304:763–71.
- [301] Nallamothu BK, Normand SL, Wang Y, Hofer TP, Brush JE Jr, Messenger JC, et al. Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study. *Lancet.* 2015;385:1114–22.
- [302] Squire BT, Tamayo-Sarver JH, Rashi P, Koenig W, Niemann JT. Effect of prehospital cardiac catheterization lab activation on door-to-balloon time, mortality, and false-positive activation. *Prehosp Emerg Care.* 2014;18:1–8.
- [303] Mehta SR, Jolly SS, Cairns J, Niemela K, Rao SV, Cheema AN, et al. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. *J Am Coll Cardiol.* 2012;60:2490–9.
- [304] Shah R, Khan B. The MATRIX trial. *Lancet.* 2019;393:1803.
- [305] Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. *Lancet.* 2011;377:1409–20.
- [306] Romagnoli E, Biondi-Zoccai G, Sciahbasi A, Politi L, Rigattieri S, Pendenza G, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: The RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) Study. *J Am Coll Cardiol.* 2012;60:2481–9.
- [307] Gargiulo G, Giacoppo D, Jolly SS, Cairns J, Le May M, Bernat J, et al. Effects on mortality and major bleeding of radial versus femoral artery access for coronary angiography or percutaneous coronary intervention: a meta-analysis of individual patient data from 7 multicenter randomized clinical trials. *Circulation.* 1329–1343.
- [308] Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation.* 2021;145(3):e4–17.
- [309] Barkagan M, Steinvil A, Berchenko Y, Finkelstein A, Keren G, Banai S, et al. Impact of routine manual aspiration thrombectomy on outcomes of patients undergoing primary percutaneous coronary intervention for acute myocardial infarction: A meta-analysis. *Int J Cardiol.* 2016;204:189–95.
- [310] Fröbert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. *N Engl J Med.* 2013;369:1587–97.
- [311] Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. *N Engl J Med.* 2015;372:1389–98.
- [312] National Guideline Centre. Evidence review for antiplatelet therapy for people with an ongoing separate indication for anticoagulation: Acute coronary syndrome: Evidence review G. London: National Institute for Health and Care Excellence (NICE); 2020.
- [313] Räber L, Yamaji K, Kelbæk H, Engström T, Baumbach A, Roffi M, et al. Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction. *Eur Heart J.* 2019;40:1909–19.
- [314] Sabaté M, Brugaletta S, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. *Lancet.* 2016;387:357–66.
- [315] Bona KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygård O, et al. Drug-eluting or bare-metal stents for coronary artery disease. *N Engl J Med.* 2016;375:1242–52.
- [316] Piccolo R, Bona KH, Efthimiou O, Varenne O, Baldo A, Urban P, et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. *Lancet.* 2019;393:2503–10.
- [317] Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. *J Am Coll Cardiol.* 2015;65:2496–507.
- [318] Carrick D, Oldroyd KG, McEntegart M, Haig C, Petrie MC, Eteiba H, et al. A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). *J Am Coll Cardiol.* 2014;63:2088–98.
- [319] Kelbæk H, Høfsten DE, Køber L, Helqvist S, Kløvgaard L, Holmvang L, et al. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. *Lancet.* 2016;387:2199–206.
- [320] Engström T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial

- infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. *Lancet*. 2015;386:665–71.
- [321] Madsen JK, Grande P, Saunamäki K, Thayssen P, Kassiss E, Eriksen U, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). *Circulation*. 1997;96:748–55.
- [322] Steg PG, Thuair C, Himbert D, Carrié D, Champagne Sp, Coisne D, et al. DECOPI (DESobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. *Eur Heart J*. 2004;25:2187–94.
- [323] Pi Y, Roe MT, Holmes DN, Chiswell K, Garvey JL, Fonarow GC, et al. Utilization, characteristics, and in-hospital outcomes of coronary artery bypass grafting in patients with ST-segment-elevation myocardial infarction, 10. *Circ Cardiovasc Qual Outcomes*; 2017, e003490.
- [324] Grothussen C, Friedrich C, Loehr J, Meinert J, Ohnewald E, Ulbricht U, et al. Outcome of stable patients with acute myocardial infarction and coronary artery bypass surgery within 48 hours: a single-center, retrospective experience. *J Am Heart Assoc*. 2017;6:e005498.
- [325] Stehli J, Duffy SJ, Koh Y, Martin C, Brennan A, Dinh DT, et al. Sex differences in radial access for percutaneous coronary intervention in acute coronary syndrome are independent of body size. *Heart Lung Circ*. 2021;30:108–14.
- [326] Fazel R, Joseph TI, Sankardas MA, Pinto DS, Yeh RW, Kumbhani DJ, et al. Comparison of reperfusion strategies for ST-segment-elevation myocardial infarction: A multivariate network meta-analysis. *J Am Heart Assoc*. 2020;9:e015186.
- [327] Borgia F, Goodman SG, Halvorsen S, Cantor WJ, Piscione F, Le May MR, et al. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. *Eur Heart J*. 2010;31:2156–69.
- [328] Madan M, Halvorsen S, Di Mario C, Tan M, Westerhout CM, Cantor WJ, et al. Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a patient-level analysis of the randomized early routine invasive clinical trials. *JACC: Cardiovasc Imaging*. 2015;8:166–74.
- [329] Wijesundera HC, Vijayaraghavan R, Nallamotheu BK, Foody JM, Krumholz HM, Phillips CO, et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: A meta-analysis of randomized trials. *J Am Coll Cardiol*. 2007;49:422–30.
- [330] White HD. Systems of care: need for hub-and-spoke systems for both primary and systematic percutaneous coronary intervention after fibrinolysis. *Circulation*. 2008;118:219–22.
- [331] Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. *N Engl J Med*. 2005;353:2758–68.
- [332] Aragam KG, Tamhane UU, Kline-Rogers E, Li J, Fox KA, Goodman SG, et al. Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores. *PLoS One*. 2009;4:e7947.
- [333] D'Ascenzo F, Biondi-Zoccai G, Moretti C, Bollati M, Omedè P, Sciuto F, et al. TIMI, GRACE and alternative risk scores in Acute Coronary Syndromes: a meta-analysis of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 patients. *Contemp Clin Trials*. 2012;33:507–14.
- [334] Bing R, Goodman SG, Yan AT, Fox K, Gale CP, Hyun K, et al. Use of clinical risk stratification in non-ST elevation acute coronary syndromes: an analysis from the CONCORDANCE registry. *Eur Heart J Qual Care Clin Outcomes*. 2018;4:309–17.
- [335] Saar A, Marandi T, Ainla T, Fischer K, Blöndal M, Eha J. The risk-treatment paradox in non-ST-elevation myocardial infarction patients according to their estimated GRACE risk. *Int J Cardiol*. 2018;272:26–32.
- [336] Ranasinghe I, Alprandi-Costa B, Chow V, Elliott JM, Waites J, Counsell JT, et al. Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. *Am J Cardiol*. 2011;108:617–24.
- [337] Scott IA, Derhy PH, O'Kane D, Lindsay KA, Atherton JJ, Jones MA. Discordance between level of risk and intensity of evidence-based treatment in patients with acute coronary syndromes. *Med J Aust*. 2007;187:153–9.
- [338] Chew DP, Hyun K, Morton E, Horsfall M, Hillis GS, Chow CK, et al. Objective risk assessment vs standard care for acute coronary syndromes: A randomized clinical trial. *JAMA Cardiol*. 2021;6:304–13.
- [339] Gale CP, Stocken DD, Aktaa S, Reynolds C, Gilberts R, Brieger D, et al. Effectiveness of GRACE risk score in patients admitted to hospital with non-ST elevation acute coronary syndrome (UKGRIS): parallel group cluster randomised controlled trial. *BMJ*. 2023;381:e073843.
- [340] Grinstein J, Bonaca MP, Jarolim P, Conrad MJ, Bohula-May E, Deenadayalu N, et al. Prognostic implications of low level cardiac troponin elevation using high-sensitivity cardiac troponin T. *Clin Cardiol*. 2015;38:230–5.
- [341] Wang TKM, Mehta OH, Liao Y-WB, Wang MTM, Stewart R, White H. Meta-analysis of bleeding scores performance for acute coronary syndrome. *Heart Lung Circ*. 2020;29:1749–57.
- [342] Urban P, Mehran R, Collieran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. *Circulation*. 2019;140:240–61.
- [343] Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, et al. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. *J Am Coll Cardiol*. 2019;73:741–54.
- [344] Wenzl FA, Kraler S, Ambler G, Weston C, Herzog SA, Räber L, et al. Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational analysis with external cohort validation. *Lancet*. 2022;400:744–56.
- [345] Hung J, Roos A, Kadesjö E, McAllister DA, Kimenai DM, Shah ASV, et al. Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction. *Eur Heart J*. 2021;42:2552–61.
- [346] Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. *Circulation*. 2009;119:1873–82.
- [347] Chung K, Wilkinson C, Veerasamy M, Kunadian V. Frailty scores and their utility in older patients with cardiovascular disease. *Interv Cardiol*. 2021;16:e05.
- [348] Damluji AA, Chung SE, Xue QL, Hasan RK, Walston JD, Forman DE, et al. Physical frailty phenotype and the development of geriatric syndromes in older adults with coronary heart disease. *Am J Med*. 2021;134:662–71.
- [349] Ratcovich H, Beska B, Mills G, Holmvang L, Adams-Hall J, Stevenson H, et al. Five-year clinical outcomes in patients with frailty aged ≥75 years with non-ST elevation acute coronary syndrome undergoing invasive management. *Eur Heart J Open*. 2022;2:oeac035.
- [350] Damluji AA, Huang J, Bandeen-Roche K, Forman DE, Gerstenblith G, Moscucci M, et al. Frailty among older adults with acute myocardial infarction and outcomes from percutaneous coronary interventions. *J Am Heart Assoc*. 2019;8:e013686.
- [351] Alfredsson J, Clayton T, Damman P, Fox KA, Fredriksson M, Lagerqvist B, et al. Impact of an invasive strategy on 5 years outcome in men and women with non-ST-segment elevation acute coronary syndromes. *Am Heart J*. 2014;168:522–9.
- [352] Damman P, Wallentin L, Fox KA, Windhausen F, Hirsch A, Clayton T, et al. Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 trials (FIR). *Circulation*. 2012;125:568–76.
- [353] Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: a meta-analysis of individual patient data. *J Am Coll Cardiol*. 2010;55:2435–45.
- [354] Elgendy IY, Mahmoud AN, Wen X, Bavry AA. Meta-analysis of randomized trials of long-term all-cause mortality in patients with non-ST-elevation acute coronary syndrome managed with routine invasive versus selective invasive strategies. *Am J Cardiol*. 2017;119:560–4.
- [355] Elgendy IY, Kumbhani DJ, Mahmoud AN, Wen X, Bhatt DL, Bavry AA. Routine invasive versus selective invasive strategies for non ST-elevation acute coronary syndromes: an updated meta-analysis of randomized trials. *Catheter Cardiovasc Interv*. 2016;88:765–74.
- [356] Hoenig MR, Aroney CN, Scott IA. Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. *Cochrane Database Syst Rev*. 2010;3:CD004815.
- [357] Lim SH, Anantharaman V, Sundram F, Chan ES-Y, Ang ES, Yo SL, et al. Stress myocardial perfusion imaging for the evaluation and triage of

- chest pain in the emergency department: a randomized controlled trial. *J Nucl Cardiol*. 2013;20:1002–12.
- [358] Nabi F, Kassi M, Muhyieddeen K, Chang SM, Xu J, Peterson LE, et al. Optimizing evaluation of patients with low-to-intermediate-risk acute chest pain: a randomized study comparing stress myocardial perfusion tomography incorporating stress only imaging versus cardiac CT. *J Nucl Cardiol*. 2016;57:378.
- [359] Siontis GCM, Mavridis D, Greenwood JP, Coles B, Nikolakopoulou A, Jüni P, et al. Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials. *BMJ*. 2018;360:k504.
- [360] Smulders MW, Kietselaer BLJH, Wildberger JE, Dagnelie PC, Brunner-La Rocca H-P, Mingels AMA, et al. Initial imaging-guided strategy versus routine care in patients with non-ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2019;74:2466–77.
- [361] Linde JJ, Kelbæk H, Hansen TF, Sigvardsen PE, Torp-Pedersen C, Bech J, et al. Coronary CT angiography in patients with non-ST-segment elevation acute coronary syndrome. *J Am Coll Cardiol*. 2020;75:453–63.
- [362] Dedic A, Lubbers MM, Schaap J, Lammers J, Lamfers EJ, Rensing BJ, et al. Coronary CT angiography for suspected ACS in the era of high-sensitivity troponins: randomized multicenter study. *J Am Coll Cardiol*. 2016;67:16–26.
- [363] Mehta SR, Granger CB, Boden WE, Steg PG, Bassand J-P, Faxon DP, et al. Early versus delayed invasive intervention in acute coronary syndromes. *N Engl J Med*. 2009;360:2165–75.
- [364] Kofoed KF, Kelbæk H, Hansen PR, Torp-Pedersen C, Høfsten D, Kløvgaard L, et al. Early versus standard care invasive examination and treatment of patients with non-ST-segment elevation acute coronary syndrome. *Circulation*. 2018;138:2741–50.
- [365] Kite TA, Kurmani SA, Bountziouka V, Cooper NJ, Lock ST, Gale CP, et al. Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials. *Eur Heart J*. 2022;43:3148–61.
- [366] Jobs A, Mehta SR, Montalescot G, Vicaute E, Van't Hof AWJ, Badings EA, et al. Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. *Lancet*. 2017;390:737–46.
- [367] Stone GW, Christiansen EH, Ali ZA, Andreasen LN, Maehara A, Ahmad Y, et al. Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis. *Lancet*. 2024;403:824–37.
- [368] Kuno T, Kiyohara Y, Maehara A, Ueyama HA, Kampaktsis PN, Takagi H, et al. Comparison of Intravascular Imaging, Functional, or Angiographically Guided Coronary Intervention. *J Am Coll Cardiol*. 2023;82:2167–76.
- [369] Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. *Lancet*. 2016;387:1057–65.
- [370] Savonitto S, Cavallini C, Petronio AS, Murena E, Antonicelli R, Sacco A, et al. Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial. *JACC: Cardiovasc Imaging*. 2012;5:906–16.
- [371] Sanchis J, Núñez E, Barrabés JA, Marín F, Consuegra-Sánchez L, Ventura S, et al. Randomized comparison between the invasive and conservative strategies in comorbid elderly patients with non-ST elevation myocardial infarction. *Eur J Intern Med*. 2016;35:89–94.
- [372] de Belder A, Myat A, Blaxill J, Haworth P, O'Kane PD, Hatrick R, et al. Revascularisation or medical therapy in elderly patients with acute anginal syndromes: the RINCAL randomised trial. *EuroIntervention*. 2021;17:67–74.
- [373] Hirlekar G, Libungan B, Karlsson T, Bäck M, Herlitz J, Albertsson P. Percutaneous coronary intervention in the very elderly with NSTEMI-ACS: the randomized 80+ study. *Scand Cardiovasc J*. 2020;54:315–21.
- [374] Mills GB, Ratcovich H, Adams-Hall J, Beska B, Kirkup E, Raharjo DE, et al. Is the contemporary care of the older persons with acute coronary syndrome evidence-based? *Eur Heart J Open*. 2022;2:oeab044.
- [375] Biscaglia S, Guiducci V, Escanet J, Moreno R, Lanzilotti V, Santarelli A, et al. Complete or culprit-only PCI in older patients with myocardial infarction. *N Engl J Med*. 2023;389:889–98.
- [376] Kaura A, Sterne J, Trickey A, Abbott S, Mulla A, Glampson B, et al. Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data. *Lancet*. 2020;396:623–34.
- [377] Gnanenthiran SR, Kritharides L, D'Souza M, Lowe HC, Brieger DB. Revascularisation compared with initial medical therapy for non-ST-elevation acute coronary syndromes in the elderly: a meta-analysis. *Heart*. 2017;103:1962–9.
- [378] Ma W, Liang Y, Zhu J. Early invasive versus initially conservative strategy in elderly patients older than 75 years with non-ST-elevation acute coronary syndrome: A meta-analysis. *Heart Lung Circ*. 2018;27:611–20.
- [379] Sanchis J, Bueno H, Miñana G, Guerrero C, Martí D, Martínez-Sellés M, et al. Effect of routine invasive vs conservative strategy in older adults with frailty and non-ST-segment elevation acute myocardial infarction: a randomized clinical trial. *JAMA Intern Med*. 407–415.
- [380] Lopez D, Katzenellenbogen JM, Sanfilippo FM, Woods JA, Hobbs MS, Knuiman MW, et al. Transfers to metropolitan hospitals and coronary angiography for rural Aboriginal and non-Aboriginal patients with acute ischaemic heart disease in Western Australia. *BMC Cardiovasc Disord*. 2014;14:58.
- [381] ISIS-2 (Second International Study of Infarct Survival) Collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. *Lancet*. 1988;2:349–60.
- [382] Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. *N Engl J Med*. 2010;363:930–42.
- [383] Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet*. 2005;366:1607–21.
- [384] Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med*. 2005;352:1179–89.
- [385] Hamilos M, Kanakakis J, Anastasiou I, Karvounis C, Vasilikos V, Goudevenos J, et al. Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial. *EuroIntervention*. 2021;16:1163–9.
- [386] Berwanger O, Nicolau JC, Carvalho AC, Jiang L, Goodman SG, Nicholls SJ, et al. Ticagrelor vs Clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a randomized clinical trial. *JAMA Cardiol*. 2018;3:391–9.
- [387] Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007;357:2001–15.
- [388] Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009;361:1045–57.
- [389] Gewehr DM, Carvalho PEdP, Dagostin CS, Cardoso R, Kubrusly TBL, Kubrusly FB, et al. Pretreatment with P2Y12 inhibitors in ST-elevation myocardial infarction: A systematic review and meta-analysis. *Catheter Cardiovasc Interv*. 2023;102:200–11.
- [390] Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med*. 2001;345:494–502.
- [391] Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. *N Engl J Med*. 2013;369:999–1010.
- [392] Dworeck C, Redfors B, Angerås O, Haraldsson I, Odenstedt J, Ioanes D, et al. Association of pretreatment with P2Y12 receptor antagonists preceding percutaneous coronary intervention in non-ST-segment elevation acute coronary syndromes with outcomes. *JAMA Netw Open*. 2020;3:e2018735.
- [393] Roe MT, Armstrong PW, Fox KAA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. *N Engl J Med*. 2012;367:1297–309.
- [394] Schüpke S, Neumann F-J, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. *N Engl J Med*. 2019;381:1524–34.
- [395] Kubica J, Jaguszewski M. ISAR-REACT 5 - What have we learned? *Cardiol J*. 2019;26:427–8.
- [396] Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van 't Hof AWJ, van der Harst P, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. *N Engl J Med*. 2019;381:1621–31.
- [397] Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention

- (TROPICAL-ACS): a randomised, open-label, multicentre trial. *Lancet*. 2017;390:1747–57.
- [398] Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. *JAMA*. 2020;324:761–71.
- [399] O'Donoghue ML, Marston NA. Time for a paradigm shift? Making the case for tailored selection of antiplatelet therapy. *Eur Heart J*. 2022;43:968–70.
- [400] Galli M, Benenati S, Franchi F, Rollini F, Capodanno D, Biondi-Zoccai G, et al. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. *Eur Heart J*. 2022;43:959–67.
- [401] Kim CJ, Park M-W, Kim MC, Choo E-H, Hwang B-H, Lee KY, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. *Lancet*. 2021;398:1305–16.
- [402] Kim H-S, Kang J, Hwang D, Han J-K, Yang H-M, Kang H-J, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. *Lancet*. 2020;396:1079–89.
- [403] Cuisset T, Deharo P, Quilici J, Johnson TW, Defarges S, Bassez C, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomised study. *Eur Heart J*. 2017;38:3070–8.
- [404] Jeong Y-H. “East asian paradox”: Challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome. *Curr Cardiol Rep*. 2014;16:485.
- [405] Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. *N Engl J Med*. 2017;377:1513–24.
- [406] Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. *N Engl J Med*. 2016;375:2423–34.
- [407] Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. *N Engl J Med*. 2019;380:1509–24.
- [408] Park DY, Wang P, An S, Grimshaw AA, Frampton J, Ohman EM, et al. Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: a systematic review and meta-analysis. *Am Heart J*. 2022;225:101–14.
- [409] ten Berg JM, van 't Hof AW, Dill T, Heestermaans T, van Werkum JW, Mosterd A, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. *J Am Coll Cardiol*. 2010;55:2446–55.
- [410] Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. *N Engl J Med*. 2008;358:2205–17.
- [411] Akpek M, Sahin O, Sarli B, Baktir AO, Saglam H, Urkmez S, et al. Acute effects of intracoronary tirofiban on no-reflow phenomena in patients with st-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention. *Angiology*. 2014;66:560–7.
- [412] Friedland S, Eisenberg MJ, Shimony A. Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome. *Am J Cardiol*. 2011;108:1244–51.
- [413] Tricoci P, Newby LK, Hasselblad V, Kong DF, Giugliano RP, White HD, et al. Upstream use of small-molecule glycoprotein IIb/IIIa inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. 4. *Circ Cardiovasc Qual Outcomes*; 2011. p. 448–58.
- [414] Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, et al. Early versus delayed, provisional Eptifibatide in acute coronary syndromes. *N Engl J Med*. 2009;360:2176–90.
- [415] Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. *Eur Heart J*. 2002;23:1441–8.
- [416] Rossini R, Iorio A, Pozzi R, Bianco M, Musumeci G, Leonardi S, et al. Aspirin desensitization in patients with coronary artery disease. *Circ Cardiovasc Interv*. 2017;10:e004368.
- [417] Dyke CM, Bhatia D, Lorenz TJ, Marso SP, Tardiff BE, Hogeboom C, et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. *Ann Thor Surg*. 2000;70:866–71.
- [418] Bizzarri F, Scolletta S, Tucci E, Lucidi M, Davoli G, Toscano T, et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. *J Thorac Cardiovasc Surg*. 2001;122:1181–5.
- [419] Lincoff AM, LeNarz LA, Despotis GJ, Smith PK, Booth JE, Raymond RE, et al. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. *Ann Thor Surg*. 2000;70:516–26.
- [420] GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl J Med*. 1993;329:673–82.
- [421] Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. *Lancet*. 2001;358:605–13.
- [422] Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. *Lancet*. 2014;384:599–606.
- [423] Capodanno D, Gargiulo G, Capranzano P, Mehran R, Tamburino C, Stone GW. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: an updated meta-analysis of 10,350 patients from five randomized clinical trials. *Eur Heart J Acute Cardiovasc Care*. 2016;5:253–62.
- [424] Li Y, Liang Z, Qin L, Wang M, Wang X, Zhang H, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. *Lancet*. 2022;400:1847–57.
- [425] The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. *Lancet*. 1990;336:827–30.
- [426] Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. *Lancet*. 1981;1:1225–8.
- [427] Thérault P, Ouimet H, McCans J, Latour JG, Joly P, Lévy G, et al. Aspirin, heparin, or both to treat acute unstable angina. *N Engl J Med*. 1988;319:1105–11.
- [428] Galli M, Andreotti F, D'Amario D, Vergallo R, Vescovo GM, Giraldo L, et al. Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. *Eur Heart J Cardiovasc Pharmacother*. 2019;6:43–56.
- [429] SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. *JAMA*. 2004;292:45–54.
- [430] Nührenberg TG, Hochholzer W, Mashayekhi K, Ferenc M, Neumann FJ. Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials. *Clin Res Cardiol*. 2018;107:807–15.
- [431] Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. *N Engl J Med*. 2006;354:1464–76.
- [432] Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. *N Engl J Med*. 2006;354:1477–88.
- [433] Fox KAA, Antman EM, Montalescot G, Agewall S, SomaRaju B, Verheugt FWA, et al. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. *J Am Coll Cardiol*. 2007;49:2249–55.
- [434] Fahrni G, Wolfrum M, De Maria GL, Banning AP, Benedetto U, Kharbanda RK. Prolonged high-dose bivalirudin infusion reduces major bleeding without increasing stent thrombosis in patients undergoing primary percutaneous coronary intervention: Novel insights from an updated meta-analysis. *J Am Heart Assoc*. e003515.
- [435] Brieger D, Solanki V, Gaynor M, Booth V, MacDonald R, Freedman SB. Optimal strategy for administering enoxaparin to patients undergoing coronary angiography without angioplasty for acute coronary syndromes. *Am J Cardiol*. 2002;89:1167–70.
- [436] Angiolillo DJ, Bhatt DL, Cannon CP, Eikelboom JW, Gibson CM, Goodman SG, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous

- coronary intervention: a North American perspective: 2021 update. *Circulation*. 2021;143:583–96.
- [437] Karam N, Bataille S, Marijon E, Tafflet M, Benamer H, Caussin C, et al. Incidence, mortality, and outcome-predictors of sudden cardiac arrest complicating myocardial infarction prior to hospital admission. *Circ Cardiovasc Genet*. 2019;12:e007081.
- [438] Garot P, Lefevre T, Eltchaninoff H, Morice M-C, Tamion F, Abry B, et al. Six-month outcome of emergency percutaneous coronary intervention in resuscitated patients after cardiac arrest complicating ST-elevation myocardial infarction. *Circulation*. 2007;115:1354–62.
- [439] Kern KB, Rahman O. Emergent percutaneous coronary intervention for resuscitated victims of out-of-hospital cardiac arrest. *Catheter Cardiovasc Interv*. 2010;75:616–24.
- [440] Dumas F, Cariou A, Manzo-Silberman S, Grimaldi D, Vivien B, Rosencher J, et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest. *Circ Cardiovasc Genet*. 2010;3:200–7.
- [441] Hamed M, Neupane G, Abdelsalam M, Elkhawas I, Morsy M, Khalili H, et al. Meta-analysis on early versus delayed coronary angiography for patients with out-of-hospital cardiac arrest without ST-elevation myocardial infarction. *Am J Cardiol*. 2023;188:41–3.
- [442] Böttiger BW, Arntz H-R, Chamberlain DA, Bluhmki E, Belmans A, Danays T, et al. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. *N Engl J Med*. 2008;359:2651–62.
- [443] Hirt LS, Kandan SR, Rahbi H, Dastidar A, Khawaja MZ, Mozid A, et al. Three factors combined predict futility of emergency coronary angiography after out-of-hospital cardiac arrest. *J Am Coll Cardiol*. 2018;72:1753–5.
- [444] Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. *N Engl J Med*. 2017;377:2419–32.
- [445] Thiele H, Akin I, Sandri M, de Waha-Thiele S, Meyer-Saraei R, Fuernau G, et al. One-year outcomes after PCI strategies in cardiogenic shock. *N Engl J Med*. 2018;379:1699–710.
- [446] Kolte D, Sardar P, Khera S, Zeymer U, Thiele H, Hochadel M, et al. Culprit vessel-only versus multivessel percutaneous coronary intervention in patients with cardiogenic shock complicating ST-segment-elevation myocardial infarction. *Circ Cardiovasc Genet*. 2017;10:e005582.
- [447] Thiele H, Zeymer U, Neumann F-J, Ferenc M, Olbrich H-G, Hausleiter J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. *N Engl J Med*. 2012;367:1287–96.
- [448] Patel MR, Smalling RW, Thiele H, Barnhart HX, Zhou Y, Chandra P, et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. *JAMA*. 2011;306:1329–37.
- [449] Sjauw KD, Engström AE, Vis MM, van der Schaaf RJ, Baan J Jr, Koch KT, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? *Eur Heart J*. 2009;30:459–68.
- [450] Thiele H, Zeymer U, Akin I, Behnes M, Rassaf T, Mahabadi AA, et al. Extracorporeal life support in infarct-related cardiogenic shock. *N Engl J Med*. 2023;389:1286–97.
- [451] Zeymer U, Freund A, Hochadel M, Ostadal P, Belohlavek J, Rokyta R, et al. Venoarterial extracorporeal membrane oxygenation in patients with infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials. *Lancet*. 1338–1346.
- [452] Möller JE, Engström T, Jensen LO, Eiskjær H, Mangner N, Polzin A, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. *N Engl J Med*. 2024;390:1382–93.
- [453] Vallabhajosyula S, Verghese D, Bell MR, Murphree DH, Cheungpasitporn W, Miller PE, et al. Fibrinolysis vs. primary percutaneous coronary intervention for ST-segment elevation myocardial infarction cardiogenic shock. *ESC Heart Fail*. 2021;8:2025–35.
- [454] Politi L, Sgura F, Rossi R, Monopoli D, Guerri E, Leuzzi C, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. *Heart*. 2010;96:662.
- [455] Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: The CvLPRIT Trial. *J Am Coll Cardiol*. 2015;65:963–72.
- [456] Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, et al. Complete revascularization with multivessel PCI for myocardial infarction. *N Engl J Med*. 2019;381:1411–21.
- [457] Dambrink J-HE, Debrauwere JP, van 't Hof AWJ, Ottervanger J-P, Gosselink ATM, Hoorntje JCA, et al. Non-culprit lesions detected during primary PCI: treat invasively or follow the guidelines? *EuroIntervention*. 2010;5:968–75.
- [458] Carlo DM, Mara S, Flavio A, Imad S, Antonio M, Anna P, et al. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEPacoat™ for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. *Int J Cardiovasc Intervent*. 2004;6:128–33.
- [459] Hamza M, Mahmoud AN, Elgendy IY. A randomized trial of complete versus culprit-only revascularization during primary percutaneous coronary intervention in diabetic patients with acute ST elevation myocardial infarction and multi vessel disease. *J Interv Cardiol*. 2016;29:241–7.
- [460] Hofsten DE, Kelbæk H, Helqvist S, Kløvgaard L, Holmvang L, Clemmensen P, et al. The third DANish study of optimal acute treatment of patients with ST-segment elevation myocardial infarction: ischemic postconditioning or deferred stent implantation versus conventional primary angioplasty and complete revascularization versus treatment of culprit lesion only: rationale and design of the DANAMI 3 trial program. *Am Heart J*. 2015;169:613–21.
- [461] Damian JK, Gerald PM, Daniel JB, Nicholas PC, Miles D, John PG, et al. Complete Versus culprit-Lesion only Primary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design. *EuroIntervention*. 2013;8:1190–8.
- [462] McCann GP, Khan JN, Greenwood JP, Nazir S, Dalby M, Curzen N, et al. Complete versus lesion-only primary PCI: the randomized cardiovascular MR CvLPRIT substudy. *J Am Coll Cardiol*. 2015;66:2713–24.
- [463] Sadjadieh G, Engström T, Helqvist S, Hofsten DE, Køber L, Pedersen F, et al. Bleeding episodes in “complete, staged” versus “culprit only” revascularisation in patients with multivessel disease and ST-segment elevation myocardial infarction: a DANAMI-3-PRIMULTI substudy. *EuroIntervention*. 2016;12:1231–8.
- [464] Smits PC, Abdel-Wahab M, Neumann F-J, Boxma-de Klerk BM, Lunde K, Schotborgh CE, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. *N Engl J Med*. 2017;376:1234–44.
- [465] Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, et al. Randomized trial of preventive angioplasty in myocardial infarction. *N Engl J Med*. 2013;369:1115–23.
- [466] Manoharan G, Belardi JA, Du Z, Lee MS, Qiao S, Serruys PW, et al. Comparison of clinical outcomes after multivessel versus single-vessel stenting with the zotarolimus-eluting stent in the RESOLUTE Global Clinical Trial Program. *EuroIntervention*. 2017;12:1605–13.
- [467] Bainey KR, Engström T, Smits PC, Gershlick AH, James SK, Storey RF, et al. Complete vs culprit-lesion-only revascularization for ST-segment elevation myocardial infarction: A systematic review and meta-analysis. *JAMA Cardiol*. 2020;5:881–8.
- [468] Stähli BE, Varbella F, Linke A, Schwarz B, Felix SB, Seiffert M, et al. Timing of complete revascularization with multivessel pci for myocardial infarction. *N Engl J Med*. 2023;389:1368–79.
- [469] Siebert VR, Borgaonkar S, Jia X, Nguyen HL, Birnbaum Y, Lakkis NM, et al. Meta-analysis comparing multivessel versus culprit coronary arterial revascularization for patients with non-ST-segment elevation acute coronary syndromes. *Am J Cardiol*. 2019;124:1501–11.
- [470] Elbadawi A, Dang AT, Hamed M, Eid M, Prakash Hiriyur Prakash M, Saleh M, et al. FFR- versus angiography-guided revascularization for nonculprit stenosis in STEMI and multivessel disease: a network meta-analysis. *JACC: Cardiovasc Imaging*. 2022;15:656–66.
- [471] Archillett F, Ricci F, Pelliccia F, Dansas G, Giuliani L, Radico F, et al. Coronary angiography- or fractional flow reserve-guided complete revascularization in multivessel disease STEMI: A Bayesian hierarchical network meta-analysis. *Int J Cardiol*. 2023;370:122–8.
- [472] Layland J, Oldroyd KG, Curzen N, Sood A, Balachandran K, Das R, et al. Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. *Eur Heart J*. 2015;36:100–11.

- [473] Ntalianis A, Sels J-W, Davidavicius G, Tanaka N, Muller O, Trana C, et al. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. *JACC: Cardiovasc Interv.* 2010;3:1274–81.
- [474] Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, et al. Multivessel PCI guided by FFR or angiography for myocardial infarction. *N Engl J Med.* 2021;385:297–308.
- [475] Lee JM, Kim HK, Park KH, Choo EH, Kim CJ, Lee SH, et al. Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial. *Eur Heart J.* 2022;44:473–84.
- [476] Yousef S, Sultan I, VonVille HM, Kahru K, Arnaoutakis GJ. Surgical management for mechanical complications of acute myocardial infarction: a systematic review of long-term outcomes. *Ann Cardiothorac Surg.* 2022;11:239–51.
- [477] Chevalier P, Burri H, Fahrat F, Cucherat M, Jegaden O, Obadia J-F, et al. Perioperative outcome and long-term survival of surgery for acute post-infarction mitral regurgitation. *Eur J Cardiothorac Surg.* 2004;26:330–5.
- [478] Kirov H, Caldono T, Rahouma M, Robinson NB, Demetres M, Serruys PW, et al. A systematic review and meta-analysis of percutaneous coronary intervention compared to coronary artery bypass grafting in non-ST-elevation acute coronary syndrome. *Sci Rep.* 2022;12:5138.
- [479] Hadaya J, Sanaiha Y, Tran Z, Downey P, Shemin RJ, Benharash P. Timing of coronary artery bypass grafting in acute coronary syndrome: a national analysis. *Ann Thor Surg.* 2022;113:1482–90.
- [480] Hayes SN, Kim ESH, Saw J, Adlam D, Arslanian-Engoren C, Economy KE, et al. Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. *Circulation.* 2018;137:e523–57.
- [481] Fahey JK, Chew A, Imdayhid AR, Rashid HN, Zaman S, Nicholls SJ, et al. Women with spontaneous coronary artery dissection are at increased risk of iatrogenic coronary artery dissection. *Heart Lung Circ.* 2020;30(1):e23–8.
- [482] Hassan S, Samuel R, Starovoytov A, Lee C, Aymong E, Saw J. Outcomes of percutaneous coronary intervention in patients with spontaneous coronary artery dissection, 2021. *J Interv Cardiol.* 2021; 6686230.
- [483] Kotecha D, Garcia-Guimaraes M, Premawardhana D, Pellegrini D, Oliver-Williams C, Bountziouka V, et al. Risks and benefits of percutaneous coronary intervention in spontaneous coronary artery dissection. *Heart.* 2021;107:1398.
- [484] Tweet MS, Eleid MF, Best PJM, Lennon RJ, Lerman A, Rihal CS, et al. Spontaneous coronary artery dissection. *Circ Cardiovasc Interv.* 2014;7:777–86.
- [485] Martins JL, Afreixo V, Santos L, Costa M, Santos J, Gonçalves L. Medical treatment or revascularisation as the best approach for spontaneous coronary artery dissection: A systematic review and meta-analysis. *Eur Heart J Acute Cardiovasc Care.* 2018;7:614–23.
- [486] Lobo AS, Cantu SM, Sharkey SW, Grey EZ, Storey K, Witt D, et al. Revascularization in patients with spontaneous coronary artery dissection and ST-segment elevation myocardial infarction. *J Am Coll Cardiol.* 2019;74:1290–300.
- [487] Jamil A, Tajrishi FZ, Kahe F, Najafi H, Montazerin SM, Shojaei F, et al. Spontaneous coronary artery dissection managed with a conservative or revascularization approach: a meta-analysis. *J Cardiovasc Med.* 2020;21:42–50.
- [488] Reynolds HR, Maehara A, Kwong RY, Sedlak T, Saw J, Smilowitz NR, et al. Coronary optical coherence tomography and cardiac magnetic resonance imaging to determine underlying causes of myocardial infarction with nonobstructive coronary arteries in women. *Circulation.* 2021;143:624–40.
- [489] White K, Kinarivala M, Scott I. Diagnostic features, management and prognosis of type 2 myocardial infarction compared to type 1 myocardial infarction: a systematic review and meta-analysis. *BMJ Open.* 2022;12:e055755.
- [490] Atherton JJ, Sindone A, De Pasquale CG, Driscoll A, MacDonald PS, Hopper I, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018. *Heart Lung Circ.* 2018;27:1123–208.
- [491] Sandau KE, Funk M, Auerbach A, Barsness GW, Blum K, Cvach M, et al. Update to practice standards for electrocardiographic monitoring in hospital settings: a scientific statement from the American Heart Association. *Circulation.* 2017;136:e273–344.
- [492] Shue McGuffin K, Ortiz S. Daily electrocardiogram electrode change and the effect on frequency of nuisance alarms. *Dimens Crit Care Nurs.* 2019;38:187–91.
- [493] Walsh-Irwin C, Jurgens CY. Proper skin preparation and electrode placement decreases alarms on a telemetry unit. *Dimens Crit Care Nurs.* 2015;34:134–9.
- [494] Dibben GO, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. *Eur Heart J.* 2023;44:452–69.
- [495] McDonagh STJ, Dalal H, Moore S, Clark CE, Dean SG, Jolly K, et al. Home-based versus centre-based cardiac rehabilitation. *Cochrane Database Syst Rev.* 2023;10:CD007130.
- [496] Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. *Circulation.* 2010;121:750–8.
- [497] Wu AD, Lindson N, Hartmann-Boyce J, Wahedi A, Hajizadeh A, Theodoulou A, et al. Smoking cessation for secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev.* CD014936.
- [498] Yudi MB, Farouque O, Andrianopoulos N, Ajani AE, Kalten K, Brennan AL, et al. The prognostic significance of smoking cessation after acute coronary syndromes: an observational, multicentre study from the Melbourne interventional group registry. *BMJ Open.* 2017;7:e016874.
- [499] Kevin C, Nicola I, Jan K, Robin PC. Evidence of poor adherence to secondary prevention after acute coronary syndromes: possible remedies through the application of new technologies. *Open Heart.* 2015;2:e000166.
- [500] Brieger D, D'Souza M, Hyun K, Weaver JC, Kritharides L. Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. *Med J Aust.* 2019;210:80–5.
- [501] Redfern J, Hyun K, Chew DP, Astley C, Chow C, Aliprandi-Costa B, et al. Prescription of secondary prevention medications, lifestyle advice, and referral to rehabilitation among acute coronary syndrome inpatients: results from a large prospective audit in Australia and New Zealand. *Heart.* 2014;100:1281–8.
- [502] Brieger D, Chow C, Gullick J, Hyun K, D'Souza M, Briffa T, et al. Improving patient adherence to secondary prevention medications 6 months after an acute coronary syndrome: observational cohort study. *Intern Med J.* 2018;48:541–9.
- [503] Verdicchio C, Freene N, Hollings M, Maiorana A, Briffa T, Gallagher R, et al. A clinical guide for assessment and prescription of exercise and physical activity in cardiac rehabilitation. A CSANZ position statement. *Heart Lung Circ.* 1035–1048.
- [504] Castellanos LR, Viramontes O, Bains NK, Zepeda IA. Disparities in cardiac rehabilitation among individuals from racial and ethnic groups and rural communities—a systematic review. *J Racial Ethn Health Disparities.* 2019;6:1–11.
- [505] Smith M, Orchard J, La Gerche A, Gallagher R, Fitzpatrick J. Fit, female or fifty-is cardiac rehabilitation "fit" for purpose for all? A systematic review and meta-analysis with meta-regression. *Front Cardiovasc Med.* 2022;9:764882.
- [506] Thomas EE, Cartledge S, Murphy B, Abell B, Gallagher R, Astley C. Expanding access to telehealth in Australian cardiac rehabilitation services: a national survey of barriers, enablers, and uptake. *Eur Heart J Digit Health.* 2024;5:21–9.
- [507] Redfern J, Maiorana A, Neubeck L, Clark AM, Briffa T. Achieving co-ordinated secondary prevention of coronary heart disease for all in need (SPAN). *Int J Cardiol.* 2011;146:1–3.
- [508] Woodruffe S, Neubeck L, Clark RA, Gray K, Ferry C, Finan J, et al. Australian Cardiovascular Health and Rehabilitation Association (ACRA) core components of cardiovascular disease secondary prevention and cardiac rehabilitation 2014. *Heart Lung Circ.* 2015;24:430–41.
- [509] Briffa TG, Kinsman L, Maiorana AJ, Zecchin R, Redfern J, Davidson PM, et al. An integrated and coordinated approach to preventing recurrent coronary heart disease events in Australia. *Med J Aust.* 2009;190:683–6.
- [510] Chow CK, Redfern J, Hillis GS, Thakkar J, Santo K, Hackett ML, et al. Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial. *JAMA.* 2015;314:1255–63.
- [511] Pfaeffli Dale L, Whittaker R, Jiang Y, Stewart R, Rolleston A, Maddison R. Text message and internet support for coronary heart disease self-management: results from the Text4Heart randomized controlled trial. *J Med Internet Res.* 2015;17:e237.

- [512] Varnfield M, Karunanithi M, Lee CK, Honeyman E, Arnold D, Ding H, et al. Smartphone-based home care model improved use of cardiac rehabilitation in postmyocardial infarction patients: results from a randomised controlled trial. *Heart*. 2014;100:1770–9.
- [513] World Health Organization. Classification of digital health interventions v1.0. Available at: iris.who.int/bitstream/handle/10665/260480/WHO-RHR-18.06-eng.pdf. [accessed 1.12.24].
- [514] Tromp J, Jindal D, Redfern J, Bhatt A, Severin T, Banerjee A, et al. World Heart Federation Roadmap for digital health in cardiology. *Global Heart*. 2022;17:61.
- [515] American College of Sports Medicine. ACSM's guidelines for exercise testing and prescription. 11th ed. Philadelphia, USA: Wolters Kluwer Health; 2021.
- [516] Black Dog Institute. Education & services: Health professionals. Available at: www.blackdoginstitute.org.au/education-services/health-professionals/. [accessed 1.12.24].
- [517] Murphy BM, Higgins RO, Jackson AC, Edington J, Jackson A, Worcester MU. Patients want to know about the 'cardiac blues'. *Aust Fam Physician*. 2015;44:826–32.
- [518] Murphy BM, Higgins RO, Jackson AC. Incidence and impacts of post-cardiac event mental health problems. *Aust J Gen Pract*. 2023;52:781–6.
- [519] Beyond Blue. Available at: www.beyondblue.org.au/. [accessed 1.12.24].
- [520] Pharmaceutical Society of Australia. Guidelines for comprehensive medication management reviews. Available at: www.ppaonline.com.au/wp-content/uploads/2020/04/PSA-Guidelines-for-Comprehensive-Medication-Management-Reviews.pdf; 2020.
- [521] Frobert O, Gotberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. *Circulation*. 2021;144:1476–84.
- [522] Yedlapati SH, Khan SU, Talluri S, Lone AN, Khan MZ, Khan MS, et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: A systematic review and meta-analysis. *J Am Heart Assoc*. 2021;10:e019636.
- [523] Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Available at: immunisationhandbook.health.gov.au/. [accessed 16.8.24].
- [524] Rodriguez F, Harrington RA. Management of antithrombotic therapy after acute coronary syndromes. *N Engl J Med*. 2021;384:452–60.
- [525] Benenati S, Crimi G, Canale C, Pescetelli F, De Marzo V, Vergallo R, et al. Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: a network meta-analysis. *Eur Heart J Cardiovasc Pharmacother*. 2022;8:56–64.
- [526] Benenati S, Galli M, De Marzo V, Pescetelli F, Toma M, Andreotti F, et al. Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. *Eur Heart J Cardiovasc Pharmacother*. 2021;7:86–93.
- [527] Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. *Lancet*. 2017;389:1025–34.
- [528] Kawashima H, Gao C, Takahashi K, Tomaniak M, Ono M, Hara H, et al. Comparative assessment of predictive performance of PRECISE-DAPT, CRUSADE, and ACUITY scores in risk stratifying 30-day bleeding events. *Thromb Haemost*. 2020;120:1087–95.
- [529] Costa F, Montalto C, Branca M, Hong SJ, Watanabe H, Franzone A, et al. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials. *Eur Heart J*. 2023;44:954–68.
- [530] Garg A, Rout A, Farhan S, Waxman S, Giustino G, Tayal R, et al. Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: a systematic review and meta-analysis. *Am Heart J*. 2022;250:1–10.
- [531] Andò G, De Santis GA, Greco A, Pistelli L, Francaviglia B, Capodanno D, et al. P2Y12 inhibitor or aspirin following dual antiplatelet therapy after percutaneous coronary intervention: A network meta-analysis. *JACC: Cardiovasc Interv*. 2022;15:2239–49.
- [532] Aggarwal D, Bhatia K, Chunawala ZS, Furtado RHM, Mukherjee D, Dixon SR, et al. P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. *Eur Heart J*. 2022;2:oeac019.
- [533] Gragnano F, Cao D, Pironi L, Franzone A, Kim HS, von Scheidt M, et al. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. *J Am Coll Cardiol*. 2023;82:89–105.
- [534] Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. *N Engl J Med*. 2015;372:1791–800.
- [535] Elliott J, Kelly SE, Bai Z, Skidmore B, Boucher M, So D, et al. Extended dual antiplatelet therapy following percutaneous coronary intervention in clinically important patient subgroups: a systematic review and meta-analysis. *CMAJ Open*. 2023;11:E118–30.
- [536] Galli M, Andreotti F, Porto I, Crea F. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. *Europace*. 2020;22:538–46.
- [537] Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: An updated network meta-analysis. *JAMA Cardiol*. 2020;5:582–9.
- [538] Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. *Circulation*. 2020;141:781–3.
- [539] Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, et al. Risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS. *Circulation*. 2020;141:1618–27.
- [540] Smits PC, Frigoli E, Tijssen J, Jüni P, Vranckx P, Ozaki Y, et al. Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: An open-label, randomized, controlled trial. *Circulation*. 2021;144:1196–211.
- [541] Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. *N Engl J Med*. 2019;381:1103–13.
- [542] Urban P, Gregson J, Owen R, Mehran R, Windecker S, Valgimigli M, et al. Assessing the risks of bleeding vs thrombotic events in patients at high bleeding risk after coronary stent implantation: the ARC-high bleeding risk trade-off model. *JAMA Cardiol*. 2021;6:410–9.
- [543] Cholesterol Treatment Trialists C. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. *Lancet*. 2022;400:832–45.
- [544] Navarese EP, Kowalewski M, Andreotti F, van Wely M, Camaro C, Kolodziejczak M, et al. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. *Am J Cardiol*. 2014;113:1753–64.
- [545] Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. *Am Heart J*. 2013;166:597–603.
- [546] Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372:2387–97.
- [547] Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittrner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*. 2018;379:2097–107.
- [548] Watts GF, Sullivan DR, Hare DL, Kostner KM, Horton AE, Bell DA, et al. Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. *Heart Lung Circ*. 2021;30:324–49.
- [549] Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019;380:11–22.
- [550] Cholesterol Treatment Trialists Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet*. 2015;385:1397–405.
- [551] Hay M, Stehli J, Martin C, Brennan A, Dinh DT, Lefkovijs J, et al. Sex differences in optimal medical therapy following myocardial infarction according to left ventricular ejection fraction. *Eur J Prev Cardiol*. 2020;27:2348–50.
- [552] Cholesterol Treatment Trialists Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet*. 2019;393:407–15.
- [553] Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. *Am J Med*. 2014;127:939–53.

- [554] Martínez-Milla J, Raposeiras-Roubin S, Pascual-Figal DA, Ibáñez B. Role of beta-blockers in cardiovascular disease in 2019. *Rev Esp Cardiol (Engl Ed)*. 2019;72:844–52.
- [555] Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. *J Am Coll Cardiol*. 1997;30:27–34.
- [556] Yndigegn T, Lindahl B, Mars K, Alfredsson J, Benatar J, Brandin L, et al. Beta-blockers after myocardial infarction and preserved ejection fraction. *N Engl J Med*. 2024;390:1372–81.
- [557] Kontos MC, Diercks DB, Ho PM, Wang TY, Chen AY, Roe MT. Treatment and outcomes in patients with myocardial infarction treated with acute β -blocker therapy: results from the American College of Cardiology's NCDR®. *Am Heart J*. 2011;161:864–70.
- [558] Zeymer U, Bueno H, Granger CB, Hochman J, Huber K, Lettino M, et al. Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology. *Eur Heart J Acute Cardiovasc Care*. 2020;9:183–97.
- [559] Hoedemaker NP, Roolvink V, de Winter RJ, van Royen N, Fuster V, García-Ruiz JM, et al. Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A patient-pooled meta-analysis of randomized clinical trials. *Eur Heart J Acute Cardiovasc Care*. 2020;9:469–77.
- [560] Desta L, Raposeiras-Roubin S, Ibanez B. The art of prescribing β -blockers after myocardial infarction. *Circ Cardiovasc Genet*. 2021;14:e010720.
- [561] Park CS, Yang HM, Ki YJ, Kang J, Han JK, Park KW, et al. Left ventricular ejection fraction 1 year after acute myocardial infarction identifies the benefits of the long-term use of β -blockers: Analysis of data from the KAMIR-NIH registry. *Circ Cardiovasc Interv*. 2021;14:e010159.
- [562] Safi S, Sethi NJ, Korang SK, Nielsen EE, Feinberg J, Gluud C, et al. Beta-blockers in patients without heart failure after myocardial infarction. *Cochrane Database Syst Rev*. CD012565.
- [563] Dahl Aarvik M, Sandven I, Dondo TB, Gale CP, Ruddox V, Munkhaugen J, et al. Effect of oral beta-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. *Eur Heart J Cardiovasc Pharmacother*. 2019;5:12–20.
- [564] Franzosi M, Santoro E, Zuanetti G, Baigent C, Collins R, Flather M, et al. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. *Circulation*. 1998;97:2202–12.
- [565] Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. *Lancet*. 2006;368:581–8.
- [566] Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. *BMJ*. 2017;356:j4.
- [567] Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med*. 2003;349:1893–906.
- [568] Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med*. 2003;348:1309–21.
- [569] Pfeffer MA, Claggett B, Lewis EF, Granger CB, Kober L, Maggioni AP, et al. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. *N Engl J Med*. 2021;385:1845–55.
- [570] Gabb GM, Mangoni AA, Anderson CS, Cowley D, Dowden JS, Colledge J, et al. Guideline for the diagnosis and management of hypertension in adults – 2016. *Med J Aust*. 2016;205:85–9.
- [571] Bao YL, Gu LF, Du C, Wang YX, Wang LS. Evaluating the utility of colchicine in acute coronary syndrome: a systematic review and meta-analysis. *J Cardiovasc Nurs*. 2022;80:639–47.